Identification and use of novopeptides for the treatment of cancer

ABSTRACT

Compositions, methods, systems, apparatus and/or articles of manufacture are disclosed for reducing the susceptibility of a population and/or members thereof to cancer, which may include anti-cancer vaccines, components thereof which may include novopeptides, and methods relating thereto.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/669,666, filed Aug. 4, 2017, which is a continuation of U.S. non-provisional application Ser. No. 14/451,374, filed Aug. 4, 2014, issued as U.S. Pat. No. 9,732,131 on Aug. 15, 2017, which is a continuation-in-part of U.S. non-provisional application Ser. No. 13/052,490, filed Mar. 21, 2011, issued as U.S. Pat. No. 8,796,414 on Aug. 5, 2014, which is a division of U.S. non-provisional application Ser. No. 12/280,389, filed Jan. 15, 2009, which is a U.S. national phase application of PCT international application No. PCT/US2007/062920 filed Feb. 27, 2007, which claims the benefit of U.S. Provisional Application No. 60/777,534, filed on Feb. 27, 2006; this application claims the benefit of each of the foregoing and each is incorporated herein by reference in its entirety.

SEQUENCE LISTING

The instant application contains a sequence listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 7, 2021 is named CALV003P1C2, and is 237,551 bytes in size.

BACKGROUND

It is estimated that in 2004 more than 2.4 million new cancer cases will be diagnosed in the U.S. and more than 1 million are expected to be skin cancers. Of those individuals with skin cancer, 96,000 will be diagnosed with melanoma (4% of newly diagnosed cancers), the most deadly form of skin cancer. Furthermore, the incidence of melanoma continues to increase faster than any other cancer. The stochastic nature of 90 to 95% of all cancers means that everyone is at risk of developing a cancer. In the United States, men have a 50% lifetime risk of developing cancer, while women have a 33% chance (ACS, 2004). With an annual mortality rate of 563,700 per year, cancer is the second leading cause of death in the United States.

Vaccination against cancer has been proposed for treatment, and occasionally prevention, of cancer, and considerable research effort has been devoted to the exploration of a variety of cancer vaccination strategies. The goal of finding vaccine compositions and treatment methods that are capable of reliably and predictably overcoming tolerance and setting in motion an immune response against tumor cells without inducing autoimmunity has, until now, proved elusive. It is nevertheless clear that cancerous cells have characteristics that can be recognized by the immune system, as demonstrated by experiments in which mice vaccinated with various kinds of tumor cell preparations show protection from tumor challenge. Antigens that are expressed in or by tumor cells are referred to as “tumor associated antigens” (“TAA's”). A particular TAA may or may not also be expressed in non-cancerous cells; TAA's that are not expressed or rarely expressed in non-cancerous cells, or whose expression in non-cancerous cells is sufficiently reduced in comparison to that in cancerous cells that an immune response induced upon vaccination is reasonably specific to cancerous cells, are referred to as “tumor specific antigens” (“TSA's”).

Over the past two decades, many labs have devised numerous techniques which aim to turn the patient's immune system against a pre-existing tumor (Berzofsky et al., 2004). These include the use of whole cells, peptides, genetically modified tumor cells, heat-shock proteins or apoptotic tumor cells to stimulate the host's immune system to respond to antigens that are characteristic of cancer cells. Arguably the most elegant approach to cancer vaccination is to use vaccine formulations composed of known and defined TAA's, since this will maximize specificity. Functionally, TAA's may be classed as self and non-self. Self TAA's are derived from non-mutated genes whose expression is limited to selected normal tissues or to overexpressed proteins. While most TAA's identified to date belong to this self class, there are two large potential problems associated with such antigens: autoimmunity and tolerance. Non-self TAA's are expressed exclusively or predominantly by cancer cells, and can be thought of as tumor-specific antigens (TSA's). TSA's can originate either exogenously (such as those derived from viral proteins in virally-associated tumors) or endogenously. Mutation-derived TSA's can arise from point mutations, translocations, and exon mis-splicing. Unlike self TAA's, TSA's pose greatly reduced risk of autoimmunity and tolerance.

SUMMARY

In general, disclosed herein are embodiments of methods, systems, apparatus, compositions, and/or articles of manufacture for reducing the susceptibility of a population and/or members thereof to cancer. Disclosed are methods for identifying and immunologically screening candidate antigens for inclusion in a prophylactic and/or therapeutic cancer vaccine. Further disclosed is a general class of antigens, referred to herein as novopeptides, as well as several specific embodiments and/or examples thereof, including non-MS novopeptides and FS-novopeptides and others. Disclosed are methods and compositions related to novopeptides for use in diagnosing, preventing and treating cancer. Also disclosed are embodiments of methods of using novopeptides to induce an immune response against cancer. Disclosed are vaccines having one or more novopeptide components, which may be used, in various embodiments, for example, prophylactically, or as a therapeutic treatment against existing cancerous cells.

In a first aspect, disclosed are embodiments of synthetic or recombinant peptide components, which may include novopeptides, for use in anti-cancer vaccines.

In a second aspect, disclosed are embodiments of anti-cancer vaccines for prophylactic or therapeutic administration or both, including, for example, anti-cancer vaccines including peptide components and/or novopeptides and anti-cancer vaccines including nucleic acids that encode peptide components and/or novopeptides.

In other aspects, disclosed are embodiments of methods including administration of an anti-cancer vaccine to a population and/or member thereof.

The foregoing summary is intended to provide a brief introduction to the subject matter of this disclosure and does not in any way limit or circumscribe the scope of the invention(s) disclosed herein, which scope is defined by the claims currently appended or as they may be amended, and as interpreted in the light of the entire disclosure, including the detailed description and drawing figures.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawing figures, which are incorporated in and constitute a part of this specification, illustrate several embodiments and together with the description illustrate various embodiments of the disclosed compositions and methods.

FIGS. 1a and 1b show PCR amplification of novopeptides FS 1-78 (SEQ ID NO: 2) and FS 6-21 (SEQ ID NO: 4), respectively, from various cancerous and non-cancerous cell types.

FIG. 2 demonstrates an embodiment of a method of determining frameshift frequency in tumor cells.

FIG. 3 shows an embodiment of a linear expression element construction (LEE).

FIG. 4 shows results of prophylactic immunization of C57B6 mice with FS 1-78 on tumor challenge.

FIG. 5 shows results of prophylactic immunization of Balb/c mice with FS 1-78 and FS 6-21 on tumor challenge.

FIG. 6 shows the survival curve in response to prophylactic vaccination by genetic immunization with a pooled vaccine.

FIGS. 7a, 7b and 7c show an example of a comparison of RNA expression levels of novopeptides in tumor cells with that in non-cancerous cells.

FIG. 8 shows ELISA results indicating reactivity of serum from 23 cancer patients to FS 6-21 (SEQ ID NO: 4).

FIG. 9 shows results of an immunological screen via a CTL assay.

FIG. 10 shows immunofluorescence images of anti-FS 6-21 serum applied to B16 and 4Tl tumor cells and pre-immune serum applied to B16 tumor cells.

FIG. 11 shows an animal survival curve in response to therapeutic vaccination with frameshift peptide-encoding sequences.

FIGS. 12a and 12b show tumor progression and survival following tumor challenge in mice receiving therapeutic vaccination with an embodiment of a novopeptide associated with a frame shift mutation or variation in FS SMC-IA (SEQ ID NO:8).

FIGS. 13a and 13b show tumor progression and tumor count in an example embodiment wherein BALB-neuT mice received prophylactic immunization with FS RBM peptide (SEQ ID NO:232) or FS THAP2 peptide (SEQ ID NO:238),

FIGS. 14a and 14b show tumor progression and tumor count in an example embodiment wherein BALB-neuT mice received prophylactic immunization with pooled antigen compositions.

FIG. 15 shows prophylactic inhibition of tumor progression in BALB/C-4Tl mice vaccinated with an embodiment of an anti-cancer vaccine.

DETAILED DESCRIPTION

Before the present compounds, compositions, articles, devices, and/or methods are disclosed and described, it is to be understood that they are not limited to specific synthetic methods or specific recombinant biotechnology methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a pharmaceutical carrier” includes mixtures of two or more such carriers, and the like.

Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “10” is disclosed the “less than or equal to 1O” as well as “greater than or equal to 10” is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point 15 are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15.

In this specification and in the claims which follow, reference will be made to a number of terms which shall be defined to have the following meanings:

“Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this pertains. The references disclosed are also individually and specifically incorporated by reference herein for the material contained in them that is discussed in the sentence in which the reference is relied upon.

The methods and compositions disclosed herein pertain in part to a class of compositions, referred to herein as novopeptides, which are useful as candidates for cancer vaccines. Herein, “novopeptide” refers to any composition, such as, for example, a TSA, comprising a polypeptide having at least 8 and no more than 40 amino acids, whose amino acid sequence is encoded by all or part of at least one novopeptide nucleic acid sequence. Thus, for example, a “novopeptide can comprise a TSA having 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, or 40 amino acids or any number of amino acid residues in between. A “novopeptide nucleic acid sequence” means any nucleic acid sequence that can be generated from any non-cancerous reference sequence by a novopeptide associated mutation or variation. “Novopeptide” includes any such polypeptide regardless of how produced or obtained, whether naturally occurring, engineered, produced by in vitro translation, synthesized, or produced in any of the many other ways of generating polypeptides known to one having ordinary skill in the art. A “novopeptide associated mutation or variation” means one or a combination of any one or more point mutations, frame shift mutations, in-frame insertions or deletions, translocations, improper splicing, post-transcriptional events, variations, or other alterations in a nucleic acid sequence from a non-cancerous reference sequence, regardless of whether heritable or not, the effect of which is to cause the amino acid sequence or composition of a polypeptide encoded thereby to differ from that of the non-cancerous reference sequence; “novopeptide associated mutation or variation” expressly includes, without limitation, deviations from non-cancerous reference sequences occurring as a result of mis-translation, mis-splicing, or other events occurring at the RNA level. A “non-cancerous reference sequence” means and includes any nucleic acid sequence occurring in any non-cancerous cell of the organism of interest, whether or not expressed therein. The terms “cancerous cell” and “cancer cell” mean and include any cell exhibiting cancerous, precancerous, dysplagic or other changes characteristic of the transformation of a normal cell into a tumor cell, whether or not malignant and whether or not immediately tumorigenic. It will be recognized that the ontogeny of cancer typically entails a succession of cellular events, and that treatment, whether prophylactic or therapeutic, is optimally applied at the earliest possible stage of that succession. The methods and compositions disclosed herein are intended to apply not only to conditions that have progressed to the point where they are diagnosable as cancer but also to any and all conditions associated with the expression of novopeptides by cells in a manner immunologically distinguishable from normal cells. “Tumor cell” means a cell obtained from or associated with a tumor. “Noncancerous cell” means and includes any cell that is not a cancerous cell or tumor cell. Typically, a novopeptide is a linear polypeptide sequence comprising naturally occurring amino acids; however, “novopeptide” also includes any other polypeptide composition including a sequence that can be expressed by a cancerous cell as a result of a novopeptide associated mutation or variation of a noncancerous reference sequence, whether occurring in DNA or RNA, whether or not comprising one or more amino acids that differ from the naturally occurring amino acids, whether or not post-translationally modified, and whether or not bonded to or associated with any one or more other moieties. A FS-novopeptide is a novopeptide whose sequence differs from that of a noncancerous reference sequence in a manner attributable to one or more novopeptide associated mutations or variations wherein the mutation or variation is a frame shift mutation or variation. A non-MS novopeptide is a novopeptide encoded by a novopeptide nucleic acid sequence that can be generated by a novopeptide associated mutation or variation from a non-cancerous reference sequence that is not a microsatellite sequence.

One interesting technology that has been developed to identify frameshifts without having to sequence genes is the high-throughput solid-phase protein truncation test (HTS-PTT) (Gite et al., 2003). However, a problem with this approach is that the user must have one or a few candidate proteins in mind at the outset, which reintroduces the problem of requiring knowledge about gene function or mechanism. In the present method, high-throughput sequencing capabilities and bioinformatics may be used to identify FS cancer vaccine candidates. In contrast to prior methodology, various embodiments of the methods disclosed herein 1) do not require knowledge about gene function or immunological mechanism, 2) are systematic and amenable to high-throughput, and 3) are generalizable to all types of cancer. No other approach has all three of these characteristics. Furthermore, testing in the melanoma mouse model confirms that these novopeptides are effective therapeutic vaccines and prophylactic vaccines.

The least explored and potentially most useful subclass of TSA is arguably that caused by frameshifts (FS). One of the consequences of transformation from a normal cell to a cancer cell is that DNA replication and RNA processing become more error prone, while DNA repair becomes less robust. This causes an increase in the frequency of FS mutations or variants where 1 or 2 (or other non-multiple of three) new bases are inserted into or deleted from a gene. When such mutations occur in the coding regions of proteins, the resulting shift in reading frames gives rise to the synthesis of truncated genes that have lost their function. On average at least 20% of the FS variants would encode a new peptide of 9 or more amino acids. Since ˜9 amino acids are required to bind in the MHC I pocket for presentation to T cells (e.g., 8, 9, 10, or 11 residues), many of the FS variants could be presented. It will be seen that even short FS variants will present new 9-residue peptides by virtue of the fusion of wild-type and FS sequences. Furthermore, as these nonsense proteins tend to be very immunogenic and are expressed predominantly (if not exclusively) in tumor cells, PS-derived antigens are ideal vaccine candidates. In addition to frameshifts, an insertion or deletion of a nucleic acid sequence that is a multiple of three will produce an in-frame deletion or insertion. These will also lead to the production of novopeptides since the junction points will be new peptide sequence.

Relative to oncogenesis, there are at least two classes of mutated proteins to consider, whether produced by frameshifts or other mechanisms: the first class, oncogenic-related variants, are those that result in or contribute to tumor formation or progression. The second class, bystander variants, are those that are not involved in oncogenesis but that happen to be altered simply because the cellular machinery is operating inefficiently or for other reasons. From the point of view of developing a vaccine, both are viable as vaccine candidates.

Disclosed herein are embodiments of methods of screening for a tumor-specific antigen, comprising obtaining a tumor cell, extracting RNA from the cell, and assaying for frameshifts. It is understood and herein contemplated that the tumor-specific antigen can be a peptide or protein.

Disclosed are embodiments of methods of identifying components for a prophylactic cancer vaccine, comprising: identifying novopeptides by informatics, genomics, proteomics or immunological screens; and detecting an immune response to the novopeptide that differentiates between tumor and normal cells. The novopeptide so identified can be used to induce a primary immune response.

Disclosed herein are embodiments of methods of identifying a novopeptide that produces an anti-cancer immune response, comprising identifying a novopeptide by informatics, genomics, proteomics, or immunological screens; and determining that the novopeptide induces an immune response that differentiates between tumor cells and normal cells. It is understood that the novopeptide of the method can be identified by any of the methods disclosed herein. Thus, for example, disclosed herein are embodiments of methods, wherein the novopeptide is identified using cancer genome and expression databases to detect novopeptides preferentially expressed in tumor cells versus normal cells. Alternatively, disclosed are methods, wherein the novopeptide is identified using nucleic acid sequencing methods to detect alterations in DNA and or RNA that lead to the novopeptide. Also disclosed are methods wherein the novopeptide is identified using mass spectrometry to detect novopeptides that are on the tumor cell surface.

It is understood and contemplated herein that any immunoassay that can measure a T cell response can be used in the disclosed methods. Thus, for example, disclosed herein are embodiments of methods of identifying a novopeptide that produces an anti-cancer immune response comprising determining that the novopeptide induces an immune response, wherein the novopeptide is identified using immune assays of human cancer patient serum or animal tumor model serum to detect reactivity to the novopeptide. Also disclosed are methods, wherein the novopeptide is identified using immune assays of human cancer patient peripheral blood mononuclear cells (PBMCs) or animal tumor model (PBMCs) to detect reactivity to the novopeptide. As noted above, the immune assay can be any assay known in the art that measures T cell activity. Thus, for example, the immune assay can be a cytolytic assay such as a 51Cr release assay, or the assay can measure cytokine production in response to the peptide such as ELISPOT, ELISA, and Intracellular Cytokine Staining. Thus, disclosed herein are embodiments of methods wherein the immune assay is selected from the group consisting of ELISPOT, ELISA, and Intracellular Cytokine Staining. Antibodies may also be used to identify T cell activity by binding to T cells specific for a novopeptide. For example, MHC class I and II tetramers, dimers, and trimers can be used to mark novopeptide specific T cells.

Also disclosed are methods of identifying a novopeptide that induces a protective immune response to cancer, comprising identifying a novopeptide by informatics (odds ratios of tumor to normals); sequencing candidate DNA or RNA; performing mass spectrometry on peptides eluted from MHCI of tumor cells and normal cells, and detecting the peptides that are expressed by tumor cells; and determining whether T-cells reactive to the novopeptide peptide react with MHCI matched tumor cells but not normal cells. It is understood that additional steps may be needed to identify novopeptides. Thus, disclosed herein are embodiments of methods, further comprising comparing the peptides eluted from tumor MHCI to a database of all possible novopeptides from the human proteome. It is also understood that antibody responses to a novopeptide can also be desirable in therapeutic methods. Therefore, disclosed herein are embodiments of methods of identifying a novopeptide that induces a protective immune response to cancer, further comprising determining if antibodies raised to the novopeptide react with tumor cells expressing the novopeptide and not with normal cells. Also disclosed are methods of identifying a novopeptide that induces a protective immune response to cancer, comprising identifying a novopeptide by informatics (odds ratios of tumor to normals); sequencing candidate DNA or RNA; performing mass spectrometry on peptides eluted from MHCI of tumor cells and normal cells, and detecting the peptides that are expressed by tumor cells; and determining if antibodies raised to the novopeptide react with tumor cells expressing the novopeptide and not with normal cells.

It is understood and herein contemplated that the disclosed methods of identifying novopeptides that produce an anti-cancer immune response will produce peptides useful in producing an immune response to cancer. Thus, the novopeptides identified by the methods disclosed herein and those specifically elucidated can be used as a therapeutic or prophylactic agent to treat or prevent a cancer either alone or in combination with other peptides or known anti-cancer agents. Thus, for example, the disclosed methods can identify novopeptides that can be used to develop an anti-cancer vaccine. Therefore, disclosed herein are cancer vaccines comprising a novopeptide or nucleic acid encoding a novopeptide that has been identified by any of the methods of identifying novopeptides disclosed herein. It is understood and herein contemplated that such a vaccine can be delivered by any method known in the art including but not limited to gene gun, as gene vaccine, viral vector or as peptide or peptide fusion to another carrier such as a protein, sugar, or oil:water emulsion.

The disclosed prophylactic and therapeutic vaccines are suitable for administration to human and non-human subjects. Thus, disclosed herein are prophylactic vaccines that are administered to a non-human animal selected from the group consisting of dog, cat, guinea pig, mouse, rat, rabbit, pig, horse, cow, monkey, chimpanzee, or other non-human primate to prevent cancer, or to any other animal susceptible to cancer.

Thus, disclosed herein are embodiments of methods of identifying a novopeptide that induces a protective immune response to cancer, comprising identifying a novopeptide by informatics (odds ratios of tumor to normals); sequencing candidate DNA or RNA; performing mass spectrometry on peptides eluted from MHCI of tumor cells and normal cells, and detecting the peptides that are expressed by tumor cells; and determining whether T-cells reactive to the novopeptide react with MHCI matched tumor cells but not normal cells. It is understood that additional steps may be needed to identify novopeptides. Thus, disclosed herein are embodiments of methods, further comprising comparing the peptides eluted from tumor MHCI to a database of all possible novopeptides from the human proteome. It is also understood that antibody responses to a novopeptide can also be desirable in therapeutic methods. Therefore, disclosed herein are embodiments of methods of identifying a novopeptide that induces a protective immune response to cancer, further comprising determining if antibodies raised to the novopeptide react with tumor cells expressing the novopeptide and not with normal cells. Also disclosed are methods of identifying a novopeptide that induces a protective immune response to cancer, comprising identifying a novopeptide by informatics (odds ratios of tumor to normals); sequencing candidate DNA or RNA; performing mass spectrometry on peptides eluted from MHCI of tumor cells and normal cells, and detecting the peptides that are expressed by tumor cells; and determining if antibodies raised to the novopeptide react with tumor cells expressing the novopeptide and not with normal cells.

The disclosed methods can also be used in conjunction with animal models. Thus, disclosed herein are embodiments of methods of identifying a novopeptide that produces an anti-cancer immune response, comprising identifying a novopeptide by informatics, genomics, proteomics, or immunological screens; and determining that the novopeptide induces an immune response that differentiates between tumor cells and normal cells, wherein the anticancer immune response of the novopeptide is further determined by administering a non-human animal homolog of a human novopeptide to the non-human animal in a prophylactic or therapeutic cancer model; and measuring the anti-cancer effect of the novopeptide in the animal model of cancer.

It is understood and herein contemplated that any of the disclosed methods benefit by the distinction and identification of immune responses limited to tumor cells (i.e., not present or present at only low levels in normal cells). Thus, disclosed herein are embodiments of methods, for further identifying the induction of an immune response that differentiates between tumor cells and normal cells, wherein human cells are exposed to the novopeptide, and the reactivity of the exposed cells to human cancer cells and normal cells is determined, wherein a stronger reactivity against human cancer cells compared to normal cells indicates a cancer-specific immune response.

Tumor specific antigens can come from many sources. One advantage of the present disclosure over previous methods is the identification of tumor-specific antigens in genes previously not associated with oncogenesis (i.e., cancer). For example, one source of tumor-specific antigens is frameshifts of genes. The genes can be oncogenic or non-oncogenic. A frameshift originating from an oncogene is an “oncogenic-related frameshift,” whereas, a frameshift derived from a non-oncogenic tumor gene is a “bystander frameshift.” Thus, for example, specifically contemplated herein are tumor-specific antigens wherein the antigen is the result of a bystander frameshift in the gene source.

In embodiments, a method for identifying novopeptide vaccine antigens comprises two major tasks. The first, hereinafter referred to as a novopeptide identification screen, entails identifying novopeptides and/or novopeptide nucleic acid sequences that are likely to be expressed and/or are experimentally determined to be expressed in one or more cancerous cell types. The second task, hereinafter referred to as a novopeptide immunological screen, entails immunological screening of the novopeptides so identified, or novopeptides encoded by the novopeptide nucleic acid sequences so identified, to evaluate each candidate novopeptide for suitability as a component of a vaccine.

An important and novel insight underlying the disclosure hereof, and verified by the experiments described below, is that the widely held assumption that antigens expressed in cancerous cells and minimally expressed or not expressed in noncancerous cells are derived from oncogenes, particularly or exclusively those containing microsatellite sequences, does not withstand scrutiny, in fact, cancer cells can express many genes that have undergone a novopeptide associated mutation or variation, resulting in the expression of one or more non-MS novopeptides or other non-oncogene associated novopeptides by the cell.

The novopeptide identification screen in one aspect relates to identification of novopeptides that are expressed, or are predicted to be expressed, in cancerous cells. This can be accomplished in a number of ways, for example, the methods described by the examples disclosed herein. The method extends to the approaches described herein, which are offered as examples only and not intended to limit the scope of the disclosure, as well as any of the other methods known to persons having ordinary skill in the art for identifying peptides, peptide sequences, and/or nucleic acid sequences encoding peptides, that are experimentally determined to be expressed or predicted to be expressed in a predetermined cell type and/or that exhibit predetermined characteristics.

One method for performing the novopeptide identification screen comprises generating a library of candidate novopeptide sequences, and/or novopeptide nucleic acid sequences, bioinformatically from a known genome sequence or subsequence, or from cDNA, mRNA, EST, protein or peptide sequence, nucleic acid or peptide microarray data, or any other data from which the sequence encoding any non-cancerous reference sequence can be determined or inferred. At least one non-cancerous reference sequence is extracted from such data. Without limiting the generality of the foregoing, and by way of example only, one way of extracting a non-cancerous reference sequence from such data is to extract the DNA or RNA sequence corresponding to a known gene or open reading frame from available sequence data. Because many novopeptide associated mutations or variations are the result of events occurring at the level of RNA processing and/or translation, RNA sequences are another important source of sequence data for identification of candidate novopeptides. Ideally, a non-cancerous reference sequence so extracted is a sequence that, when mutated and fragmented and/or recombined to form novopeptide nucleic acid sequences, is likely to be expressed in a cancerous cell; however, novopeptide identification is in part a trial and error process, so not all non-cancerous reference sequences so extracted will be ideal. Nevertheless, the selection of non-cancerous reference sequences can, in appropriate circumstances, be optimized by any of the methods known to a person having ordinary skill in the art for estimating the likelihood of expression of a sequence, such as, by way of example only, taking into account the locus of the sequence in question with respect to a known promoter and/or other regulatory elements, and/or taking into account the relationship of the sequence in question to a gene known to be expressed in cancerous cells of a type for which a vaccine is desired. From each non-cancerous reference sequence extracted from the sequence data, one or more novopeptide nucleic acid sequences is generated by applying a novopeptide associated mutation or variation and extracting one or more subsequences affected by the novopeptide associated mutation or variation and having lengths corresponding to novopeptides of the desired length. Many other methods for identifying candidate novopeptide sequences from genomic, proteomic, or other similar data will be apparent to a person having ordinary skill in the art. Once a library of candidate novopeptide sequences has been generated, physical novopeptides can readily be generated therefrom by any of the many methods known to a person having ordinary skill in the art for synthesizing or producing physical polypeptides from specified sequences, including without limitation and by way of example only, FMOC synthesis, in vitro translation, and genetically engineered bacterial, phage, or yeast expression systems.

There exist large public databases that contain the sequences of DNA or cDNA from various tumor samples and from normal tissues. The NCI EST database currently contains more than 41 million entries. The Cancer Genome Atlas Project is another source of tumor cell sequence data. Comparison of sequences in the tumor databases to non-cancerous reference sequence open reading frames reveals putative insertions, deletions, mis-splicings, and other variations that can lead to translation and expression of novopeptides.

The disclosure hereof in one aspect relates to the task of identifying novopeptides likely to be expressed in cancer cells and not at all or at a low level in non-cancerous cells, which may, in embodiments, be accomplished by comparing EST sequences from a tumor database with EST sequences from a non-tumor related EST database or other sequence database to identify sequences arising from frame shift mutations or variations. EST sequences are particularly useful because they represent sequences known to be expressed, and capture variation occurring at the RNA level that may not be apparent in the corresponding DNA sequence. In some embodiments, all possible frame shifted sequences are generated from the non-tumor EST database, and the tumor EST database is then searched for sequences matching the frame shifted sequences so generated. The matching sequences found in the tumor EST database are then ranked for selection taking into account the number of times each frame shifted sequence appears in the tumor EST database as compared to the number of times the unshifted noncancerous reference sequence appears in the non-tumor EST database. Both databases are highly redundant, being repositories for data from many experiments by many researchers, and represent a reasonable sample of expression in tumor and non-tumor cells, respectively. Another factor to be taken into account is the size of the insertion or deletion resulting in a frameshift found in the tumor EST database. Insertions or deletions of three or fewer nucleotides have a significant likelihood of being due to sequencing errors, while longer insertions or deletions, particularly those appearing in multiple EST's deposited from multiple sources, are highly likely to represent true novopeptides that are actually expressed in tumor cells. It will be noted that the bioinformatic approach just described also provides information useful for selecting novopeptides that are expressed in multiple tumor types.

In embodiments, another method for identifying novopeptides expressed in tumor cells may entail extracting RNA from tumor cells and sequencing the RNA so extracted, using any of the methods familiar to a person having ordinary skill in the art for extracting and purifying RNA from cells and determining the sequence of the RNA. An interesting finding upon sequencing genes in human tumor cell lines for frame shift variants that are predicted to occur based on the bioinformatic prediction methods described herein is that many frame shifted sequences terminate at a shorter length than statistically expected. Since three of the 64 possible codons are stop codons, one would expect a stop codon to occur on average approximately once every 21 codons, or about once every 63 amino acids, if codons were randomly distributed, but many immediate terminations were observed and frame shift variants longer than about 20 amino acids were rarely encountered.

Also disclosed herein are embodiments of methods of performing a novopeptide identification screen comprising extracting novopeptides in physical form from a sample containing known or suspected cancerous cells, and identifying the novopeptides so extracted. A variety of methods exist that are capable of extracting any novopeptides that can be present in or on one or more cells (typically but not necessarily together with other substances that can be present in the sample including other cellular proteins and peptides). Several such methods are known to those of skill in the art, and include without limitation and by way of example only, washing with selected solvents or buffers, acid elution, sonication, and elution from MHC by competition with other chemical entities having an affinity for MHC. A method may be chosen that can extract antigens present on the surface of cells in the sample. Methods that preferentially extract antigens displayed in MHC are of particular utility since novopeptides expressed by cancerous cells are likely to be so displayed. Once an extraction containing novopeptides has been obtained, the novopeptides contained therein can be characterized and their sequence determined by any of the methods known to a person having ordinary skill in the art for extracting and sequencing peptides from an inhomogeneous sample. Commonly used methods include without limitation sample separation by chromatographic and/or electrophoretic means, followed by characterization of the fractions thus separated, which can be by sequencing methods such as Edman degradation, or by mass spectroscopy. Other methods exist for identification of specific sequences using antibody or other probes, including without limitation ELISA and microarray analysis. A particularly useful and heretofore unfeasible approach enabled by various embodiments of the methods disclosed herein is separation and identification of novopeptides by liquid chromatography and mass spectroscopy (LC-MS/MS). For a novopeptide to be most effective as a target for a vaccine, it should be presented on the outside of the tumor cells. For T-cell killing of the tumor the peptides should be presented in the context of an MHC molecule. For anti-tumor antibody binding the novopeptides need to be accessible on the surface in some form. Mass spectrometry allows the direct detection of particular sequences of peptides. Identification of novopeptides by MS has heretofore not been possible, in part because mass spectrometers having resolution sufficient to resolve peaks corresponding to novopeptides have only recently become available, and, more importantly, because identification of novopeptides by MS requires a database of novopeptide sequences and corresponding masses, and no such database has existed until created at the inventors' direction for purposes of the methods disclosed herein. In embodiments, such a database can be constructed by assembling a set of candidate novopeptide nucleic acid sequences by any of the methods for doing so disclosed herein or known to a person of ordinary skill in the art, and analyzing each sequence using software (such as, by way of example only, BIMAS and/or SYFPEITHI) for predicting the ability of a sequence to bind to or be displayed in the MHC types present in the tumor cells from which the novopeptides are being eluted and to identify preferred 9-mer sequences or subsequences that are capable of being displayed in those MHC types. Spectra corresponding to each preferred 9-mer sequence so determined may be generated and compared with spectra measured via LC-MS/MS using software (such as, by way of example only, Spectrum Mill) suitable for generating spectra from peptide sequences, comparing the spectra so generated with measured spectra, and from such comparison assessing whether a peptide sequence corresponds to any of the measured spectra. Because novopeptides may be present at low levels and only one sequence presented, until recently the sensitivity of mass spectrometry was not high enough to detect them. It should be noted that the method just described can be used both for identification of candidate novopeptides and as a screen to support or verify the identification by one of the other methods described.

Particularly with regard to human cancers, it is useful to perform bioinformatic screening of candidate novopeptides for likely HLA compatibility, since humans are outbred, while laboratory mice are not. It is understood and herein contemplated that the effectiveness of a particular novopeptide as a vaccine for human use depends in part upon the ability of the novopeptide to be displayed by the HLA types present in the human patient to whom it is administered. Vaccine candidate novopeptides can be assessed for likely ability to be displayed by given HLA types using algorithms known to those having ordinary skill in the art, such as, for example, those described herein. For vaccination of a particular human patient, the vaccine should preferably include one or more novopeptides predicted to have a high probability of binding to at least one of the HLA types expressed in the cells of the patient. For a vaccine intended for non-personalized use in humans, the vaccine should include one or more novopeptides in each of a number and selection of HLA types sufficient that a high percentage of individuals in the target population will have at least one of the HLA types represented in the vaccine, keeping in mind that it is not uncommon for one peptide to be presented by two or more MHC molecules, thereby reducing the number of distinct novopeptides required for a desired level of population coverage. It is also useful to take into account the particular tumor types in which particular novopeptides are expressed or are predicted to be expressed, the frequency with which those tumor types appear in the target population, the urgency of finding effective treatment or prophylaxis for those tumor types (keeping in mind that no effective treatments exist for some cancers and that cancer types differ in terms of life expectancy after diagnosis and severity of effects), and any other criteria deemed important in designing a vaccine. The methods and compositions disclosed herein enable preferential selection for further testing of novopeptides that are expressed in multiple tumors, that are more commonly occurring, that are more urgently in need of an effective vaccine, or that meet other criteria.

Also disclosed are embodiments of methods of performing a novopeptide identification screen comprising comparing the RNA expression level of a particular novopeptide in tumor cells of the type being targeted to the RNA expression level of the same novopeptide in one or more non-cancerous cell types. This can be accomplished by any of the methods known to a person having ordinary skill in the art for assaying for RNA expression levels, such as, without limitation and by way of example only, microarray expression analysis, reverse transcriptase PCR, and SAGE analysis. For inclusion in vaccines, novopeptides that are highly expressed in tumor cells and minimally expressed or not expressed in non-cancerous cells are preferred. For an effective vaccine, the novopeptide or a functionally similar peptide should preferably be expressed in the tumor being targeted, and ideally not in non-cancerous cells, and since some novopeptides are highly differentially expressed in tumor vs. non-cancerous cells and others are not, the RNA expression level screen is useful for optimizing the selection of novopeptides for inclusion in vaccine formulations.

Disclosed herein are embodiments of methods for performing novopeptide immunological screens. For example, disclosed herein are embodiments of methods for immunologically screening for the existence of a B cell response to a particular novopeptide comprising assaying for the presence of antibodies reactive to that novopeptide in serum samples from individuals having a type of cancerous cells predicted to express the novopeptide, and for the absence, or presence below a prespecified titer, of such reactive antibodies in serum obtained from one or more individuals not having such cancer. The presence in sera of antibodies reactive to a given novopeptide may be detected and quantified by an ELISA assay in which the novopeptide is adsorbed onto a solid surface, serum is applied, and antibodies remaining bound to the novopeptides after washing are detected. The initial immune response to variant antigens displayed on naturally occurring tumors is suppression and tolerization due to the absence of the co-regulatory signals required for mounting of an immune response; this has been demonstrated in animal models and is probably the case in humans. However, in at least some individuals, a strong immune response develops late in the tumor progression process. Therefore, serum antibody reactivity to a candidate novopeptide, even if detected in the serum of only one or a few individuals having the cancer type in question, is strong evidence that the novopeptide is expressed in that cancer type.

Disclosed herein are embodiments of methods for immunologically screening for a T cell response to a particular novopeptide comprising first preparing cytotoxic T lymphocytes (“CTL's”) having T cell receptors specific for the novopeptide as displayed in MHC or HLA. These CTL's may then be tested for reactivity against each of (1) cancerous cells, and (2) non-cancerous cells, each having an MHC or HLA type matching that of the MHC or HLA for which the CTL's are specific.

In embodiments, another method for screening of novopeptides entails testing in a suitable animal model by immunizing with a novopeptide to be evaluated and observing whether the immunization is effective in producing a prophylactically or therapeutically beneficial immune response upon challenge with tumor cells, or in an animal having or prone to having a tumor. The response can be assessed by, for example, measuring tumor volume over time, or assessing survival rates, in comparison to non-immunized controls. Example 2 is illustrative of these methods.

Any one or more of the screening methods described in the preceding discussion can be used to identify novopeptides that are prevalent in tumors relative to noncancerous cells. By screening a panel of tumor and non-cancerous cells it is possible to establish the frequency of a novopeptide in specific tumor types as well as in tumors generally. Further, by screening a novopeptide against the known frequencies of HLA types it is possible to establish the percentage of a population that are likely to respond to the antigen.

As already noted, a second task to which the disclosure hereof is directed is that of performing a novopeptide immunological screen of the candidate novopeptides identified via the novopeptide identification screen or otherwise. A goal of the novopeptide immunological screen is to determine the suitability of a given candidate novopeptide for inclusion in a therapeutic or prophylactic vaccine. In embodiments, a novopeptide immunological screen can be carried out by employing the methods disclosed in the preceding paragraphs, or by any of the methods known to a person having ordinary skill in the art for determining or estimating the likely efficacy and safety of a biomolecule as a vaccine component, singly or in combination and in any appropriate order. In an embodiment, a novopeptide immunological screen entails determining whether T-cells made reactive to the novopeptide exclusively or disproportionately react with cancerous cells but not normal cells. With regard to B-cell response, an embodiment of a novopeptide immunological screen may entail determining whether antibodies against the novopeptide specifically react against tumor cells and not normal cells. Novopeptides are inherently relatively unlikely to be expressed in non-cancerous cells, since novopeptides are derived from altered nucleic acid sequences. It is preferable that novopeptide vaccine antigens not be expressed in non-cancerous cells, since such expression would imply a likelihood of existing tolerance, and since it is preferable that a vaccine not produce an immune response against non-cancerous cells. However, the preference for non-expression in non-cancerous cells is not a rigid one, since even treatments that produce undesired side effects can be therapeutically useful.

Disclosed herein are embodiments of methods and compositions useful in the formulation of prophylactic and/or therapeutic vaccines to be administered for the purpose of raising an immune response against tumor cells. The disclosure hereof extends to the composition of novopeptide-based vaccines and to methods of administration thereof. A novopeptide-based vaccine can be prepared and administered in any of the ways familiar to persons having ordinary skill in the art, including the very simple approach of preparing a vaccine comprising a novopeptide dissolved or suspended in a suitable carrier, and administering it once or at predetermined intervals to the animal or human patient to be vaccinated. However, in embodiments, better success may be had by other methods, and a particular approach entails genetic immunization using gene gun technology, in which the vaccine is administered in the form of a linear expression element encoding the desired novopeptide, as illustrated in the examples below. The composition of a vaccine can include both novopeptide and other components. The inclusion of multiple distinct novopeptides can improve the level of immunoprotection conferred, and may be employed to confer immunoprotection against additional tumor types. Single novopeptides may be found that confer immunoprotection against more than one tumor type, but the repertoire of target tumor types can be expanded by inclusion of additional novopeptides. The inclusion of multiple novopeptides is of particular utility in vaccines intended for administration in humans, due to the need for including a number and selection of novopeptides sufficient to ensure that at least one novopeptide in the vaccine will be capable of being displayed by at least one HLA type present in each individual in a predetermined percentage of the target population. In embodiments, two or more novopeptides can be fused into a single entity. In embodiments, novopeptide-based vaccines can include other components familiar to a person having ordinary skill in the art for improving the immunoprotection conferred or otherwise improving the efficacy and/or safety of the vaccine formulation, including without limitation and by way of example only, adjuvants and hapten carriers.

Experiments have been performed to assess directly the feasibility of creating general prophylactic cancer vaccines and therapeutic cancer vaccines. In contrast to existing dogma, results from these experiments indicate that it is possible to immunize prophylactically with novopeptide vaccines that cross-protect across different tumor types and in different MHC backgrounds. These results show that cancer vaccines do not have to be personalized; can contain a defined set of tumor specific antigens (novopeptides) that cover the majority of human MHCs; and can be administered prophylactically and so avoid the necessity of delaying treatment until an individual develops a tumor (at which point the battle is harder to win) so that a sufficient personalized sample can be obtained to allow formulation of a drug or vaccine.

In embodiments, the tumor-specific antigens (novopeptides) disclosed herein can come from or relate to any known tumor cell. Thus contemplated herein are methods of screening for tumor specific antigens, wherein the tumor cell is from a cancer selected from the group of cancers consisting of lymphomas (Hodgkin's and non-Hodgkin's), B cell lymphoma, T cell lymphoma, leukemias, myeloid leukemia, carcinomas, carcinomas of solid tissues, squamous cell carcinomas, squamous cell carcinomas of the mouth, throat, larynx, and lung, adenocarcinomas, sarcomas, gliomas, high grade gliomas, blastomas, neuroblastomas, plasmacytomas, histiocytomas, melanomas, adenomas, hypoxic tumours, myelomas, AIDS-related lymphomas or sarcomas, metastatic cancers, mycosis fungoides, bladder cancer, brain cancer, nervous system cancer, lung cancers such as small cell lung cancer and non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, hepatic cancer, colon cancer, cervical cancer, cervical carcinoma, breast cancer, and epithelial cancer, renal cancer, genitourinary cancer, esophageal carcinoma, head and neck carcinoma, large bowel cancer, hematopoietic cancers, and testicular cancer. The source of novopeptides can be from sequences relating to any tumor type, and some novopeptides are applicable to a wide variety of tumors; when pooled, an appropriate selection of such novopeptides can give rise to a universal prophylactic vaccine.

An advantage of the disclosed approach is that it provides insights into cancer. For example, one of the 11-mer frameshift peptides that was isolated (peptide FS 6-21) was found to have homology to a region of Huntingtin interacting protein (HIP1), the level of which is positively correlated with disease progression in patients with Huntington's disease (Kerr, 2002). Interestingly, there are a number of studies that have shown that this disorder is associated with a significantly lower incidence of cancer (Sorenson et al., 1999).

In embodiments, novopeptides are provided that are associated with cancer cells. The disclosed components can be used to prepare the disclosed compositions as well as in the compositions themselves to be used within the methods disclosed herein. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed, while specific reference of each various individual and collective combinations and permutations of these compounds may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular novopeptide or novopeptide associated mutation or variation (e.g., peptide FS 1-78, peptide FS 6-21, or peptide FS SMC IA) is disclosed and discussed and a number of modifications that can be made to a number of molecules including the FS 1-78, FS 6-21, and FS SMC IA are discussed, specifically contemplated is each and every combination and permutation of FS1-78, FS 6-21, and FS SMC IA and the modifications that are possible unless specifically indicated to the contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-Dis disclosed, then even if each is not individually recited each is individually and collectively contemplated meaning combinations, A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are considered disclosed. Likewise, any subset or combination of these is also disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E would be considered disclosed. This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the disclosed methods.

The disclosed screening methods can be used to identify novopeptide associated mutations or variations associated with cancers. The disclosed novopeptide associated mutations or variations are differentially expressed in cancerous cells as compared to noncancerous cells. Since novopeptide associated mutations or variations occur in all cancers tested, the novopeptides furnish a basis for therapeutic vaccines. Therefore, disclosed herein are vaccines for a cancer comprising one or more novopeptides, wherein the novopeptide is derived from a novopeptide associated mutation or variation, and wherein the novopeptide(s) is identified via the disclosed screening methods or by any other method. Specifically disclosed herein are novopeptides, wherein the novopeptide is associated with a frameshift of the SMC IA gene.

Disclosed herein, are frameshift mutation peptides that have been identified that are present only or predominantly in cancerous tissue. See, for example, the list of peptides in the Sequence Listing. Specifically disclosed herein are tumor-specific antigens, wherein the antigen is a peptide as set forth in SEQ ID NOs: 2, 4, 6, and 8. It is understood that there are numerous nucleotide sequences that can encode for the peptides disclosed herein. For example, one example of a nucleotide that encodes the peptide set forth in SEQ ID NOs: 2, 4, and 6 are the nucleotide sequences of SEQ ID NOs: 1, 3, and 5, respectively. It is understood and herein contemplated are each and every nucleotide sequence that encodes the disclosed peptides.

Because the novopeptides in the Sequence Listing have been shown by the present screening method to be present only or predominantly in non-normal (e.g., cancerous) tissue, each disclosed novopeptide can be used as a reagent for detecting the presence of anti-novopeptide antibodies in a subject. Thus, the novopeptides have utility in a method of detecting the presence of non-normal (e.g., cancerous) tissue in a subject as further described below.

Because the novopeptide associated mutation or variation is present and/or expressed at higher levels in cancerous tissue as compared to normal or noncancerous tissue, the novopeptide associated mutations or variations itself can be used as the basis for a target for drug or antibody treatment as well as methods of identifying subjects at risk for a cancer by virtue of the presence of the novopeptide associated mutation or variation. Therefore, the disclosure hereof extends to antibodies to novopeptides or to FS-novopeptides or to non-MS novopeptides. It is understood that the antibody can be specific to any novopeptide disclosed herein. For example, the antibody can be directed to a frameshift mutant of the SMCIA gene. The disclosure hereof extends, by way of example only, to antibodies directed toward a novopeptide comprising a sequence set forth in SEQ ID NOs: 2, 4, 6, or 8. It is understood that the antibody can be administered by itself or as a component of another composition. Thus, herein disclosed are compositions comprising antibodies specific for the tumor specific antigens disclosed herein.

The vaccines disclosed herein can be used to treat or prevent cancer due to the presence of the novopeptides or novopeptide associated mutations or variations in tumor cells. Alternatively, since the mutation does not occur or is not prevalent in normal cells it can also be used as a prophylactic vaccine. Thus disclosed herein are compositions comprising a prophylactic vaccine including components as disclosed herein such that they would be predicted to provide protection to 10% or more of a population against a particular tumor or group of tumors by taking into account the frequency of the peptides in the tumors and the frequency of the MHCI types in the population.

Thus, disclosed herein are embodiments of methods of treating cancer comprising administering to a subject in need thereof the vaccines disclosed herein. Also disclosed herein are embodiments of methods of preventing a cancer comprising administering to a subject at risk thereof the vaccines disclosed herein. The disclosed vaccines can be used to treat cancer due to the presence of disclosed tumor-specific antigens in all cancers. Contemplated and disclosed herein are vaccinations and compositions for treating or preventing cancer wherein the cancer is of any type, including, by way of example only, those selected from the group of cancers consisting of lymphomas (Hodgkin's and non-Hodgkin's), B cell lymphoma, T cell lymphoma, leukemias, myeloid leukemia, carcinomas, carcinomas of solid tissues, squamous cell carcinomas, squamous cell carcinomas of the mouth, throat, larynx, and lung, adenocarcinomas, sarcomas, gliomas, high grade gliomas, blastomas, neuroblastomas, plasmacytomas, histiocytomas, melanomas, adenomas, hypoxic tumours, myelomas, AIDS-related lymphomas or sarcomas, metastatic cancers, mycosis fungoides, bladder cancer, brain cancer, nervous system cancer, lung cancers such as small cell lung cancer and non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, hepatic cancer, colon cancer, cervical cancer, cervical carcinoma, breast cancer, and epithelial cancer, renal cancer, genitourinary cancer, esophageal carcinoma, head and neck carcinoma, large bowel cancer, hematopoietic cancers, and testicular cancer.

The antibodies disclosed herein can be combined with other agents, molecules, or compounds to increase binding, elicit additional immune responses, or deliver toxic effects to the proximity of the target antigen, e.g., to cells that express the frameshift mutation. Such combinations can occur through the formation of fusion constructs, immunoconjugates, or other combination platforms as known in the art. Thus, in embodiments, the antibodies disclosed herein can be combined with a toxin such as diphtheria toxin, ricin toxin, tetanus toxoid, botulinum toxin, or any other toxin as a fusion construct to form an antibody-toxin fusion. For example, the antibody-toxin fusion construct can comprise the disclosed antibody fused to a diphtheria toxin. In embodiments, the disclosed toxins such as tetanus and diphtheria can comprise truncation mutants to avoid the antibody response from previous exposure to the toxin. For example, a diphtheria toxin can comprise a truncation mutant diphtheria toxin wherein the toxin comprises a 145-152 amino acid truncation of the c-terminal end of the diphtheria toxin.

Immunogenic fusion protein derivatives, such as those described in the examples, may be made by fusing a polypeptide sufficiently large to improve immunogenicity to the target sequence by cross-linking in vitro or by recombinant cell culture transformed with DNA encoding the fusion. For example, a FS novopeptide can be fused to a carrier such as a protein or sugar. Methods for improving the immunogenic properties of a peptide by fusing, conjugating or otherwise associating it with a hapten or other carrier are well known to persons having ordinary skill in the art of immunology.

The terms homology, similarity, and identity may be used interchangeably herein and have equivalent meaning except where otherwise specifically indicated or where context requires otherwise. Thus, for example, if the use of the word homology is used between two non-natural sequences it is understood that this is not necessarily indicating an evolutionary relationship between these two sequences, but rather refers to the similarity or relatedness between their nucleic acid sequences. Many of the methods for determining homology between two evolutionarily related molecules are routinely applied to any two or more nucleic acids or proteins for the purpose of measuring sequence similarity regardless of whether they are evolutionarily related or not.

In general, it is understood that one way to define any known variants and derivatives or those that might arise, of the disclosed genes and proteins herein, is through defining the variants and derivatives in terms of homology to specific known sequences. In general, variants of genes and proteins herein disclosed typically have at least, about 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent homology or sequence identity to the stated sequence or the native sequence or other sequence with which comparison is made. Those of skill in the art readily understand how to determine the homology of two proteins or nucleic acids, such as genes. For example, the homology can be calculated after aligning the two sequences so that the homology is at its highest level.

In embodiments, homology can be computed using published algorithms. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman Adv. Appl. Math. 2: 482 (1981), by the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 48: 443 (1970), by the search for similarity method of Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A. 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, PASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by inspection.

Homology can be determined for nucleic acids by any of the methods known to a person having ordinary skill in the art, including without limitation, for example, the algorithms disclosed in Zuker, M. Science 244:48-52, 1989, Jaeger et al. Proc. Natl. Acad. Sci. USA 86:7706-7710, 1989, Jaeger et al Methods Enzymol. 183:281-306, 1989 which are herein incorporated by reference for at least the material related to nucleic acid alignment. In embodiments, any of the methods typically can be used and in certain instances the results of these various methods may differ, but the skilled artisan understands that if identity is found with at least one of these methods, the sequences would be said to have the stated identity, and be disclosed herein.

For example, as used herein, a sequence may be recited as having a particular percent homology to another sequence when the sequences have the recited homology as calculated by any one or more of the calculation methods described above. For example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using the Zuker calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by any of the other calculation methods. As another example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using both the Zuker calculation method and the Pearson and Lipman calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by the Smith and Waterman calculation method, the Needleman and Wunsch calculation method, the Jaeger calculation methods, or any of the other calculation methods. As yet another example, a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using each of calculation methods (although, in practice, the different calculation methods will often result in different calculated homology percentages).

A variety of molecules disclosed herein that are nucleic acid based, including for example the nucleic acids that encode FS1-78, FS 6-21, FS SMClA, or fragments thereof, as well as various functional nucleic acids. In embodiments, the disclosed nucleic acids may be made up of, for example, nucleotides, nucleotide analogs, or nucleotide substitutes. Non-limiting examples of these and other molecules are discussed herein. For example, when a vector is expressed in a cell, the expressed mRNA will typically be made up of A, C, G, and U. The disclosure hereof extends to the nucleic acid sequences described herein and to any and all other nucleic acids that are similar or homologous thereto, regardless of whether comprised in whole or in part of nucleotides, nucleotide analogs, or nucleotide substitutes, or any combination thereof and regardless of whether or not linked to conjugates or other molecules or moieties. Likewise, if, for example, an antisense molecule is introduced into a cell or cell environment through exogenous delivery, it is advantageous that the antisense molecule be made up of nucleotide analogs that reduce the degradation of the antisense molecule in the cellular environment.

A nucleotide is a molecule that contains a base moiety, a sugar moiety and a phosphate moiety. Nucleotides can be linked together through their phosphate moieties and sugar moieties creating an intemucleoside linkage. The base moiety of a nucleotide can be adenin-9-yl (A), cytosin-1-yl (C), guanin-9-yl (G), uracil-1-yl (U), and thymin-1-yl (T). The sugar moiety of a nucleotide is a ribose or a deoxyribose. The phosphate moiety of a nucleotide is pentavalent phosphate. A non-limiting example of a nucleotide would be 3′-AMP (3′-adenosine monophosphate) or 5′-GMP (5′-guanosine monophosphate). There are many varieties of these types of molecules available in the art and available herein.

A nucleotide analog is a nucleotide which contains some type of modification to either the base, sugar, or phosphate moieties. Modifications to nucleotides are well known in the art and would include for example, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, and 2-aminoadenine as well as modifications at the sugar or phosphate moieties. There are many varieties of these types of molecules available in the art and available herein.

Nucleotide substitutes are molecules having similar functional properties to nucleotides, but which do not contain a phosphate moiety, such as peptide nucleic acid (PNA). Nucleotide substitutes are molecules that will recognize nucleic acids in a Watson-Crick or Hoogsteen manner, but which are linked together through a moiety other than a phosphate moiety. Nucleotide substitutes are able to conform to a double helix type structure when interacting with the appropriate target nucleic acid. There are many varieties of these types of molecules available in the art and available herein.

It is also possible to link other types of molecules (conjugates) to nucleotides or nucleotide analogs to enhance for example, cellular uptake. Conjugates can be chemically linked to the nucleotide or nucleotide analogs. Such conjugates include but are not limited to lipid moieties such as a cholesterol moiety. (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556). There are many varieties of these types of molecules available in the art and available herein.

A Watson-Crick interaction is at least one interaction with the Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute. The Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute includes the C2, NI, and C6 positions of a purine based nucleotide, nucleotide analog, or nucleotide substitute and the C2, N3, C4 positions of a pyrimidine based nucleotide, nucleotide analog, or nucleotide substitute.

A Hoogsteen interaction is the interaction that takes place on the Hoogsteen face of a nucleotide or nucleotide analog, which is exposed in the major groove of duplex DNA. The Hoogsteen face includes the N7 position and reactive groups (NH2 or 0) at the C6 position of purine nucleotides.

There are a variety of sequences related to the protein and/or peptide molecules disclosed herein, including without limitation and by way of example only, FS 1-78 (SEQ ID NO: 2), FS 6-21, and FS SMC IA, or any of the nucleic acids disclosed herein, including without limitation and by way of example only, those encoding all or part of FS 1-78, FS 6-21, and FS SMC IA. The disclosure hereof extends to analogs of these genes, as well as other alleles of these genes, and splice variants and other types of variants, in humans and in any other species exhibiting specific immunity including without limitation mammals, fish, and birds. The sequences of various of the foregoing to the extent currently known are available in a variety of protein and gene databases, including Genbank. Such sequences available at the time of filing this application at Genbank are herein incorporated by reference in their entireties as well as for individual subsequences contained therein. Genbank can be accessed via the web site of the National Center for Biotechnology Information. Those of skill in the art understand how to resolve sequence discrepancies and differences and to adjust the compositions and methods relating to a particular sequence and to other related sequences. Primers and/or probes can be designed for any given sequence given the information disclosed herein and known in the art.

As discussed herein there are numerous variants of the FS1-78, FS 6-21 and FS SMC IA protein that are known and herein contemplated. In addition to the known functional FS 1-78, FS 6-21, FS SMCIA, and other novopeptide variants there are derivatives of the FS1-78, FS6-2, and FS SMC IA and other novopeptides which also function in the disclosed methods and compositions. Protein and peptide variants and derivatives are well understood to those of skill in the art and can involve amino acid sequence modifications. For example, amino acid sequence modifications typically fall into one or more of three classes: substitutional, insertional or deletional variants. Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to ten residues. Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. These variants may be prepared by site specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture, or by any of the other methods known to a person having ordinary skill in the art for making or obtaining proteins or peptides having a specified sequence. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example M1 3 primer mutagenesis and PCR mutagenesis. Amino acid substitutions are typically of single residues, but can occur at a number of different locations at once; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final construct. Mutations to DNA encoding the variant should typically not place the sequence out of reading frame and preferably will not create complementary regions that could produce undesired secondary mRNA structure. Substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place. Substitutions in which a residue is replaced with a different amino acid having chemical, biological, or other properties similar to those of the residue that it is replacing, such as, for example, those shown in the following tabulation, are referred to as conservative substitutions.

Conservative Amino Acid Abbreviation Substitution alanine ala A ser allosoleucine alle arginine arg R lys, gin asparagine asn N gin, his aspartic acid asp D glu cysteine cys C ser glutamic acid glu E asn glutamine gin Q asp glycine gly G pro histidine his H asn, gin isoleucine ile I leu, val leucine leu L ile, val lysine lys K arg, gin phenylalanine phe F leu, ile praline pro p met, leu, tyr pyroglutamic acid pyr serine ser s thr threonine thr T ser tyrosine tyr y tyr tryptophan trp w trp, phe valine val V ile, leu

As discussed herein there are numerous variants of the FS1-78, FS 6-21 and FS SMC IA protein that are known and herein contemplated. In addition to the known functional FS 1-78, FS 6-21, FS SMCIA, and other novopeptide variants there are derivatives of the FS1-78, FS6-2, and FS SMC IA and other novopeptides which also function in the disclosed methods and compositions. Protein and peptide variants and derivatives are well understood to those of skill in the art and can involve amino acid sequence modifications. For example, amino acid sequence modifications typically fall into one or more of three classes: substitutional, insertional or deletional variants. Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to ten residues. Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. These variants may be prepared by site specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture, or by any of the other methods known to a person having ordinary skill in the art for making or obtaining proteins or peptides having a specified sequence. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example M1 3 primer mutagenesis and PCR mutagenesis. Amino acid substitutions are typically of single residues, but can occur at a number of different locations at once; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final construct. Mutations to DNA encoding the variant should typically not place the sequence out of reading frame and preferably will not create complementary regions that could produce undesired secondary mRNA structure. Substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place. Substitutions in which a residue is replaced with a different amino acid having chemical, biological, or other properties similar to those of the residue that it is replacing, such as, for example, those shown in the following tabulation, are referred to as conservative substitutions.

The replacement of one amino acid residue with another that is biologically and/or chemically similar is known to those skilled in the art as a conservative substitution. Without limiting the generality of the foregoing, and by way of example only, the substitutions tabulated above are conservative substitutions. In embodiments, conservative substitutions may also include any substitution that would be regarded by one having ordinary skill in the art as conservative, and may include, without limitation, substitutions having a log odds score of zero or above in the BLOSUM 62 matrix, or having a relatively high log odds score in any other substitution matrix in common usage. For example, a conservative substitution may entail replacing one hydrophobic residue for another, or one polar residue for another. Such substitutions include combinations such as, for example, Gly, Ala; Val, Ile, Leu; Asp, Giu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. Such conservatively substituted variations of each explicitly disclosed sequence are included within the polypeptides disclosed herein.

Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those shown above, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the protein properties will be those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g., glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine; or (e) by increasing the number of sites for sulfation and/or glycosylation.

Substitutional or deletional mutagenesis can be employed to insert sites for N-glycosylation (Asn-X-Thr/Ser) or O-glycosylation (Ser or Thr). Deletions of cysteine or other labile residues also may be desirable. Deletions or substitutions of potential proteolysis sites, e.g. Arg, is accomplished for example by deleting one of the basic residues or substituting one by glutaminyl or histidyl residues.

Certain post-translational derivatizations are the result of the action of recombinant host cells on the expressed polypeptide. Glutaminyl and asparaginyl residues are frequently post-translationally deamidated to the corresponding glutamyl and asparyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the o-amino groups of lysine, arginine, and histidine side chains (T. E. Creighton, Proteins: Structure and Molecular Properties, W. H. Freeman & Co., San Francisco pp 79-86 [1983]), acetylation of the N-terminal amine and, in some instances, amidation of the C-terminal carboxyl.

It is understood that one way to define the variants and derivatives of the disclosed proteins herein is through defining the variants and derivatives in terms of homology/identity to specific known sequences. For example, SEQ ID NO: 2 sets forth a particular sequence of peptide 1-78 and SEQ ID NO:4 sets forth a particular sequence of peptide 6-21. Specifically disclosed are variants of these and other proteins herein disclosed which have at least 70% or 75% or 80% or 85% or 90% or 95% homology to the stated sequence. Those of skill in the art readily understand how to determine the homology of two proteins. For example, the homology can be calculated after aligning the two sequences so that the homology is at its highest level. It is understood that the description of conservative mutations and homology can be combined together in any combination, such as embodiments that have at least 70% homology to a particular sequence wherein the variants are conservative mutations.

As this specification discusses various proteins and protein sequences it is understood that the nucleic acids that can encode those protein sequences are also disclosed. This would include all degenerate sequences related to a specific protein sequence, i.e. all nucleic acids having a sequence that encodes one particular protein sequence as well as all nucleic acids, including degenerate nucleic acids, encoding the disclosed variants and derivatives of the protein sequences. Thus, while each particular nucleic acid sequence may not be written out herein, it is understood that each and every sequence is in fact disclosed and described herein through the disclosed protein sequence. For example, one of the many nucleic acid sequences that can encode the protein sequence set forth in SEQ ID NO:2 is set forth in SEQ ID NO:1. In addition, nucleic acid sequences encoding disclosed conservative derivatives of SEQ ID NO:2 are also disclosed. It is also understood that while no amino acid sequence indicates what particular DNA sequence encodes that protein within an organism, where particular variants of a disclosed protein or peptide are disclosed herein, the known nucleic acid sequence that encodes that protein is also known and herein disclosed and described.

It is understood that there are numerous amino acid and peptide analogs which can be incorporated into the disclosed compositions. For example, there are numerous D amino acids or amino acids which have a different functional substituent than the 20 naturally occurring amino acids tabulated above. The opposite stereoisomers of naturally occurring peptides are disclosed, as well as the stereoisomers of peptide analogs. These analog amino acids can readily be incorporated into polypeptide chains by charging tRNA molecules with the amino acid of choice and engineering genetic constructs that utilize, for example, amber codons, to insert the analog amino acid into a peptide chain in a site specific way (Thorson et al., Methods in Molec. Biol. 11:A2>-12> (1991), Zoller, Current Opinion in Biotechnology, 3:348-354 (1992); Ibba, Biotechnology & Genetic Engineering Reviews 13:197-216 (1995), Cahill et al., TIBS, 14(10):400-403 (1989); Benner, TIB Tech, 12:158-163 (1994); Ibba and Hennecke, Biotechnology, 12:678-682 (1994) all of which are herein incorporated by reference at least for material related to amino acid analogs).

Molecules can be produced that resemble peptides, but which are not connected via a natural peptide linkage. For example, linkages for amino acids or amino acid analogs can include CH2NH—, —CH₂S—, —CH2-CH2-CH═CH-(cis and trans), —COCH2, —CH(OH)CH2-, and —CHH2SO—. (These and others can be found in Spatola, A. F. in Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, B. Weinstein, eds., Marcel Dekker, New York, p. 267 (1983); Spatola, A. F., Vega Data (March 1983), Vol. 1, Issue 3, Peptide Backbone Modifications (general review); Morley, Trends Pharm Sci (1980) pp. 463-468; Hudson, D. et al., Int J Pept Prot Res 14:177-185 (1979) (—CH2NH—, CH2CH2-); Spatola et al. Life Sci 38:1243-1249 (1986) (—CHH2-S); Hann J. Chem. Soc Perkin Trans. 1307-314 (1982) (—CH—CH—, cis and trans); Almquist et al. J. Med. Chem. 23:1392-1398 (1980) (—COCH2-); Jennings-White et al. Tetrahedron Lett 23:2533 (1982) (—COCH2-); Szelke et al. European Appln, EP 45665 CA (1982): 97:39405 (1982) (—CH(OH)CH2-); Holladay et al. Tetrahedron. Lett 24:4401-4404 (1983) (—C(OH)CH2-); and Hruby V., Sci 31:189-199 (1982) (—CH2-S—); each of which is incorporated herein by reference. A particularly preferred non-peptide linkage is —CH2NH—. It is understood that peptide analogs can have more than one atom between the bond atoms, such as b-alanine, g-aminobutyric acid, and the like.

Amino acid analogs and peptide analogs may have enhanced or desirable properties, such as, more economical production, greater chemical stability, enhanced pharmacological properties (half-life, absorption, potency, efficacy, etc.), altered specificity (e.g., a broad-spectrum of biological activities), reduced antigenicity, and others.

D-amino acids can be used to generate more stable peptides, because D-amino acids are not recognized by peptidases. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place ofL-lysine) can be used to generate more stable peptides. Cysteine residues can be used to cyclize or attach two or more peptides together. This can be beneficial to constrain peptides into particular conformations. (Rizo and Gierasch Ann. Rev. Biochem. 61:387 (1992), incorporated herein by reference).

The compositions disclosed herein can be used for treatment or prophylaxis against any disease where uncontrolled cellular proliferation occurs, such as cancers. It is understood and herein contemplated that, in embodiments, such compositions may be characterized by any novopeptide associated mutation or variation disclosed herein. Therefore, disclosed herein are embodiments of methods of treating a cancer comprising administering a composition to a subject in need thereof, wherein the composition comprises a novopeptide, a FS-novopeptide, a non-MS novopeptide, a non-MS novopeptide that is also a FS-novopeptide, and/or any combination of the foregoing. Thus, for example, the novopeptide associated mutation or variation can be a frameshift of the SMCIA gene. It is also understood that the frameshift can be a peptide. Thus, by way of example only and without limiting the generality of the foregoing, disclosed herein are embodiments of methods of treating cancer comprising administering to a subject in need thereof a composition comprising a novopeptide, wherein the novopeptide comprises the sequence set forth in SEQ ID NO: 2, 4, 6, or 8.

An aspect of the disclosure hereof relates to the identification of novopeptides, including, for example, novopeptides referred to herein as novopeptide vaccine antigens, suitable for inclusion in a prophylactic or therapeutic cancer vaccine. A novopeptide vaccine antigen is a novopeptide that is capable, when administered in an appropriately constituted prophylactic or therapeutic vaccine, of fostering an appreciable immune response, which may be humoral, cellular, or both, against at least one cancerous cell type in at least one individual.

The utility of the methods, compositions, and articles of manufacture disclosed herein has been convincingly demonstrated in an animal model, as disclosed herein in the examples, and selected aspects of the disclosed technology capable of being demonstrated without a need for human clinical testing have been experimentally confirmed in other experiments disclosed herein. The disclosure hereof is applicable to human and murine cancers, and similarly to cancers of all other organisms having mechanisms for specific immunity, specifically including all mammals, as well as birds and fish. The disclosure hereof is of high potential significance not only in providing prophylactic and therapeutic interventions for human cancer, but also for its veterinary applications, particularly in companion animals such as dogs and cats, for which cancer is a leading cause of death. Embodiments disclosed herein can readily be applied to dog cancer since the dog genome sequence determination has been completed.

While significant progress has been made over the past decade in understanding the basic immunology underlying cancer, thus far no one has produced a cancer vaccine that can, reliably and consistently, induce tumor destruction or improve patient survival (Lewis, 2004; Leaf, 2004). The scientific literature discloses a variety of cancer vaccination strategies that have been investigated by others, each proving less than ideal. The majority of personalized cancer vaccine studies to date have focused on the use of undefined whole tumor-cell extracts prepared from a patient's own tumor. Experiments using autologous vaccines in melanoma have shown that, in principle, immunologic intervention can enhance specific anti-tumor immune responses, and even mediate regression in some cases, but this approach presents difficult challenges, including (1) the potential for causing autoimmunity; (2) dilution of TAAs since the majority of antigens will be “normal”; (3) undermining of specificity (one of the most attractive unique features of immunotherapy); (4) dependence on the patient having a large enough tumor to make the vaccine, precluding early treatment; and (5) the need for custom preparation of a personalized vaccine for each patient.

Another approach to cancer vaccination is to use vaccine formulations composed of known and defined TAAs, since this maximizes specificity and obviates the problem of antigen dilution. To date, several hundred human TAAs have been identified using a variety of strategies, and criteria exist for selecting TAAs suitable for immunotherapy. Functionally, TAAs may be classified as self and non-self. Self-TAAs are derived from non-mutated genes whose expression is limited to certain tissues or to over-expressed proteins. Most TAAs identified and tested to date are self antigens. Potential problems associated with such antigens include autoimmunity and tolerance. For practical purposes, this limits the use of self TAAs to non-vital organs (such as reproductive organs). Pre-existing immune tolerance to self antigens is also problematic, for not only does it suppress a desired anti-tumor immune response, but more recently it has emerged as a possible mechanism of immune escape.

All or most TSAs are non-self antigens and can originate either exogenously (such as those derived from viral proteins in virally-associated tumors, e.g. human papilloma virus) or endogenously. The latter subclass includes un-mutated proteins that might never have been presented to the immune system before (some embryonic or immune privileged antigens), as well as mutated proteins that arise as a consequence of mutations in tumors. Mutation-derived TSAs can arise from events such as point mutations, frame shift mutations, translocations, improper splicing, and post transcriptional events. TSAs have a great advantage over self TAAs as cancer vaccines since they avoid the problems of autoimmunity and systemic tolerance. In mouse models TSAs have been shown to generate high-avidity T cell responses more readily than self TAAs.

In principle, vaccination can be used either prophylactically or therapeutically. As a practical matter, therapeutic vaccination strategies face several difficult challenges, and, in general, have failed to fulfill their early promise. Many or most antigens presented by cells in an established tumor are recognized as self by the immune system. To the extent that tumor cells do display mutated antigens that the immune system is capable of recognizing as non-self, by the time tumor development has advanced sufficiently to allow diagnosis, immune tolerance to the mutated antigens will have developed owing to their gradual exposure to the immune system in the absence of the co-regulatory danger signals that would be required for an immune response. Recent studies have shown that in the absence of co-stimulatory signals, tolerance can be induced even to foreign antigens expressed by a tumor. MHC expression is often down-regulated or impaired in established tumor cells, reducing the display of any non-self antigen, and the reduced MHC expression is of course selected for to the extent that any therapeutic immunization strategy is effective in killing cells that do display recognizable non-self antigen in MHC. (The term “MHC” is used herein in a generic sense and is intended to include MHC, HLA, and any other entities at least one of whose functions is to display endogenous or exogenous antigens or fragments thereof on the surface of a cell. Where reference is made to a particular MHC class, the reference includes any corresponding class of HLA or other such entity.) Finally, it has been shown by multiple groups that immunization with irradiated tumor cells, tumor cell lysate, or tumor-derived heat shock proteins (HSPs) protects only against challenge with the same tumor; it does not protect against challenge with a different tumor; vaccines derived from one tumor did not protect against another. These findings have led to an assumption nearly universally held in the field of cancer immunology, but disproved by the experimental evidence disclosed herein, that cancer vaccines must be personalized. Companies exist based on a technology in which they receive a tumor from a patient, isolate HSPs or extracts from that tumor, and return the tumor derived HSPs or extracts as a patient-specific vaccine. Early clinical trials implementing this approach showed promise, but it is expensive and not every cancer patient has enough tumor from which to make a vaccine. A recent Phase III trial by Antigenics, Inc. using this strategy was stopped for lack of efficacy.

A fundamental problem for prophylactic vaccination as a cancer preventative treatment has been the supposition that each tumor in each organism presents a unique immunological profile, and the consequent assumption that no prophylactic vaccine could offer a practicable breadth of protection against multiple tumor types or even against multiple variants of a single tumor type. The problem is exacerbated by the assumed need for any vaccine to be personalized to the organism receiving it. In contrast, a basic contention hereof is that there are novopeptides that are produced in common between two or more types of cancers and that these can be used to formulate a prophylactic vaccine. The challenge was to develop a systematic method to find such novopeptides; such a method is disclosed herein.

The peptides disclosed herein can be administered to a subject as a peptide or encoded by a nucleic acid. Thus, for example, disclosed herein are embodiments of methods of treating a cancer comprising administering a composition to a subject in need thereof, wherein the composition comprises a tumor-specific antigen, and wherein the tumor-specific antigen is a novopeptide, a FS-novopeptide, a non-MS novopeptide, a non-MS novopeptide that is also a FS-novopeptide, and/or any combination of the foregoing, and/or wherein the tumor-specific antigen is a peptide encoded by a nucleic acid set forth in SEQ ID NOs: 1, 3, or 5. The nucleic acids encoding the novopeptides disclosed herein can be provided by any gene delivery system disclosed herein such as gene gun, viral vector, or plasmid.

“Treatment” means a method of reducing the effects of a disease or condition. Treatment can also refer to a method of reducing the disease or condition itself rather than just the symptoms. The treatment can be any reduction from native levels and can be but is not limited to the complete ablation of the disease, condition, or the symptoms of the disease or condition. For example, a disclosed method for reducing the effects of a cancer is considered to be a treatment if there is a 10% reduction in one or more symptoms of the disease (e.g., tumor size) in a subject with the disease when compared to native levels in the same subject or control subjects. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels. It is also understood and contemplated herein that treatment can refer to any reduction in the progression of a disease or cancer. Thus, for example, a method of reducing the effects of a cancer is considered to be a treatment if there is a 10% reduction in the tumor growth rate relative to a control subject or tumor growth rates in the same subject prior to the treatment. It is understood that the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.

“Inhibit,” “inhibiting,” and “inhibition” mean to decrease an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.

The disclosed methods can be used for the treatment or inhibition of any cancer. Thus disclosed herein are embodiments of methods of treating, preventing, or inhibiting cancer, wherein the cancer may be of any type, such as, by way of example only, a cancer selected from the group of cancers consisting of lymphomas (Hodgkin's and non-Hodgkin's), B cell lymphoma, T cell lymphoma, leukemias, myeloid leukemia, carcinomas, carcinomas of solid tissues, squamous cell carcinomas, squamous cell carcinomas of the mouth, throat, larynx, and lung, adenocarcinomas, sarcomas, gliomas, high grade gliomas, blastomas, neuroblastomas, plasmacytomas, histiocytomas, melanomas, adenomas, hypoxic tumours, myelomas, AIDS-related lymphomas or sarcomas, metastatic cancers, mycosis fungoides, bladder cancer, brain cancer, nervous system cancer, lung cancers such as small cell lung cancer and non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, hepatic cancer, colon cancer, cervical cancer, cervical carcinoma, breast cancer, and epithelial cancer, renal cancer, genitourinary cancer, esophageal carcinoma, head and neck carcinoma, large bowel cancer, hematopoietic cancers, and testicular cancer.

It is understood that, in addition to the present methods of identifying a subject at risk of developing cancer, the identification of subjects at risk of developing a cancer can be accomplished by any means known in the art. Thus, for example, a subject at risk can be identified by exposure to a known carcinogen, behavioral activities associated with cancer (e.g., smoking with respect to lung cancer), or genetic predisposition to a given cancer. Specifically disclosed herein are embodiments of methods of preventing a cancer in a subject at risk thereof wherein the subject is identified by genetic screening. Because the frameshift peptides disclosed herein are associated with cancer, the presence of the frameshift can be used to identify subjects at risk of developing a cancer. Therefore, disclosed herein are embodiments of methods of identifying a subject at risk for developing a cancer comprising obtaining a tissue sample from the subject and contacting an antibody with the tissue sample, wherein antibody binding indicates the subject is at risk for the cancer.

Compounds disclosed herein may also be used for the treatment of precancer conditions such as cervical and anal dysplasias, other dysplasias, severe dysplasias, hyperplasias, atypical hyperplasias, and neoplasias.

The disclosed methods can be used to treat or protect any subject in need thereof or at risk of acquiring any disease disclosed herein. In embodiments, a subject may include any animal capable of displaying specific immunity such as bird, fish, and mammal. Thus, for example, a subject for use with any of the disclosed methods can be human, chimpanzee (or other non-human primate), monkey, cow, horse, pig, dog, cat, rat, guinea pig, and mouse.

A significant advantage of the methods, compositions, and articles of manufacture disclosed herein is that vaccination with a single novopeptide has been shown capable of conferring immunoprotection against more than one tumor type and in unrelated individuals, as demonstrated by the examples disclosed herein. This is a highly novel result, particularly in the light of the widely held dogma based on the whole-cell vaccine studies previously noted that immunization with one tumor cell line does not cross-protect against another. The results shown here may be reconciled with the whole-cell vaccine studies by observing that tumors do have antigens in common, but immunization with cell lysates or irradiated tumors do not show cross-protection because the concentration of cross protective peptides in MHC is not high enough in whole-cell vaccines to activate T cells; in other words, whole-cell vaccine strategies fail because of antigen dilution. Prevaccination with one or a few novopeptides concentrates the immune system on these antigens and confers protection. This experimental finding leads to the very important result that novopeptides expressed in common by multiple tumor types can support prophylactic vaccination conferring immunoprotection against those tumor types. This is an important conceptual, experimental, and practical breakthrough. It will be noted that the disclosure hereof provides an effective and systematic method for finding and evaluating novopeptides that are commonly expressed among multiple tumor types.

In some cases a novopeptide produced in human tumors will be the same or very similar to that produced in an animal tumor model such as mouse or dog. For example, the FS 1-78 and FS 6-21 novopeptides described below were found in mouse tumors as there described, but have also been identified in certain human tumors. The SMC1A novopeptide, described below, was found originally by searching human databases, but also is expressed in mouse tumors. If a novopeptide is found in both human and mouse tumors, significant evidence of the potential effectiveness of the novopeptide as a tumor vaccine antigen in humans can be obtained by immunizing mice and challenging with the appropriate tumor line. Alternatively, cancer prone mice can be vaccinated with the novopeptide to determine whether tumorigenesis and/or tumor progression is reduced or eliminated.

Disclosed herein are therapeutic antibodies to a tumor-specific antigen, wherein the antigen is a novopeptide identified by the steps comprising identifying a novopeptide by informatics, genomics, proteomics, or immunological screens; and determining that the novopeptide induces an immune response that differentiates between tumor cells and normal cells. It is understood and herein contemplated that the novopeptide can be a tumor-specific antigen. Thus, for example, the novopeptide can comprise the sequence set forth in SEQ ID NO: 2, 3, or 6. Similarly, the novopeptide can comprise a frameshift of the SMC1A gene. Thus for example, the novopeptide can comprise the sequence set forth in SEQ ID NO: 8. It is also understood that the disclosed therapeutic antibodies can be used alone or in combination with another agent as a therapeutic treatment. It is also contemplated herein that the therapeutic treatments disclosed herein can be used to treat cancer. In other words, disclosed herein are embodiments of methods of treating a cancer comprising administering to a subject the therapeutic antibodies disclosed herein or identified by the methods disclosed herein. Thus, for example, disclosed herein are embodiments of methods of therapeutic treatment, wherein the cancer may be of any type, such as, by way of example only, a cancer selected from the group of cancers consisting of lymphomas (Hodgkin's and non-Hodgkin's), B cell lymphoma, T cell lymphoma, leukemias, myeloid leukemia, carcinomas, carcinomas of solid tissues, squamous cell carcinomas, squamous cell carcinomas of the mouth, throat, larynx, and lung, adenocarcinomas, sarcomas, gliomas, high grade gliomas, blastomas, neuroblastomas, plasmacytomas, histiocytomas, melanomas, adenomas, hypoxic tumours, myelomas, AIDS-related lymphomas or sarcomas, metastatic cancers, mycosis fungoides, bladder cancer, brain cancer, nervous system cancer, lung cancers such as small cell lung cancer and non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, hepatic cancer, colon cancer, cervical cancer, cervical carcinoma, breast cancer, and epithelial cancer, renal cancer, genitourinary cancer, esophageal carcinoma, head and neck carcinoma, large bowel cancer, hematopoietic cancers, and testicular cancer.

In embodiments, the compositions disclosed herein can be used for example as targets in combinatorial chemistry protocols or other screening protocols to isolate molecules that possess desired functional properties related to inhibiting tumor growth and treating cancer. Thus, disclosed herein are embodiments of methods of screening for a cancer therapeutic or prophylactic comprising contacting the candidate therapeutic or prophylactic with a novopeptide, wherein a candidate therapeutic or prophylactic that binds the novopeptide is selected for further evaluation as a therapeutic or prophylactic.

The disclosed compositions can also be used as diagnostic tools related to diseases such as cancer. For example, the disclosed methods can be used to determine if a cell growth is cancerous. Thus, disclosed herein are embodiments of methods of diagnosing a tumor or other growth as cancerous or precancerous comprising screening for a novopeptide comprising obtaining a tumor cell, extracting RNA from the cell, and assaying for novopeptide associated mutations or variations, wherein the presence of a novopeptide associated mutation or variation indicates the tumor is cancerous or potentially cancerous. Also disclosed are methods of diagnosing an individual with cancer comprising obtaining a tissue sample, and screening for the presence of a novopeptide associated mutation or variation. It is understood that the tissue can be any tissue present in the subject. For example, the tissue can be blood, saliva, skin, or cells from a tissue biopsy. It is also understood that the disclosed tissues can be obtained by any method known in the art such as, for example, lung lavage, venous bleeding, tissue biopsy, or mucosal tissue swab. Thus, for example, disclosed herein are embodiments of methods of diagnosing wherein the sample is blood. The method can involve determining the presence of a novopeptide associated mutation or variation identified to be associated with cancer. Alternatively, the method can involve screening for the presence of an immune response to a novopeptide. It is understood that the immune response can be an antibody or cell-mediated response. Thus, for example, the immune response can be a T cell response such as a CD8 T cell response (e.g., cytolytic killing or cytokine secretion) or CD4 T cell response (cytokine secretion). It is specifically contemplated herein that any known immunological measure may be used to determine the presence of the immune response. For example, antibody responses can be measured by ELISA, ELISPOT, or agglutination assays. T cell responses can be detected by, for example, ELISA, ELISPOT, tetramer staining, intracellular cytokine staining, or chromium release assays.

It is possible that novopeptide associated mutations or variations identified by the methods disclosed herein may result in an otherwise non-oncogenic gene becoming oncogenic. For example, the SMC1A gene is not oncogenic; however, a frameshift of the SMC1A gene as disclosed herein may be oncogenic. The methods of detecting novopeptide associated mutations or variations in tumor cells disclosed herein showed a frameshift in the SMC IA gene which as a frameshift mutant is oncogenic. Thus, disclosed herein are embodiments of methods of identifying oncogenes, comprising detecting a novopeptide associated mutation or variation in a gene not previously associated with cancer.

The compositions disclosed herein and the compositions necessary to perform the disclosed methods can be made using any method known to those of skill in the art for that particular reagent or compound unless otherwise specifically noted.

For example, nucleic acids, such as, for example, oligonucleotides to be used as primers or nucleic acids encoding novopeptides, can be made using standard chemical synthesis methods or can be produced using enzymatic methods or any other known method. Such methods can range from standard enzymatic digestion followed by nucleotide fragment isolation (see for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) Chapters 5, 6) to purely synthetic methods, for example, by the cyanoethyl phosphoramidite method using a Milligen or Beckman System 1Plus DNA synthesizer (for example, Model 8700 automated synthesizer of Milligen-Biosearch, Burlington, Mass. or ABI Model 380B). Synthetic methods useful for making oligonucleotides are also described by Ikuta et al., Ann. Rev. Biochem. 53:323-356 (1984), (phosphotriester and phosphite-triester methods), and Narang et al., Methods EnzymoL, 65:610-620 (1980), (phosphotriester method). Protein nucleic acid molecules can be made using known methods such as those described by Nielsen et al., Bioconjug. Chem. 5:3-7 (1994).

An example of a method of producing the disclosed proteins and peptides is to link two or more peptides or polypeptides together by protein chemistry techniques. For example, peptides or polypeptides can be chemically synthesized using currently available laboratory equipment using either Fmoc (9-fluorenylmethyloxycarbonyl) or Boe (Xert-butyloxycarbonoyl) chemistry. (Applied Biosystems, Inc., Foster City, Calif.). One skilled in the art can readily appreciate that a peptide or polypeptide corresponding to the disclosed proteins, for example, can be synthesized by standard chemical reactions. For example, a peptide or polypeptide can be synthesized and not cleaved from its synthesis resin whereas the other fragment of a peptide or protein can be synthesized and subsequently cleaved from the resin, thereby exposing a terminal group which is functionally blocked on the other fragment. By peptide condensation reactions, these two fragments can be covalently joined via a peptide bond at their carboxyl and amino termini, respectively, to form an antibody, or fragment thereof, or other polypeptide of interest. (Grant GA (1992) Synthetic Peptides: A User Guide. W.H. Freeman and Co., N.Y. (1992); Bodansky Mand Trost B., Ed. (1993) Principles of Peptide Synthesis. Springer-Verlag Inc., NY (which is herein incorporated by reference at least for material related to peptide synthesis). Alternatively, a peptide or polypeptide may be independently synthesized in vivo as described herein. Once isolated, these independent peptides or polypeptides may be linked to form a peptide or fragment thereof via similar peptide condensation reactions.

For example, enzymatic ligation of cloned or synthetic peptide segments allow relatively short peptide fragments to be joined to produce larger peptide fragments, polypeptides or whole protein domains (Abrahmsen L et al., Biochemistry, 30:4151 (1991)). Alternatively, native chemical ligation of synthetic peptides can be utilized to synthetically construct large peptides or polypeptides from shorter peptide fragments. This method consists of a two step chemical reaction (Dawson et al. Synthesis of Proteins by Native Chemical Ligation. Science, 266:776-779 (1994)). The first step is the chemoselective reaction of an unprotected synthetic peptide-thioester with another unprotected peptide segment containing an amino-terminal Cys residue to give a thioester-linked intermediate as the initial covalent product. Without a change in the reaction conditions, this intermediate undergoes spontaneous, rapid intramolecular reaction to form a native peptide bond at the ligation site (Baggiolini M et al. (1992) FEBS Lett. 307:97-101; Clark-Lewis I et al., J. Biol. Chem., 269:16075 (1994); Clark-Lewis I et al., Biochemistry, 30:3128 (1991); Rajarathnam K et al., Biochemistry 33:6623-30 (1994)).

Alternatively, unprotected peptide segments may be chemically linked where the bond formed between the peptide segments as a result of the chemical ligation is an unnatural (nonpeptide) bond (Schnolzer, M et al. Science, 256:221 (1992)). This technique has been used to synthesize analogs of protein domains as well as large amounts of relatively pure proteins with full biological activity (deLisle Milton R C et al., Techniques in Protein Chemistry IV. Academic Press, New York, pp. 257-267 (1992)).

The term “antibodies” is used herein in a broad sense and includes both polyclonal and monoclonal antibodies. In addition to intact immunoglobulin molecules, also included in the term “antibodies” are fragments or polymers of immunoglobulin molecules, and human or humanized versions of immunoglobulin molecules or fragments thereof. These may be chosen for their ability to interact with FS 1-78, FS 6-21, FS SMC1A, or other novopeptides or targets of interest, and in embodiments may be used such that tumor growth is inhibited. The antibodies can be tested for their desired activity using the in vitro assays described herein, or by analogous methods, after which their in vivo therapeutic and/or prophylactic activities may be tested according to known clinical testing methods.

As used herein, the term “antibody” encompasses, but is not limited to, whole immunoglobulin (i.e., an intact antibody) of any class. Native antibodies are usually heterotetrameric glycoproteins, composed of two identical light (L) chains and two identical heavy (H) chains. Typically, each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V(H)) followed by a number of constant domains. Each light chain has a variable domain at one end (V(L)) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light and heavy chain variable domains. The light chains of antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (k) and lambda (l), based on the amino acid sequences of their constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of human immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG-I, IgG-2, IgG-3, and IgG-4; IgA-I and IgA-2. One skilled in the art would recognize the comparable classes for mouse. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively.

The term “variable” is used herein to describe certain portions of the variable domains that differ in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not usually evenly distributed through the variable domains of antibodies. It is typically concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of the variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a beta sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the beta sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of antibodies (see Kabat E. A. et al., “Sequences of Proteins of Immunological Interest,” National Institutes of Health, Bethesda, Md.). The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.

As used herein, the term “antibody or fragments thereof encompasses chimeric antibodies and hybrid antibodies, with dual or multiple antigen or epitope specificities, and fragments, such as F(ab′)2, Fab′, Fab, sFv, scFv, and the like, including hybrid fragments. Thus, fragments of the antibodies that retain the ability to bind their specific antigens are provided. For example, fragments of antibodies which maintain FS 1-78, FS 6-21, FS SMC IA binding activity are included within the meaning of the term “antibody or fragment thereof” Such antibodies and fragments can be made by techniques known in the art and can be screened for specificity and activity according to the methods set forth in the Examples and in general methods for producing antibodies and screening antibodies for specificity and activity (See Harlow and Lane. Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988)).

Also included within the meaning of “antibody or fragments thereof” are conjugates of antibody fragments and antigen binding proteins (single chain antibodies) as described, for example, in U.S. Pat. No. 4,704,692, the contents of which are hereby incorporated by reference.

The fragments, whether attached to other sequences or not, can also include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the antibody or antibody fragment is not significantly altered or impaired compared to the non-modified antibody or antibody fragment. These modifications can provide for some additional property, such as to remove/add amino acids capable of disulfide bonding, to increase its bio-longevity, to alter its secretory characteristics, etc. In any case, the antibody or antibody fragment must possess a bioactive property, such as specific binding to its cognate antigen. Functional or active regions of the antibody or antibody fragment may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the antibody or antibody fragment. (Zoller, M J. Curr. Opin. Biotechnol. 3:348-354, 1992).

The term “monoclonal antibody” as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies within the population are identical except for possible naturally occurring mutations that may be present in a small subset of the antibody molecules. The monoclonal antibodies herein specifically include “chimeric” antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired antagonistic activity (See, U.S. Pat. No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sd. USA, 81:6851-6855 (1984)).

The disclosed monoclonal antibodies can be made using any procedure which produces monoclonal antibodies. For example, disclosed monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro, e.g., using the HIV Env-CD4-co-receptor complexes described herein.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567 (Cabilly et al.). DNA encoding the disclosed monoclonal antibodies can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). Libraries of antibodies or active antibody fragments can also be generated and screened using phage display techniques, e.g., as described in U.S. Pat. No. 5,804,440 to Burton et al. and U.S. Pat. No. 6,096,441 to Barbas et al.

In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can be performed using papain. Examples of papain digestion are described in WO 94/29348 published Dec. 22, 1994 and U.S. Pat. No. 4,342,566. Papain digestion of antibodies typically produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fe fragment. Pepsin treatment yields a fragment that has two antigen combining sites and is still capable of cross-linking antigen.

As used herein, the term “antibody” or “antibodies” can also refer to a human antibody and/or a humanized antibody, where context so indicates. Many non-human antibodies (e.g., those derived from mice, rats, or rabbits) are naturally antigenic in humans, and thus can give rise to undesirable immune responses when administered to humans. Therefore, the use of human or humanized antibodies in the methods serves to lessen the chance that an antibody administered to a human will evoke an undesirable immune response.

In embodiments, human antibodies can be prepared using any operable technique. Examples of techniques for human monoclonal antibody production include those described by Cole et al. (Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77, 1985) and by Boemer et al. (J. Immunol., 147(1):86-95, 1991). Human antibodies (and fragments thereof) can also be produced using phage display libraries (Hoogenboom et al., J. Mol. Biol, 227:381, 1991; Marks et al., J Mol. Biol, 222:581, 1991).

Human antibodies can also be obtained from transgenic animals. For example, transgenic, mutant mice that are capable of producing a full repertoire of human antibodies, in response to immunization, have been described (see, e.g., Jakobovits et al., Proc. Natl Acad. ScL USA, 90:2551-255 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggermann et al., Year in Immunol., 7:33 (1993)). Specifically, the homozygous deletion of the antibody heavy chain joining region (J(H)) gene in these chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production, and the successful transfer of the human germ-line antibody gene array into such germ-line mutant mice results in the production of human antibodies upon antigen challenge. Antibodies having the desired activity are selected using Env-CD4-co-receptor complexes as described herein.

Antibody humanization techniques generally involve the use of recombinant DNA technology to manipulate the DNA sequence encoding one or more polypeptide chains of an antibody molecule. Accordingly, a humanized form of a non-human antibody (or a fragment thereof) is a chimeric antibody or antibody chain (or a fragment thereof, such as an Fv, Fab, Fab′, or other antigen-binding portion of an antibody) which contains a portion of an antigen binding site from a non-human (donor) antibody integrated into the framework of a human (recipient) antibody.

To generate a humanized antibody, residues from one or more complementarity determining regions (CDRs) of a recipient (human) antibody molecule are replaced by residues from one or more CDRs of a donor (non-human) antibody molecule that is known to have desired antigen binding characteristics (e.g., a certain level of specificity and affinity for the target antigen), in some instances, Fv framework (FR) residues of the human antibody are replaced by corresponding non-human residues. Humanized antibodies may also contain residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human, in practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. Humanized antibodies generally contain at least a portion of an antibody constant region (Fe), typically that of a human antibody (Jones et al., Nature, 321:522-525 (1986), Reichmann et al., Nature, 332:323-327 (1988), and Presta, Curr. Opin. Struct. Biol, 2:593-596 (1992)).

Methods for humanizing non-human antibodies are well known in the art. For example, humanized antibodies can be generated according to the methods of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986), Riechmann et al., Nature, 332:323-327 (1988), Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Methods that can be used to produce humanized antibodies are also described in U.S. Pat. No. 4,816,567 (Cabilly et al.), U.S. Pat. No. 5,565,332 (Hoogenboom et al.), U.S. Pat. No. 5,721,367 (Kay et al.), U.S. Pat. No. 5,837,243 (Deo et al.), U.S. Pat. No. 5,939,598 (Kucherlapati et al.), U.S. Pat. No. 6,130,364 (Jakobovits et al.), and U.S. Pat. No. 6,180,377 (Morgan et al.).

Administration of the antibodies can be carried out as disclosed herein. Nucleic acid approaches for antibody delivery also exist. Broadly neutralizing antibodies and antibody fragments can also be administered to patients or subjects as a nucleic acid preparation (e.g., DNA or RNA) that encodes the antibody or antibody fragment, such that the patient's or subject's own cells take up the nucleic acid and produce and secrete the encoded antibody or antibody fragment. The delivery of the nucleic acid can be by any operable means, such as, for example, those disclosed herein.

In embodiments, compositions disclosed herein can be used as targets for any combinatorial technique to identify molecules or macromolecular molecules that interact with the disclosed compositions in a desired way. Also disclosed are the compositions that are identified through combinatorial techniques or screening techniques in which the compositions disclosed in SEQ ID NOS: 2, 4, 6, and 8 or portions thereof, or other novopeptides disclosed herein or portions thereof, are used as the target in a combinatorial or screening protocol.

It is understood that when using the disclosed compositions in combinatorial techniques or screening methods, molecules, such as macromolecules, may be identified that have particular desired properties such as inhibition or stimulation of the target molecule's function. The molecules identified and isolated when using the disclosed compositions are also disclosed.

Combinatorial chemistry includes but is not limited to all art-accepted methods for isolating small molecules or macromolecules that are capable of binding either a small molecule or another macromolecule, typically in an iterative process. Proteins, oligonucleotides, and sugars are examples of macromolecules. For example, oligonucleotide molecules with a given function, such as, for example, catalysis or ligand-binding, can be isolated from a complex mixture of random oligonucleotides in what has been referred to as “in vitro genetics” (Szostak, TIBS 19:89, 1992). One synthesizes a large pool of molecules bearing random and defined sequences and subjects that complex mixture, for example, approximately 1015 individual sequences in 100 μg of a 100 nucleotide RNA, to some selection and enrichment process. Through repeated cycles of affinity chromatography and PCR amplification of the molecules bound to the ligand on the column, Ellington and Szostak (1990) estimated that 1 in 1010 RNA molecules folded in such a way as to bind a small molecule dye. DNA molecules with such ligand-binding behavior have been isolated as well (Ellington and Szostak, 1992; Bock et al, 1992). Techniques aimed at similar goals exist for small organic molecules, proteins, antibodies and other macromolecules known to those of skill in the art. Screening sets of molecules for a desired activity whether based on small organic libraries, oligonucleotides, or antibodies is broadly referred to as combinatorial chemistry. Combinatorial techniques are particularly suited for defining binding interactions between molecules and for isolating molecules that have a specific binding activity, often called aptamers when the macromolecules are nucleic acids.

There are a number of methods for isolating proteins which either have de novo activity or a modified activity. For example, phage display libraries have been used to isolate numerous peptides that interact with a specific target. (See for example, U.S. Pat. Nos. 6,031,071; 5,824,520; 5,596,079; and 5,565,332 which are herein incorporated by reference at least for their material related to phage display and methods relate to combinatorial chemistry)

A method for isolating proteins that have a given function is described by Roberts and Szostak (Roberts R. W. and Szostak J. W. Proc. Natl. Acad. Sci. USA, 94(23)12997-302 (1997). This combinatorial chemistry method couples the functional power of proteins and the genetic power of nucleic acids. An RNA molecule is generated in which a puromycin molecule is covalently attached to the 3′ end of the RNA molecule. An in vitro translation of this modified RNA molecule causes the correct protein, encoded by the RNA to be translated. In addition, because of the attachment of the puromycin, a peptidyl acceptor which cannot be extended, the growing peptide chain is attached to the puromycin which is attached to the RNA. Thus, the protein molecule is attached to the genetic material that encodes it. Normal in vitro selection procedures can now be employed to isolate functional peptides. Once the selection procedure for peptide function is complete traditional nucleic acid manipulation procedures are performed to amplify the nucleic acid that codes for the selected functional peptides. After amplification of the genetic material, new RNA is transcribed with puromycin at the 3′ end, new peptide is translated and another functional round of selection is performed. Thus, protein selection can be performed in an iterative manner similar to nucleic acid selection techniques. The peptide which is translated is controlled by the sequence of the RNA attached to the puromycin. This sequence can be anything from a random sequence engineered for optimum translation (i.e. no stop codons etc.) or it can be a degenerate sequence of a known RNA molecule to look for improved or altered function of a known peptide. The conditions for nucleic acid amplification and in vitro translation are well known to those of ordinary skill in the art and may be performed as in Roberts and Szostak (Roberts R. W. and Szostak J. W. Proc. Natl. Acad. Sci. USA, 94(23)12997-302 (1997)).

Another combinatorial method designed to isolate peptides is described in Cohen et al. (Cohen B. A., et al., Proc. Natl. Acad. Sci. USA 95(24): 14272-7 (1998)). This method utilizes and modifies two-hybrid technology. Yeast two-hybrid systems are useful for the detection and analysis of protein-protein interactions. The two-hybrid system, initially described in the yeast Saccharomyces cerevisiae, is a powerful molecular genetic technique for identifying new regulatory molecules, specific to the protein of interest (Fields and Song, Nature 340:245-6 (1989)). Cohen et al., modified this technology so that novel interactions between synthetic or engineered peptide sequences could be identified which bind a molecule of choice. The benefit of this type of technology is that the selection is done in an intracellular environment. The method utilizes a library of peptide molecules that attach to an acidic activation domain. For example, a peptide such as FS 1-78 may be attached to a DNA binding domain of a transcriptional activation protein, such as Gal 4. By performing the two-hybrid technique on this type of system, molecules that bind peptide FS 1-78, can be identified.

Using methodology well known to those of skill in the art, in combination with various combinatorial libraries, one can isolate and characterize those small molecules or macromolecules, which bind to or interact with the desired target. The relative binding affinity of these compounds can be compared and optimum compounds identified using competitive binding studies, which are well known to those of skill in the art.

Techniques for making combinatorial libraries and screening combinatorial libraries to isolate molecules which bind a desired target are well known to those of skill in the art. Representative techniques and methods can be found in but are not limited to U.S. Pat. Nos. 5,084,824, 5,288,514, 5,449,754, 5,506,337, 5,539,083, 5,545,568, 5,556,762, 5,565,324, 5,565,332, 5,573,905, 5,618,825, 5,619,680, 5,627,210, 5,646,285, 5,663,046, 5,670,326, 5,677,195, 5,683,899, 5,688,696, 5,688,997, 5,698,685, 5,712,146, 5,721,099, 5,723,598, 5,741,713, 5,792,431, 5,807,683, 5,807,754, 5,821,130, 5,831,014, 5,834,195, 5,834,318, 5,834,588, 5,840,500, 5,847,150, 5,856,107, 5,856,496, 5,859,190, 5,864,010, 5,874,443, 5,877,214, 5,880,972, 5,886,126, 5,886,127, 5,891,737, 5,916,899, 5,919,955, 5,925,527, 5,939,268, 5,942,387, 5,945,070, 5,948,696, 5,958,702, 5,958,792, 5,962,337, 5,965,719, 5,972,719, 5,976,894, 5,980,704, 5,985,356, 5,999,086, 6,001,579, 6,004,617, 6,008,321, 6,017,768, 6,025,371, 6,030,917, 6,040,193, 6,045,671, 6,045,755, 6,060,596, and 6,061,636.

Combinatorial libraries can be made from a wide array of molecules using a number of different synthetic techniques. For example, libraries containing fused 2,4-pyrimidinediones (U.S. Pat. No. 6,025,371) dihydrobenzopyrans (U.S. Pat. Nos. 6,017,768 and 5,821,130), amide alcohols (U.S. Pat. No. 5,976,894), hydroxy-amino acid amides (U.S. Pat. No. 5,972,719) carbohydrates (U.S. Pat. No. 5,965,719), 1,4-benzodiazepin-2,5-diones (U.S. Pat. No. 5,962,337), cyclics (U.S. Pat. No. 5,958,792), biaryl amino acid amides (U.S. Pat. No. 5,948,696), thiophenes (U.S. Pat. No. 5,942,387), tricyclic tetrahydroquinolines (U.S. Pat. No. 5,925,527), benzofurans (U.S. Pat. No. 5,919,955), isoquinolines (U.S. Pat. No. 5,916,899), hydantoin and thiohydantoin (U.S. Pat. No. 5,859,190), indoles (U.S. Pat. No. 5,856,496), imidazol-pyrido-indole and imidazol-pyrido-benzothiophenes (U.S. Pat. No. 5,856,107) substituted 2-methylene-2, 3-dihydrothiazoles (U.S. Pat. No. 5,847,150), quinolines (U.S. Pat. No. 5,840,500), PNA (U.S. Pat. No. 5,831,014), containing tags (U.S. Pat. No. 5,721,099), polyketides (U.S. Pat. No. 5,712,146), morpholino-subunits (U.S. Pat. Nos. 5,698,685 and 5,506,337), sulfamides (U.S. Pat. No. 5,618,825), and benzodiazepines (U.S. Pat. No. 5,288,514).

The disclosure hereof provides methods, compositions, and articles of manufacture useful in the formulation of prophylactic and/or therapeutic vaccines to be administered for the purpose of raising an immune response against tumor cells. The disclosure hereof extends to the composition of novopeptide-based vaccines and to methods of administration thereof. A novopeptide-based vaccine may be prepared and administered in any of the ways familiar to persons having ordinary skill in the art, including the very simple approach of preparing a vaccine comprising a novopeptide dissolved or suspended in a suitable carrier, and administering it once or at predetermined intervals to the animal or human patient to be vaccinated. However, success may also be had by other methods, and a particular approach entails genetic immunization using gene gun technology, in which a vaccine is administered in the form of a linear expression element encoding the desired novopeptide, as illustrated in the examples below. The composition of a vaccine may include both novopeptide and other components. The inclusion of multiple distinct novopeptides may prove useful in improving the level of immunoprotection conferred, and/or by conferring immunoprotection against additional tumor types, as illustrated by the examples below. In some embodiments, single novopeptides may be found to confer immunoprotection against more than one tumor type, but the repertoire of target tumor types may also be expanded by inclusion of additional novopeptides. The inclusion of multiple novopeptides is of particular utility in vaccines intended for administration in humans, due to the desirability of including a number and selection of novopeptides sufficient to ensure that at least one novopeptide in the vaccine will be capable of being displayed by at least one HLA type present in each individual in a predetermined percentage of the target population. In embodiments, two or more novopeptides may be fused into a single entity; this is a standard practice in the field of vaccine design. Novopeptide-based vaccines may include other components familiar to a person having ordinary skill in the art for improving the immunoprotection conferred or otherwise improving the efficacy and/or safety of the vaccine formulation, including without limitation and by way of example only, adjuvants and hapten carriers.

There are a number of compositions and methods which can be used to deliver nucleic acids to cells, either in vitro or in vivo. These methods and compositions can largely be broken down into two classes: viral based delivery systems and non-viral based delivery systems. For example, the nucleic acids can be delivered through a number of direct delivery systems such as electroporation, lipofection, calcium phosphate precipitation, plasmids, viral vectors, viral nucleic acids, phage nucleic acids, phages, cosmids, or via transfer of genetic material in cells or carriers such as cationic liposomes. Appropriate means for transfection, including viral vectors, chemical transfectants, or physico-mechanical methods such as electroporation and direct diffusion of DNA, are described by, for example, in Wolff, J. A., et al., Science, 247, 1465-1468, (1990); and Wolff, J. A. Nature, 352, 815-818, (1991). Such methods are well known in the art and readily adaptable for use with the compositions and methods described herein. In certain cases, the methods will be modifed to specifically function with large DNA molecules. Further, these methods can be used to target certain diseases and cell populations by using the targeting characteristics of the carrier.

Transfer vectors can be any nucleotide construction used to deliver genes into cells (e.g., a plasmid), or as part of a general strategy to deliver genes, e.g., as part of recombinant retrovirus or adenovirus (Ram et al. Cancer Res. 53:83-88, (1993)).

As used herein, plasmid or viral vectors are agents that transport the disclosed nucleic acids, such as peptide FS 1-78 into the cell without degradation and include a promoter yielding expression of the gene in the cells into which it is delivered. Viral vectors may include, for example, Adenovirus, Adeno-associated virus, Herpes virus, Vaccinia virus, Polio virus, AIDS virus, neuronal trophic virus, Sindbis and other RNA viruses, including these viruses with the HIV backbone. Also preferred are any viral families which share the properties of these viruses which make them suitable for use as vectors. Retroviruses include Murine Maloney Leukemia virus, MMLV, and retroviruses that express the desirable properties of MMLV as a vector. Retroviral vectors are able to carry a larger genetic payload, i.e., a transgene or marker gene, than other viral vectors, and for this reason are a commonly used vector. However, they are not as useful in non-proliferating cells. Adenovirus vectors are relatively stable and easy to work with, have high titers, and can be delivered in aerosol formulation, and can transfect non-dividing cells. Pox viral vectors are large and have several sites for inserting genes, they are thermostable and can be stored at room temperature. A preferred embodiment is a viral vector which has been engineered so as to suppress the immune response of the host organism, elicited by the viral antigens. Preferred vectors of this type will carry coding regions for Interleukin 8 or 10.

Viral vectors can have higher transaction (ability to introduce genes) abilities than chemical or physical methods to introduce genes into cells. Typically, viral vectors contain, nonstructural early genes, structural late genes, an RNA polymerase II transcript, inverted terminal repeats necessary for replication and encapsidation, and promoters to control the transcription and replication of the viral genome. When engineered as vectors, viruses typically have one or more of the early genes removed and a gene or gene/promoter cassette is inserted into the viral genome in place of the removed viral DNA. Constructs of this type can carry up to about 8 kb of foreign genetic material. The necessary functions of the removed early genes are typically supplied by cell lines which have been engineered to express the gene products of the early genes in trans.

A retrovirus is an animal virus belonging to the virus family of Retroviridae, including any types, subfamilies, genus, or tropisms. Retroviral vectors, in general, are described by Verma, L M., Retroviral vectors for gene transfer, in Microbiology-1985, American Society for Microbiology, pp. 229-232, Washington, (1985), which is incorporated by reference herein. Examples of methods for using retroviral vectors for gene therapy are described in U.S. Pat. Nos. 4,868,116 and 4,980,286; PCT applications WO 90/02806 and WO 89/07136; and Mulligan, (Science 260:926-932 (1993)); the teachings of which are incorporated herein by reference.

A retrovirus is essentially a package which has packed into it nucleic acid cargo. The nucleic acid cargo carries with it a packaging signal, which ensures that the replicated daughter molecules will be efficiently packaged within the package coat. In addition to the package signal, there are a number of molecules which are needed in cis, for the replication, and packaging of the replicated virus. Typically a retroviral genome, contains the gag, pol, and env genes which are involved in the making of the protein coat. It is the gag, pol, and env genes which are typically replaced by the foreign DNA that it is to be transferred to the target cell. Retrovirus vectors typically contain a packaging signal for incorporation into the package coat, a sequence which signals the start of the gag transcription unit, elements necessary for reverse transcription, including a primer binding site to bind the tRNA primer of reverse transcription, terminal repeat sequences that guide the switch of RNA strands during DNA synthesis, a purine rich sequence 5′ to the 3′ LTR that serve as the priming site for the synthesis of the second strand of DNA synthesis, and specific sequences near the ends of the LTRs that enable the insertion of the DNA state of the retrovirus to insert into the host genome. The removal of the gag, pol, and env genes allows for about 8 kb of foreign sequence to be inserted into the viral genome, become reverse transcribed, and upon replication be packaged into a new retroviral particle. This amount of nucleic acid is sufficient for the delivery of a one to many genes depending on the size of each transcript. It is preferable to include either positive or negative selectable markers along with other genes in the insert.

Since the replication machinery and packaging proteins in most retroviral vectors have been removed (gag, pol, and env), the vectors are typically generated by placing them into a packaging cell line. A packaging cell line is a cell line which has been transfected or transformed with a retrovirus that contains the replication and packaging machinery, but lacks any packaging signal. When the vector carrying the DNA of choice is transfected into these cell lines, the vector containing the gene of interest is replicated and packaged into new retroviral particles, by the machinery provided in cis by the helper cell. The genomes for the machinery are not packaged because they lack the necessary signals.

The construction of replication-defective adenoviruses has been described (Berkner et al., J. Virology 61:1213-1220 (1987); Massie et al., Mol. Cell. Biol. 6:2872-2883 (1986); Raj-Ahmad et al., J. Virology 51:261-21 A (1986); Davidson et al., J. Virology 61:1226-1239 (1987); Zhang “Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis” BioTechniques 15:868-872 (1993)). The benefit of the use of these viruses as vectors is that they are limited in the extent to which they can spread to other cell types, since they can replicate within an initial infected cell, but are unable to form new infectious viral particles. Recombinant adenoviruses have been shown to achieve high efficiency gene transfer after direct, in vivo delivery to airway epithelium, hepatocytes, vascular endothelium, CNS parenchyma and a number of other tissue sites (Morsy, J. Clin. Invest. 92:1580-1586 (1993); Kirshenbaum, J. Clin. Invest. 92:381-387 (1993); Roessler, J Clin. Invest. 92:1085-1092 (1993); Moullier, Nature Genetics 4:154-159 (1993); La Salle, Science 259:988-990 (1993); Gomez-Foix, J Biol. Chem. 267:25129-25134 (1992); Rich, Human Gene Therapy 4:461-476 (1993); Zabner, Nature Genetics 6:75-83 (1994); Guzman, Circulation Research 73:1201-1207 (1993); Bout, Human Gene Therapy 5:3-10 (1994); Zabner, Cell 75:207-216 (1993); Caillaud, Eur. J. Neuroscience 5:1287-1291 (1993); and Ragot, J. Gen. Virology 74:501-507 (1993)). Recombinant adenoviruses achieve gene transduction by binding to specific cell surface receptors, after which the virus is internalized by receptor-mediated endocytosis, in the same manner as wild type or replication-defective adenovirus (Chardonnet and Dales, Virology 40:462-477 (1970); Brown and Burlingham, J. Virology 12:386-396 (1973); Svensson and Persson, J. Virology 55:442-449 (1985); Seth, et al., J. Virol. 51:650-655 (1984); Seth, et al., Mol. Cell. Biol. 4:1528-1533 (1984); Varga et al., J. Virology 65:6061-6070 (1991); Wickham et al., Cell 73:309-319 (1993)).

A viral vector can be one based on an adenovirus which has had the E1 gene removed and these virions are generated in a cell line such as the human 293 cell line. In another embodiment both the E1 and E3 genes are removed from the adenovirus genome.

Another type of viral vector is based on an adeno-associated virus (AAV). This defective parvovirus is a preferred vector because it can infect many cell types and is nonpathogenic to humans. AAV type vectors can transport about 4 to 5 kb and wild type AAV is known to stably insert into chromosome 19. Vectors which contain this site specific integration property are preferred. An especially preferred embodiment of this type of vector is the P4.1 C vector produced by Avigen, San Francisco, Calif., which can contain the herpes simplex virus thymidine kinase gene, HSV-tk, and/or a marker gene, such as the gene encoding the green fluorescent protein, GFP.

In another type of AAV virus, the AAV contains a pair of inverted terminal repeats (ITRs) which flank at least one cassette containing a promoter which directs cell-specific expression operably linked to a heterologous gene. Heterologous in this context refers to any nucleotide sequence or gene which is not native to the AAV or B19 parvovirus.

Typically the AAV and B 19 coding regions have been deleted, resulting in a safe, non-cytotoxic vector. The AAV ITRs, or modifications thereof, confer infectivity and site-specific integration, but not cytotoxicity, and the promoter directs cell-specific expression. U.S. Pat. No. 6,261,834 is herein incorporated by reference for material related to the AAV vector.

The disclosed vectors thus provide DNA molecules which are capable of integration into a mammalian chromosome without substantial toxicity.

The inserted genes in viral and retroviral vectors usually contain promoters, and/or enhancers to help control the expression of the desired gene product. A promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site. A promoter contains core elements required for basic interaction of RNA polymerase and transcription factors, and may contain upstream elements and response elements.

Molecular genetic experiments with large human herpes viruses have provided a means whereby large heterologous DNA fragments can be cloned, propagated and established in cells permissive for infection with herpes viruses (Sun et al., Nature Genetics 8: 33-41, 1994; Cotter and Robertson, Curr Opin Mol Ther 5: 633-644, 1999). These large DNA viruses (herpes simplex virus (HSV) and Epstein-Barr virus (EBV), have the potential to deliver fragments of human heterologous DNA>150 kb to specific cells. EBV recombinants can maintain large pieces of DNA in the infected B-cells as episomal DNA. Individual clones carried human genomic inserts up to 330 kb appeared genetically stable the maintenance of these episomes requires a specific EBV nuclear protein, EBNA1, constitutively expressed during infection with EBV. Additionally, these vectors can be used for transfection, where large amounts of protein can be generated transiently in vitro. Herpes virus amplicon systems are also being used to package pieces of DNA>220 kb and to infect cells that can stably maintain DNA as episomes.

Other useful systems include, for example, replicating and host-restricted non-replicating Vaccinia virus vectors.

In embodiments, compositions disclosed herein can be delivered to target cells in a variety of ways. For example, the compositions can be delivered through electroporation, or through lipofection, or through calcium phosphate precipitation. The delivery mechanism chosen will depend in part on the type of cell targeted and whether the delivery is occurring for example in vivo or in vitro.

Thus, the compositions can comprise, in addition to the disclosed FS 1-78, FS 6-21, FS SMC1A, and other disclosed novopeptides, vectors, such as, for example, lipids such as liposomes, which may include cationic liposomes (e.g., DOTMA, DOPE, DC-cholesterol) and/or anionic liposomes. Liposomes can further comprise proteins to facilitate targeting a particular cell, if desired. Administration of a composition comprising a compound and a cationic liposome can be administered to the blood afferent to a target organ or inhaled into the respiratory tract to target cells of the respiratory tract. Regarding liposomes, see, e.g., Brigham et al. Am. J. Resp. Cell. Mol. Biol. 1:95-100 (1989); Feigner et al. Proc. Natl. Acad. Sci USA 84:7413-7417 (1987); U.S. Pat. No. 4,897,355. Furthermore, the compound can be administered as a component of a microcapsule that can be targeted to specific cell types, such as macrophages, or where the diffusion of the compound or delivery of the compound from the microcapsule is designed for a specific rate or dosage.

In the methods described above which include the administration and uptake of exogenous DNA into the cells of a subject (i.e., gene transduction or transfection), delivery of the compositions to cells can be via a variety of mechanisms. As one example, delivery can be via a liposome, using commercially available liposome preparations such as LIPOFECTIN, LIPOFECTAMINE (GIBCO-BRL, Inc., Gaithersburg, Md.), SUPERFECT (Qiagen, Inc. Hilden, Germany) and TRANSFECTAM (Promega Biotec, Inc., Madison, Wis.), as well as other liposomes developed according to procedures standard in the art. In addition, the disclosed nucleic acid or vector can be delivered in vivo by electroporation, the technology for which is available from Genetronics, Lie. (San Diego, Calif.) as well as by means of a SONOPORATION machine (hnaRx Pharmaceutical Corp., Tucson, Ariz.).

In embodiments, the materials may be in solution or suspension (for example, incorporated into microparticles, liposomes, or cells). These may be targeted to a particular cell type via antibodies, receptors, or receptor ligands. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al., Bioconjugate Chem., 2:447-451, (1991); Bagshawe, K. D., Br. J. Cancer, 60:275-281, (1989); Bagshawe, et al., Br. J. Cancer, 58:700-703, (1988); Senter, et al., Bioconjugate Chem., 4:3-9, (1993); Battelli, et al., Cancer Immunol. Immunother., 35:421-425, (1992); Pietersz and McKenzie, Immunolog. Reviews, 129:57-80, (1992); and Roffler, et al., Biochem. Pharmacol, 42:2062-2065, (1991)). These techniques can be used for a variety of other specific cell types. Vehicles such as “stealth” and other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic retroviral targeting of murine glioma cells in vivo. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Hughes et al., Cancer Research, 49:6214-6220, (1989); and Litzinger and Huang, Biochimica et Biophysica Acta, 1104:179-187, (1992)). In general, receptors are involved in pathways of endocytosis, either constitutive or ligand induced. These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome in which the receptors are sorted, and then either recycle to the cell surface, become stored intracellularly, or are degraded in lysosomes. The internalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligand, and receptor-level regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and ligand concentration. Molecular and cellular mechanisms of receptor-mediated endocytosis have been reviewed (Brown and Greene, DNA and Cell Biology 10:6, 399-409 (1991)).

Nucleic acids that are delivered to cells which are to be integrated into the host cell genome typically contain integration sequences. These sequences are often viral related sequences, particularly when viral based systems are used. These viral integration systems can also be incorporated into nucleic acids which are to be delivered using a non-nucleic acid based system of delivery, such as a liposome, so that the nucleic acid contained in the delivery system can become integrated into the host genome.

Other general techniques for integration into the host genome include, for example, systems designed to promote homologous recombination with the host genome. These systems typically rely on sequence flanking the nucleic acid to be expressed that has enough homology with a target sequence within the host cell genome that recombination between the vector nucleic acid and the target nucleic acid takes place, causing the delivered nucleic acid to be integrated into the host genome. These systems and the methods necessary to promote homologous recombination are known to those of skill in the art.

In embodiments, compositions disclosed herein can be administered in a pharmaceutically acceptable carrier and can be delivered to the subject's cells in vivo and/or ex vivo by a variety of mechanisms well known in the art (e.g., uptake of naked DNA, liposome fusion, intramuscular injection of DNA via a gene gun, endocytosis and the like).

If ex vivo methods are employed, cells or tissues can be removed and maintained outside the body according to standard protocols well known in the art. The compositions can be introduced into the cells via any gene transfer mechanism, such as, for example, calcium phosphate mediated gene delivery, electroporation, microinjection or proteoliposomes. The transduced cells can then be infused (e.g., in a pharmaceutically acceptable carrier) or homotopically transplanted back into the subject per standard methods for the cell or tissue type. Standard methods are known for transplantation or infusion of various cells into a subject.

The nucleic acids that are delivered to cells typically contain expression controlling systems. For example, the inserted genes in viral and retroviral systems usually contain promoters, and/or enhancers to help control the expression of the desired gene product. A promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site. A promoter contains core elements required for basic interaction of RNA polymerase and transcription factors, and may contain upstream elements and response elements.

Promoters controlling transcription from vectors in mammalian host cells may be obtained from various sources, for example, the genomes of viruses such as: polyoma, Simian Virus 40 (SV40), adenovirus, retroviruses, hepatitis-B virus and most preferably cytomegalovirus, or from heterologous mammalian promoters, e.g. beta actin promoter. The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment which also contains the SV40 viral origin of replication (Fiers et al., Nature, 273: 113 (1978)). The immediate early promoter of the human cytomegalovirus is conveniently obtained as a HmdlH E restriction fragment (Greenway, P J. et al., Gene 18: 355-360 (1982)). Of course, promoters from the host cell or related species also are useful herein.

Enhancer generally refers to a sequence of DNA that functions at no fixed distance from the transcription start site and can be either 5′ (Laimins, L. et al., Proc. Natl. Acad. ScL 78:993 (1981)) or 3′ (Lusky, M. L., et al., Mol. Cell Bio. 3: 1108 (1983)) to the transcription unit. Furthermore, enhancers can be within an intron (Banerji, J. L. et al., Cell 33: 729 (1983)) as well as within the coding sequence itself (Osborne, T. F., et al., Mol. Cell Bio. 4: 1293 (1984)). They are usually between 10 and 300 bp in length, and they function in cis. Enhancers function to increase transcription from nearby promoters. Enhancers also often contain response elements that mediate the regulation of transcription. Promoters can also contain response elements that mediate the regulation of transcription. Enhancers often determine the regulation of expression of a gene. While many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, -fetoprotein and insulin), typically one will use an enhancer from a eukaryotic cell virus for general expression. Preferred examples are the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

The promoter and/or enhancer may be specifically activated either by light or specific chemical events which trigger their function. Systems can be regulated by reagents such as tetracycline and dexamethasone. There are also ways to enhance viral vector gene expression by exposure to irradiation, such as gamma irradiation, or alkylating chemotherapy drugs.

In certain embodiments the promoter and/or enhancer region can act as a constitutive promoter and/or enhancer to maximize expression of the region of the transcription unit to be transcribed, in certain constructs the promoter and/or enhancer region be active in all eukaryotic cell types, even if it is only expressed in a particular type of cell at a particular time. A preferred promoter of this type is the CMV promoter (650 bases). Other preferred promoters are SV40 promoters, cytomegalovirus (full length promoter), and retroviral vector LTF.

It has been shown that regulatory elements can be cloned and used to construct expression vectors that are selectively expressed in specific cell types such as melanoma cells. The glial fibrillary acetic protein (GFAP) promoter has been used to selectively express genes in cells of glial origin.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human or nucleated cells) may also contain sequences necessary for the termination of transcription which may affect mRNA expression. These regions are transcribed as polyadenylated segments in the untranslated portion of the mRNA encoding tissue factor protein. The 3′ untranslated regions also include transcription termination sites. It is preferred that the transcription unit also contains a polyadenylation region. One benefit of this region is that it increases the likelihood that the transcribed unit will be processed and transported like mRNA. The identification and use of polyadenylation signals in expression constructs is well established. It is preferred that homologous polyadenylation signals be used in the transgene constructs, in certain transcription units, the polyadenylation region is derived from the SV40 early polyadenylation signal and consists of about 400 bases. It is also preferred that the transcribed units contain other standard sequences alone or in combination with the above sequences improve expression from, or stability of, the construct.

In embodiments, viral vectors may include nucleic acid sequence encoding a marker product. This marker product is used to determine if the gene has been delivered to the cell and once delivered is being expressed. Example marker genes are the E. Coli lacZ gene, which encodes P-galactosidase, and green fluorescent protein.

In some embodiments a marker may be a selectable marker. Examples of suitable selectable markers for mammalian cells are dihydrofolate reductase (DHFR), thymidine kinase, neomycin, neomycin analog G418, hydromycin, and puromycin. When such selectable markers are successfully transferred into a mammalian host cell, the transformed mammalian host cell can survive if placed under selective pressure. There are two widely used distinct categories of selective regimes. The first category is based on a cell's metabolism and the use of a mutant cell line which lacks the ability to grow independent of a supplemented media. Two examples are: CHO DHFR-cells and mouse LTK-cells. These cells lack the ability to grow without the addition of such nutrients as thymidine or hypoxanthine. Because these cells lack certain genes necessary for a complete nucleotide synthesis pathway, they cannot survive unless the missing nucleotides are provided in a supplemented media. An alternative to supplementing the media is to introduce an intact DHFR or TK gene into cells lacking the respective genes, thus altering their growth requirements. Individual cells which were not transformed with the DHFR or TK gene will not be capable of survival in non-supplemented media.

A second category is dominant selection, which refers to a selection scheme that may be used in any cell type and does not require the use of a mutant cell line. These schemes typically use a drug to arrest growth of a host cell. Those cells which have a novel gene would express a protein conveying drug resistance and would survive the selection. Examples of such dominant selection use the drugs neomycin, (Southern P. and Berg, P., J. Molec. Appl. Genet. 1: 327 (1982)), mycophenolic acid, (Mulligan, R. C. and Berg, P. Science 209: 1422 (1980)) or hygromycin, (Sugden, B. et al., Mol. Cell. Biol. 5: 410-413 (1985)). These three examples employ bacterial genes under eukaryotic control to convey resistance to the appropriate drug G418 or neomycin (geneticin), xgpt (mycophenolic acid) or hygromycin, respectively. Others include the neomycin analog G418 and puramycin.

In embodiments, compositions disclosed herein may be administered in vivo in a pharmaceutically acceptable carrier. By “pharmaceutically acceptable” is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject, along with the nucleic acid or vector, without causing unacceptable biological effects or interacting in a deleterious manner with other components of the pharmaceutical composition in which it is contained. The carrier may be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.

In embodiments, compositions disclosed herein may be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermally, extracorporeally, topically or the like, including topical intranasal administration or administration by inhalant. As used herein, “topical intranasal administration” means delivery of the compositions into the nose and nasal passages through one or both of the nares and can comprise delivery by a spraying mechanism or droplet mechanism, or through aerosolization of the nucleic acid or vector. Administration of the compositions by inhalant can be through the nose or mouth via delivery by a spraying or droplet mechanism. Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation. The exact amount of the compositions required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the allergic disorder being treated, the particular nucleic acid or vector used, its mode of administration and the like. Thus, it is not possible to specify an exact amount for every composition. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.

Parenteral administration of the composition, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Pat. No. 3,610,795, which is incorporated by reference herein.

In embodiments, materials to be administered may be in solution or suspension (for example, incorporated into microparticles, liposomes, or cells). These may be targeted to a particular cell type via antibodies, receptors, or receptor ligands. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al., Bioconjugate Chem., 2:447-451, (1991); Bagshawe, K. D., Br. J. Cancer, 60:275-281, (1989); Bagshawe, et al., Br. J. Cancer, 58:700-703, (1988); Senter, et al., Bioconjugate Chem., 4:3-9, (1993); Battelli, et al., Cancer Immunol. Immunother., 35:421-425, (1992); Pietersz and McKenzie, Immunolog. Reviews, 129:57-80, (1992); and Roffler, et al., Biochem. Pharmacol, 42:2062-2065, (1991)). Vehicles such as “stealth” and other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic retroviral targeting of murine glioma cells in vivo. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Hughes et al., Cancer Research, 49:6214-6220, (1989); and Litzinger and Huang, Biochimica et Biophysica Acta, 1104:179-187, (1992)). In general, receptors are involved in pathways of endocytosis, either constitutive or ligand induced. These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome in which the receptors are sorted, and then either recycle to the cell surface, become stored intracellularly, or are degraded in lysosomes. The internalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligand, and receptor-level regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and ligand concentration. Molecular and cellular mechanisms of receptor-mediated endocytosis have been reviewed (Brown and Greene, DNA and Cell Biology 10:6, 399-409 (1991)).

In embodiments, compositions disclosed herein, including antibodies, can be used therapeutically in combination with a pharmaceutically acceptable carrier. Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy (19th ed.) ed. A. R. Gennaro, Mack Publishing Company, Easton, Pa. 1995. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically-acceptable carrier include, but are not limited to, saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of composition being administered.

Pharmaceutical carriers are known to those skilled in the art. These most typically would be standard carriers for administration of drugs to humans, including solutions such as sterile water, saline, and buffered solutions at physiological pH. The compositions can be administered intramuscularly or subcutaneously. Other compounds will be administered according to standard procedures used by those skilled in the art.

In embodiments, compositions disclosed herein may be administered in or with pharmaceutical compositions, which may include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice. Pharmaceutical compositions may also include one or more active ingredients such as antimicrobial agents, anti-inflammatory agents, anesthetics, and the like.

In embodiments, pharmaceutical compositions may be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. Administration may be topically (including ophthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip, subcutaneous, intraperitoneal or intramuscular injection. The disclosed antibodies can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.

Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be desirable.

In embodiments, compositions may be administered as or with a pharmaceutically acceptable acid- or base-addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.

In embodiments, effective dosages and schedules for administering compositions disclosed herein may be determined empirically, and making such determinations is within the skill in the art. In embodiments, a dosage range for the administration of the compositions may include a dosage large enough to produce a desired effect in which the symptoms/disorder are/is affected. In embodiments, a dosage should preferably not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like, although adverse effects cannot always be avoided and may be outweighed by the benefits sought. In embodiments, dosage may vary with the age, condition, sex and extent of the disease in the patient, route of administration, or whether other drugs are included in the regimen, and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician in the event of any counter indications. Dosage can vary, and can be administered in one or more dose administrations daily, or according to any dosing schedule found beneficial. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. For example, guidance in selecting appropriate doses for antibodies can be found in the literature on therapeutic uses of antibodies, e.g., Handbook of Monoclonal Antibodies, Ferrone et al., eds., Noges Publications, Park Ridge, N.J., (1985) ch. 22 and pp. 303-357; Smith et al., Antibodies in Human Diagnosis and Therapy, Haber et al., eds., Raven Press, New York (1977) pp. 365-389. A typical daily dosage of an antibody used alone might range from about 1 mg/kg to up to 100 mg/kg of body weight or more per day, depending on the factors mentioned above.

Following administration of a disclosed composition, such as a vaccine or an antibody, for treating, inhibiting, or preventing a cancer, the efficacy of the therapy or prophylaxis can be assessed in various ways well known to the skilled practitioner. For instance, one of ordinary skill in the art will understand that a composition, such as a vaccine or an antibody, disclosed herein is efficacious in treating, inhibiting, or preventing a cancer in a subject by observing that the composition reduces tumor growth or prevents a further increase in tumor size.

Also disclosed herein are embodiments of kits that are drawn to reagents that can be used in practicing the methods disclosed herein. The kits can include any reagent or combination of reagent discussed herein or that would be understood to be required or beneficial in the practice of the disclosed methods. For example, the kits could include primers to perform the amplification reactions discussed in certain embodiments of the methods, as well as the buffers and enzymes required to use the primers as intended. For example, disclosed is a kit for assessing a subject's risk for acquiring prostate cancer, comprising the peptides set forth in SEQ ID Nos: 2, 4, and 8.

In embodiments, there is provided an anti-cancer vaccine, to be administered prophylactically or therapeutically or both to a population comprising a plurality of mammalian subjects in accordance with the disclosure hereof, useful for reducing the susceptibility of the population to at least one cancer. (The use of the word ‘vaccine’ is not intended to limit the disclosure hereof to a particular mechanism of action; although there is sound theoretical and experimental support for an immunological basis for their effectiveness, the disclosure hereof extends to the disclosed compositions and methods regardless of their mechanism of action.) Reducing the susceptibility of the population to at least one cancer may include any improvement in the health status of at least one subject relative to at least one cancer, such as, by way of example only, a temporary or permanent reduction in the likelihood of at least one member of the population contracting a cancer; a temporary or permanent reduction in the incidence rate of a cancer in the population; a temporary or permanent improvement in the average severity, amenability to treatment, and/or average prognosis of the cancer in the population; a temporary or permanent reduction in a rate of tumor progression in at least one member of the population; an improvement in the efficacy of a cancer treatment in at least one member of the population; and/or an improvement in a survival rate in the population relative to at least one cancer; and/or an improvement in the survival time of at least one member of the population after contracting a cancer.

In some embodiments, an anti-cancer vaccine may include at least one peptide component. In embodiments, a peptide component of an anti-cancer vaccine may include a continuous synthetic or recombinant amino acid chain, from about 8 to about 40 amino acids in length, having at least 75%, or 80%, or 85%, or 90%, or 95%, or 99% sequence identity over its length with a continuous amino acid sequence (or continuous portion thereof) according to the formula D1-D2, wherein DI and D2 are amino acid sequences each encoded by a different nucleic acid sequence or portion thereof of a genome of a mammalian species for which the vaccine is intended, wherein D1 is read in its wild-type reading frame, and D2 is read in a non-wild-type reading frame. In some embodiments, the nucleic acid sequence encoding D2 is not contiguous, in the genome of the mammalian species, with the nucleic acid sequence encoding D1; for example, the nucleic acid sequence encoding D2 may comprise all or part of a different gene, a different exon, a non-coding region, a different nucleic acid strand, and/or a different chromosome, relative to the nucleic acid sequence encoding D1. A synthetic or recombinant amino acid chain may include and extend to any non-naturally occurring amino acid chain, such as, for example, an amino acid chain produced by chemical synthesis, by an expression system, by in vitro translation, by chemical, physical, or other isolation, by inducing expression in a host cell such as by genetic immunization, or by any other method resulting in an amino chain having a sequence and/or other characteristics not obtainable from nature.

It will be apparent to persons of skill in the art that the functional characteristics of a peptide may typically be retained in whole or part by other peptides having similar or related sequences, such as where insertions, deletions, and/or substitutions are made that are not so significant in character or degree to disrupt the interactions giving rise to the function of interest. The disclosure hereof extends to anti-cancer vaccine peptide components comprising peptide sequences within the range of similarity to the disclosed sequences that would be regarded by persons of skill in the art as of probable full or partial functional similarity to any of the disclosed sequences. In some embodiments, an anti-cancer vaccine may include in lieu of a peptide component as disclosed herein, a biochemically acceptable substitute. A biochemically acceptable substitute may include any molecular entity that a person of skill in the art would regard as functionally similar or equivalent to a peptide component disclosed herein, such as, for example, a peptide having, relative to a peptide component disclosed herein, an alignment score, obtained according to an art-recognized sequence alignment method, that a person of skill in the art would regard as implying likely full or partial functional similarity, or a peptide differing from a peptide component disclosed herein by reason of fewer than 10, or fewer than 7, or fewer than 5, or fewer than 4, or fewer than 3, or fewer than 2, or fewer than 1 conservative substitutions, or any of the other molecular entities disclosed elsewhere herein or recognized in the art as fully or partially functionally equivalent in their biochemical characteristics to a peptide component disclosed herein.

In embodiments, there is provided a method of reducing the susceptibility of a population including a plurality of mammalian subjects to at least one cancer, the method including administering to at least one member of the population an effective dose of an anti-cancer vaccine.

In some embodiments an anti-cancer vaccine may be administered by any method of administration operable to expose the organism to be vaccinated to an effective dose of the vaccine, such as, for example, by subcutaneous, intramuscular, or other direct administration of an embodiment of the anti-cancer vaccine including one or more peptide components in a pharmaceutically acceptable carrier, and optionally accompanied by a suitable adjuvant, according to an effective administration protocol. In some embodiments, an anti-cancer composition may be administered as a genetic vaccine, and/or may include, for example, a nucleic acid sequence encoding one or more peptide components. In some embodiments, the nucleic acid sequence may form part of a vector, plasmid, LEE, or other entity whereby a cell of the mammalian subject may be induced to express the peptide component. The disclosure hereof extends to nucleic acid sequences adapted for administration by genetic immunization and/or for inclusion in a vector, plasmid, LEE, or other entity or carrier adapted for genetic immunization or for expression in an expression system, encoding any of the peptide components disclosed herein, and to vectors, plasmids, LEE's, or other entities comprising the nucleic acid sequences. By way of example, the nucleic acid sequences of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:231, SEQ ID NO:233, SEQ ID NO:235, SEQ ID NO:237, SEQ ID NO:239, and SEQ ID NO:241 are disclosed as nucleic acid sequences that in whole or part encode the peptide component sequences SEQ ID NO:294, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:232, SEQ ID NO:234, SEQ ID NO:236, SEQ ID NO:238, SEQ ID NO:240, and SEQ ID NO:242, respectively.

An effective dose of an anti-cancer vaccine may be any quantity operable to reduce the susceptibility of a mammalian subject to which an anti-cancer vaccine is administered, or a population to which the subject belongs, to at least one cancer. In some embodiments, an effective dose of an anti-cancer vaccine may include any quantity operable to expose the immune system of a subject to a peptide component thereof. By way of example only, an effective dose of an anti-cancer vaccine administered in the form of synthetic or recombinant peptides in a carrier may be a quantity operable to produce in the subject an antibody response, which may be detected, for example, by an ELISA or other assay confirming the presence in serum of the subject antibodies specific for one or more of the peptide components. In some embodiments, for example, an effective dose of an anti-cancer vaccine for administration in the form of peptides in or on a carrier may be at least 50 μg KLH-conjugated peptide, or at least 100 μg KLH-conjugated peptide, or at least 200 μg KLH-conjugated peptide. By way of example only, an effective dose of an anti-cancer vaccine administered in the form of a genetic vaccine including nucleic acid(s) encoding the peptide components may be a quantity operable to cause expression of at least one peptide component in a cell, such as, for example, an antigen presenting cell, of the subject, and display of the peptide component or a fragment thereof in MHC. In embodiments, for example, an effective dose for genetic immunization by gene gun may be at least 20 ng per bullet, or at least 50 ng per bullet, or at least 100 ng per bullet, in at least one shot, or at least two shots, or at least four shots, or at least six shots.

In some embodiments of an anti-cancer vaccine, it may be found useful to select peptide components having a cancer association ratio of at least 2:1, or at least 3:1, or at least 4:1, or at least 5:1. A cancer association ratio of a peptide component may be employed as a measure of the presence of the peptide component (or its homolog or equivalent) in cancer tissue relative to its presence in comparable non-cancerous tissue. Thus a peptide that presents an epitope abundantly present in identical or recognizable form in cancerous tissue and rarely or never present in comparable non-cancerous tissue would have a relatively high cancer association ratio, making it a desirable candidate as a peptide component of a vaccine. In embodiments, the cancer association ratio of a peptide component may be measured or estimated in any way operable to yield an informative indication, of the degree of presence of an epitope equivalent or immunologically similar to an epitope of the peptide component in a cancerous tissue of interest, relative to a comparable non-cancerous tissue. In some embodiments, a cancer association ratio may preferably be determined and/or computed in a manner that would be regarded by a person of skill in the art as providing acceptable statistical and experimental validity. In some embodiments, for example, a cancer association ratio may be estimated by measuring or estimating a level of expression of the sequence (or relevant portion or homolog thereof) in mRNA transcripts in cells of a tissue sample of the cancer type of interest, making a similar measurement or estimate in cells of a sample of non-cancerous tissue of similar or comparable type, and taking the ratio of the two. In some embodiments, a cancer association ratio may be measured or estimated as an odds ratio, computed as disclosed in Example 5 herein. In some embodiments, a cancer association ratio may be measured or estimated by determining the prevalence of the sequence (or relevant portion or homolog thereof) in a cancer EST library or database, as compared to a non-cancer EST library or database. In some embodiments wherein it would be apparent from art-accepted principles of molecular biology that the sequence of interest would not be expressed by normal cells, a cancer association ratio may be assumed to be >>1 if significant presence of the sequence is confirmed in the cancerous tissue of interest, or in mRNA or cDNA thereof.

In some embodiments, of an anti-cancer vaccine, it may be found useful to select peptide components having a cancer serum recognition percentage of at least 40%, or at least 60%, or at least 80%. A cancer serum recognition percentage may be determined or estimated in any way operable to provide an informative and reasonably repeatable measure, in a mammalian population cohort consisting of subjects having a cancer, of the percentage of subjects whose serum shows specific antibody reactivity to the peptide component or a portion or homolog thereof. In embodiments, such reactivity may be measured or estimated in any operable way, such as, for example, by ELISA or by microarray assay. In embodiments, the population cohort should preferably include a representative selection and quantity of subjects, such as, for example, at least 10, or at least 20, or at least 30 independent samples from distinct cancerous individuals. In embodiments, a cancer serum recognition percentage should preferably be determined and/or computed in a manner that would be regarded by a person of skill in the art as providing acceptable statistical and experimental validity.

In some embodiments, there is provided a peptide component of an anti-cancer vaccine to be administered to a mammalian subject belonging to a first mammalian species, having a sequence determined by homology to a peptide component whose utility has been assessed relative to a second mammalian species recognized in the art as an appropriate model with respect to the first mammalian species. Thus, by way of example only, a peptide component for use in a human vaccine may have a sequence determined in whole or part by reference to a peptide component that has been assessed in a mouse model, by combining the non-frame-shifted human sequence corresponding to the homologous gene or gene fragment comprising the non-frame-shifted portion of the mouse peptide component with the frame-shifted human sequence corresponding to the nucleic acid sequence homologous to the gene or gene fragment from which the frame-shifted portion of the mouse peptide component is transcribed. Accordingly, where peptide components are disclosed herein corresponding to novopeptides relating to human, mouse, or dog sequences, the disclosure hereof extends to the homologous counterparts of these peptide components in the others of these species. Thus, for example, in addition to the mouse-targeted sequences FS 1-78 (SEQ ID NO: 294), FS 6-21 (SEQ ID NO: 291), FS SMC1A (SEQ ID NO: 297), FS RBM (SEQ ID NO: 232), and FS THAP2 (SEQ ID NO: 238) as disclosed, also disclosed herein are the corresponding sequences for human (SEQ ID NO: 293, SEQ ID NO: 290, SEQ ID NO: 296, SEQ ID NO: 234, and SEQ ID NO: 240, respectively) and dog (SEQ ID NO: 295, SEQ ID NO: 292, SEQ ID NO: 298, SEQ ID NO: 236, and SEQ ID NO: 242, respectively).

In some embodiments there is provided an anti-cancer vaccine including a peptide component or a plurality of distinct peptide components, and a pharmaceutically acceptable carrier. Peptide components may include peptide chains as disclosed herein which may be in any form operable for administration as disclosed herein, such as, for example, free and/or unbound peptide chains in a carrier solution or suspension, peptide chains bound or associated to other entities, or peptide chains conjugated to other entities, such as KLH-conjugated peptides. Carriers may be any pharmaceutically acceptable entities or compositions operable to contain, suspend, bind to, or otherwise associate with peptide components for administration to a mammalian subject. In some embodiments there is provided an anti-cancer vaccine for administration by genetic immunization, including a nucleic acid or a plurality of nucleic acids, encoding a peptide component or a plurality of peptide components, and a carrier adapted for administration of the anti-cancer vaccine by genetic immunization, which may include any pharmaceutically acceptable entity or composition operable to facilitate the administration of the nucleic acid(s) to a mammalian subject whereby the peptide components encoded by the nucleic acids may be expressed by cells of the subject. Examples include vectors, plasmids, LEE's, or other entities incorporating sequences or functionality for facilitating such expression, which may in some embodiments be applied, adsorbed, conjugated to, or otherwise associated with a physical delivery entity such as a gold nanoparticle or other genetic immunization ‘bullet’.

In some embodiments an anti-cancer vaccine includes a plurality of peptide components, or a nucleic acid portion encoding peptide components, wherein each peptide component is targeted to a different cancer type, so that the susceptibility of a receiving subject or population may be reduced with respect to more than one cancer type. In some embodiments an anti-cancer vaccine includes a plurality of peptide components, or a plurality of nucleic acids encoding peptide components, wherein the peptide components are displayable in different MHC or HLA types, so that the coverage of the anti-cancer vaccine extends to subjects of more than one MHC or HLA type. In some embodiments, it may be found useful to confirm by art-recognized computational methods that a peptide component is displayable in MHC of a type expressed by a mammalian subject, which may be a member of a population for which a vaccine composition is intended. In embodiments, a population for which a vaccine composition is intended may be the population of all mammals of a species or subspecies of interest, or may be a sub-population defined by one or more characteristics of interest such as, for example, a sub-population having a particular genetic trait, or a particular susceptibility. In some embodiments, a peptide component may be displayable by MHC of a type expressed by a minimum percentage of a population of a mammalian species or sub-population for which an anti-cancer vaccine is intended, such as, for example, at least 2%, or at least 4%, or at least 6%, or at least 10%, or at least 20% of the population or sub-population. In some embodiments, an anti-cancer vaccine may include two or more peptide components (or nucleic acid(s) encoding them, in the case of a genetic vaccine), wherein a first peptide components is displayable by a first MHC type expressed in one cohort of the target population or sub-population, and a second peptide component is displayable by a second MHC type expressed in a different cohort of the target population or sub-population, so that the potential coverage of the vaccine extends to both cohorts. It will be apparent that by appropriate selection of peptide components displayable by different MHC types, it is possible for a cocktail vaccine to extend the benefit of the vaccine to an arbitrary proportion of the target population.

In some embodiments, disclosed herein is a synthetic or recombinant peptide component for an anti-cancer vaccine for administration in a population of a mammalian species, including a continuous amino acid chain, or a continuous portion thereof from 8 to 40 amino acids in length, according to the formula D1-D2, wherein DI and D2 each have at least threshold identity to a polypeptide sequence encoded by a different exon or continuous portion thereof of the genome of the mammalian species, wherein D1 is encoded in a wild type reading frame and D2 is encoded in a non-wild type reading frame. In embodiments, a threshold identity may be any level of sequence identity or similarity, determined according to metric thereof, that would be regarded by a person of skill in the art as providing a reasonable measure of functional similarity, such as, by way of example only, 75% sequence identity, or 80% sequence identity, or 85% sequence identity, or 90% sequence identity, or 95% sequence identity.

In some embodiments of a peptide component, the portion of DI immediately adjacent to D2 is not a microsatellite or portion thereof. In some embodiments neither DI nor D2 has above a threshold identity to a peptide sequence encoded by an oncogene. In some embodiments of a peptide component, the RefSeq of the mammalian species does not contain a nucleic acid sequence encoding the sequence of the peptide component. In some embodiments of a peptide component, the normal transcriptome of the mammalian species does not contain a nucleic acid sequence encoding the sequence of the peptide component. In some embodiments of a peptide component, the peptide component aligns with at least threshold identity to all or a portion of an mRNA transcript expressed in at least one cancer type of the mammalian species. In some embodiments of a peptide component, the peptide component has a cancer association ratio of at least 2:1 with respect to at least one cancer type of the mammalian species. In some embodiments of a peptide component, the peptide component has a cancer serum recognition percentage of at least 40% with respect to at least one cancer type of the mammalian species. In some embodiments of a peptide component, the peptide component is capable of being displayed in a Class I major histocompatibility complex (MHC-I) of a type expressed by at least 4 percent of the population.

In some embodiments of a peptide component, the mammalian species is mouse and the continuous amino acid chain has at least threshold sequence identity to a sequence selected from: peptide FS 1-78 (SEQ ID NO: 294), peptide FS 6-21 (SEQ ID NO:291), peptide FS SMC IA (SEQ ID NO: 297), peptide FS RBM (SEQ ID NO: 232), or peptide FS THAP2 (SEQ ID NO: 238). In some embodiments of a peptide component, the mammalian species is human and the continuous amino acid chain has at least threshold sequence identity to a sequence selected from: peptide FS 1-78 (SEQ ID NO: 293), peptide FS 6-21 (SEQ ID NO: 290), peptide FS SMC IA (SEQ ID NO: 296), peptide FS RBM (SEQ ID NO: 234), or peptide FS THAP2 (SEQ ID NO: 240). In some embodiments of a peptide component, the mammalian species is dog and the continuous amino acid chain has at least threshold sequence identity to a sequence selected from: peptide FS 1-78 (SEQ ID NO: 295), peptide FS 6-21 (SEQ ID NO: 292), peptide FS SMC IA (SEQ ID NO: 298), peptide FS RBM (SEQ ID NO: 236), or peptide FS THAP2 (SEQ ID NO: 242).

Also disclosed herein are embodiments of an anti-cancer vaccine for administration in a population of a mammalian species, including a plurality of any of the peptide components disclosed herein, in a pharmaceutically acceptable carrier; also disclosed herein are embodiments of a method including administering to a mammal an effective dose of the anti-cancer vaccine. Also disclosed herein are embodiments of an anti-cancer vaccine for administration in a population of a mammalian species, including a synthetic or recombinant nucleic acid or plurality thereof encoding a plurality of any of the peptide components disclosed herein, and a carrier adapted for administration of the anti-cancer vaccine by genetic immunization; also disclosed herein are embodiments of a method including administering to a mammal an effective dose of the anti-cancer vaccine, which may employ genetic immunization methods. In some embodiments of an anti-cancer vaccine, there is provided a plurality of peptide components including a first peptide component displayable in a first MHC type expressed in a first cohort of the population and a second peptide component displayable in a second WIC type expressed in a second cohort of the population, wherein the first and second cohort together are more numerous by at least 2 percent of the population than either cohort.

In some embodiments, there is disclosed a method including: administering to a mammal by genetic immunization an effective dose of an anti-cancer vaccine including a synthetic or recombinant nucleic acid or plurality thereof, encoding a plurality of any of the peptide components as disclosed herein, and a carrier adapted for administration of the anti-cancer vaccine by genetic immunization; and at least two weeks thereafter, administering to the mammal an effective dose of an anti-cancer vaccine including at least one of the plurality of peptide components in a pharmaceutically acceptable carrier.

In embodiments, disclosed herein is a composition including synthetic or recombinant peptides each including a continuous amino acid chain, or continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof of SEQ ID NO: 310, SEQ ID NO: 311, and SEQ ID NO: 312. Also disclosed are embodiments of a synthetic or recombinant nucleic acid or plurality thereof encoding peptides each including a continuous amino acid chain, or continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof of SEQ ID NO: 310, SEQ ID NO: 311, and SEQ ID NO: 312.

Also disclosed are embodiments of a synthetic or recombinant peptide including a continuous amino acid chain, or a continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof selected from the group consisting of SEQ ID NO: 240 and SEQ ID NO: 243 through SEQ ID NO: 289. Also disclosed are embodiments of a synthetic or recombinant nucleic acid encoding a continuous amino acid chain, or a continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof selected from the group consisting of SEQ ID NO: 240 and SEQ ID NO: 243 through SEQ ID NO: 289. Also disclosed are embodiments of a synthetic or recombinant peptide including a continuous amino acid chain, or a continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof selected from the group consisting of SEQ ID NO: 242, SEQ ID NO: 236, and SEQ ID NO: 306 through SEQ ID NO: 309. Also disclosed are embodiments of a synthetic or recombinant nucleic acid encoding a continuous amino acid chain, or a continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof selected from the group consisting of SEQ ID NO: 242, SEQ ID NO: 236, and SEQ ID NO: 306 through SEQ ID NO: 309. Also disclosed are embodiments of a synthetic or recombinant peptide including a continuous amino acid chain, or a continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof selected from the group consisting of SEQ ID NO: 238, SEQ ID NO: 242, and SEQ ID NO: 299 through SEQ ID NO: 305. Also disclosed are embodiments of a synthetic or recombinant nucleic acid encoding a continuous amino acid chain, or a continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof selected from the group consisting of SEQ ID NO: 238, SEQ ID NO: 242, and SEQ ID NO: 299 through SEQ ID NO: 305. Also disclosed are embodiments of a composition including synthetic or recombinant peptides each including a continuous amino acid chain, or continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof of SEQ ID NO: 310, SEQ ID NO: 311, and SEQ ID NO: 312. Also disclosed are embodiments of a synthetic or recombinant nucleic acid or plurality thereof encoding peptides each including a continuous amino acid chain, or continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof of SEQ ID NO: 310, SEQ ID NO: 311, and SEQ ID NO: 312. Also disclosed are embodiments of a synthetic or recombinant peptide including a continuous amino acid chain, or a continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof selected from the group consisting of SEQ ID NO: 310 through SEQ ID NO: 332. Also disclosed are embodiments of a synthetic or recombinant nucleic acid encoding a continuous amino acid chain, or a continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof selected from the group consisting of SEQ ID NO: 310 through SEQ ID NO: 332. Also disclosed are embodiments of a synthetic or recombinant peptide including a continuous amino acid chain, or a continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof selected from the group consisting of SEQ ID NO: 333 through SEQ ID NO: 341. Also disclosed are embodiments of a synthetic or recombinant nucleic acid encoding a continuous amino acid chain, or a continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof selected from the group consisting of SEQ ID NO: 333 through SEQ ID NO: 341. Also disclosed are embodiments of a synthetic or recombinant peptide including a continuous amino acid chain, or a continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof selected from the group consisting of and SEQ ID NO: 342 through SEQ ID NO: 348. Also disclosed are embodiments of a synthetic or recombinant nucleic acid encoding a continuous amino acid chain, or a continuous portion thereof from 8 to 40 amino acids in length, having at least threshold identity to a sequence or continuous portion thereof selected from the group consisting of SEQ ID NO: 342 through SEQ ID NO: 348.

EXAMPLES

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the disclosure. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in degrees Celsius or is at ambient temperature, and pressure is at or near atmospheric.

Example 1

To determine the amount of coding sequence that must be sequenced to identify a sufficient number of novopeptides that are expressed in tumor cells and not in non-cancerous cells to produce a practicable cancer vaccine, it is first instructive to determine the frequency of novopeptide associated mutation or variation in a tumor. To assess this frequency, the C-terminal 600 bp of 550 genes that are expressed in the mouse melanoma cell line, B16-FIO were sequenced. To confirm that the in vitro-derived FS were expressed in vivo, RNA was extracted from B16 lung metastases after injection of cells systemically, cDNA was generated, and the FS confirmed by RT-PCR sequencing. As illustrated in FIG. 2a , cDNA was generated from RNA isolated from cultured cells. It was sequenced directly by RT-PCR sequencing. FIG. 2b illustrates in vivo confirmation of in vitro-derived FS mutations. To confirm that the FS was expressed in vivo, RNA was extracted from B16 lung metastases after injection of cells systemically. cDNA was generated and the FS confirmed by RT-PCR sequencing.

Three novopeptides were isolated, indicating that FS occur at a frequency of roughly one per 183 segments of 600 bp of genes (FIG. 2). FS 1-78 (SEQ ID NO: 2) was identified as a frameshift relative to the normal reference sequence. One other frameshift peptide, FS 6-21 (SEQ ID NO: 4) was also identified, as was a 3 amino acid insertion. The parent protein of FS 1-78 is a zinc finger protein, but a deletion of 396 bp results in expression of an 11 amino acid novopeptide in an alternate frame before termination. Table 1 shows the sequences identified. Underlined amino acids comprise the peptide predicted to be presented by H-2 Db (C57BL6 mice) and H-2 Kd (Balb/c mice). Upper case amino acids indicate primary frame and lower case amino acids indicate the frame shift residues. Fusions of primary and alternate frames often form antigenic peptides. FIG. 1a shows PCR amplification of FS 1-78. Arrow indicates FS 1-78 band; other bands are wild type alleles. Lane 1: B16/F10 tumor cells; Lane 2: B16/F10 tumor cells; Lane 3: normal heart; Lane 4: normal intestine; Lane 5: normal kidney; Lane 6: normal liver; Lane 7: normal lung; Lane 8: normal skeletal muscle; Lane 9: normal skin; Lane 10: normal spleen; Lane M: Molecular weight marker. FIG. 1b shows the analysis of the occurrence of the FS 6-21 frameshift in the mouse tumor versus RNA from normal tissue. Arrow indicates FS 6-21 FS band. Lanes are as in FIG. 1a . It is noted that FS 1-78 expression is detected in the tumor cells and not in any of the noncancerous cells tested.

TABLE 1 Gene  FS  Name mutation Novopeptide Sequence SEQ ID NO 1-78 396 bp  IPRM QPQASAn hcgllkvmva * SEQ ID NO: 2 deletion 6-21  95 bp  AVLLMCQLYQpwmckeyyrll* SEQ ID NO: 4 deletion 3-83   3 aa  . . . GTEDsrdSDDALL . . . SEQ ID NO: 6 insertion

Example 2

The FS 1-78 novopeptide identified above was chemically synthesized as a genetic linear expression element (LEE) as diagrammed in FIG. 3 according to the methods described in (Sykes, K. F., and S. A. Johnston (1999) Nat. Biotechnol. 17:355). Each LEE comprises a fragment that may contain a mammalian promoter 301, a ubiquitin gene (Ub) 303 for stronger intracellular processing, and a fragment 305 that contains transcriptional and translational terminators. The two fragments are linked via the frameshift sequence 307, here FS 1-78. Using gene gun technology, C57BL6 mice were then genetically immunized with the FS 1-78 LEE construct in doses as shown in FIG. 4 and a plasmid expressing GM-CSF (1 μg of pGM-CSF). Mice were boosted 2 weeks later with the same FS 1-78 LEE and pGM-CSF and then challenged one week after boost (day 0) with 1×105 B16 F1O melanoma tumor cells. As shown in FIG. 4, tumor growth was markedly delayed compared to mice administered control empty LEE and compared to those receiving no immunization, and at the highest dose (3.2 ng), tumor volume decreased after the already delayed rise.

Example 3

Immunization with a single FS-novopeptide identified based on one tumor type may be immunoprotective against a different tumor type in a different mouse strain. Disclosed herein is a procedure for such immunization. Immunization with novopeptides common to multiple types of tumors can result in cross-protection, obviating the requirement that a patient must develop a tumor before a personalized vaccine can be formulated, prepared and administered. Balb/c mice were immunized in the same manner as the C57BL6 mice in Example 2 above, with 3.2 ng of FS 1-78 LEE+1 μg of pGM-CSF, and boosted with the same gene vaccine after 2 weeks. One week after the boost, mice were challenged with 1×104 4Tl breast tumor cells. Seventeen days after 4Tl challenge, tumors started to grow. As shown in FIG. 5, prophylactic immunization of Balb/c mice with FS 1-78 novopeptide significantly delayed and reduced 4Tl tumor growth in comparison to both controls immunized with pGM-CSF plasmid alone and controls immunized with another novopeptide (FS 6-21) that is not found in 4Tl tumors.

Example 4

Vaccines combining more than one novopeptide can be highly effective in conferring immunoprotection against cancer. Mice were vaccinated using a vaccine comprising a combination of FS 1-78 and FS 6-21 novopeptides. On challenge with B16 tumor cells, most vaccinated mice were completely protected from tumor growth. FIG. 6 compares the relative protection of the FS 1-78 and FS 6-21 peptides by themselves and when pooled as a single vaccine. On Day −8, mice were immunized with the FS 6-21 peptide (squares), the FS 1-78 peptide (crosses), a combination of both (triangles), or an irrelevant peptide sequence (diamonds). Tumor cells were implanted on Day 0. The 80 percent of mice in the group receiving the combined vaccine that were alive on day 15 remained alive and apparently healthy thereafter and until the experiment was terminated. This experiment demonstrates that pooling of novopeptides can give increased protection over single peptide immunization.

Example 5

Candidate novopeptide nucleic acid sequences, expressed by cancerous cells and not by non-cancerous cells, can be identified and predicted by bioinformatics analysis comparing tumor database data with genomic data. This example illustrates an embodiment of the methods by which this was done. FS-novopeptide candidates were identified by bioinformatic analysis of frame shifts by comparing sequences obtained from tumor and normal EST library databases. Exact FS peptide sequences were then confirmed by DNA sequencing across the frame shift region and comparison to the non-cancerous reference sequence. It is noteworthy that several of the tumor-specific variants are not encoded at the DNA level but involve RNA splicing variants that are predominant in the tumors. Table 2a shows frame shift sequences predicted by the bioinformatic comparison and verified by DNA sequence analysis, and shows that these sequences are present in the indicated number of tumor EST's and not in non-cancerous EST's.

TABLE 2a Gene FS Name mutation EST analysis Novopeptide Sequence RIPK2 154 bp Tumor:6 of 16 . . . HIHTPLLDrklnilmllgh* SEQID deletion Normal: 0 of 8 NO:9 DTYMK  91 bp Tumor: 3 of 86 . . . SANRWEQVifp* SEQ ID deletion Normal: O of 30 NO: 10 6-21  95 bp Tumor: NA . . . LLMCQCQLY SEQ ID deletion Normal: NA Qpwmckeyyrll* NO: 11 DYRK4  61 bp Tumor: 4 of 10 . . . EQLACIMEipkvflki* SEQ ID deletion Normal: O of 11 NO: 12 MTCH2  68 bp Tumor: 5 of 88 . . . SYSQAVTGscwwmpsllpniyvld SEQ ID deletion Normal: O of 63 rll NO: 13 vhatkrgeyeprk * FTH1  62 bp Tumor: 17 of . . . ASYVYLSMivtatclwgslv* SEQ ID insertion  2157 NO: 14 Normal: O of 243

Bioinformatic identification of possible novopeptides was performed as follows: the NCBI EST database was screened using information obtained from the NCI EST database to classify each NCBI EST into one of three sets: tumor EST's, normal EST's and EST's for which there was insufficient information to classify as tumor or normal. The latter were discarded. Each human reference sequence in the NCBI database was then aligned with both the normal EST set and the tumor EST set using BLAST, and the number of frameshifted and unframeshifted hits of at least 100 base pairs and 85% sequence identity were counted. To identify candidates for further screening, an odds ratio was computed for each FS variant sequence arising from an indel of at least 10 base pairs. The odds ratio provides an indication of the relative expression of the FS variant in tumor and normal cells, as compared to the expression of the nonvariant wild type sequence in tumor and normal cells. The ratio of FS variants to wild type in tumor cells (the “tumor cell variant ratio”) was computed as the ratio of the number of sequence matches obtained upon search of the tumor EST databases for the FS variant sequence to the number of sequence matches obtained upon search of the tumor EST databases for the wild type sequence. The ratio of FS variants to wild type in normal cells (the “normal cell variant ratio”) was computed as the ratio of the number of sequence matches obtained upon search of the normal EST databases for the FS variant sequence to the number of sequence matches obtained upon search of the normal EST databases for the wild type sequence. In computing this ratio, the former number was arbitrarily set to 1 if the number of matches were zero so as to avoid division by zero in computing the odds ratio; this approximation was deemed reasonable since the difference between zero and 1 is likely within the range of uncertainty associated with sequence alignment and the setting of alignment parameters. An odds ratio was computed as the ratio of the tumor cell variant ratio to the normal cell variant ratio, with FS variant sequences having a ratio above 2.0 being selected for further study. Table 2b shows six FS variant sequences for which RNA expression ratios of the FS variant in tumor vs. normal cells were determined, confirming the differential expression.

TABLE 2b Accession Gene Name FS Peptides RNA NM SMC1L1 GCCGIYCHEEPQREDSSI   98X 006306 (SEQ ID NO: 15) NM HIP 14 PWMCKKYYRLL    4X 015336 (SEQ ID NO: 16) XM KIAA 1458 NPCQLLKPMVA  6.3X 044434 (SEQ ID NO: 17) NM MTCH2 SCWWMPSLLPNIYVLDRLL VHA  2.2X 014342 TKRGEYEPRK f Fn 1n Nn• 1 R\ NM COPS6 RGPL (SEQ ID NO: 19) 9.75X 006833 NM PTEN   41X 000314

Table 2c shows FS variants having high odds ratios, computed as described above; for CIAPINI and STYXLI, RNA expression ratios were measured to be 2.6× and 2.0×, respectively; RNA expression in tumor cells exceeding that in normal cells was confirmed by PCR and inspection of electrophoresis gel band intensities in BCL2L12 and DNPEP; and expression in tumor cells was verified by RNA extraction and sequencing for BCL2L12, DNPEP, and STYXLI.

TABLE 2c Gene  Accession ID name  FS peptide OddsRatio NM 001745 CAMLG VHICSISYFTTCVHGIIQIFSQE  2.50 (SEQ ID NO: 20) NM 001014438 CARS GSVHTSRWEKGDVVLLWANRL  2.86 (SEQ ID NO: 21) NM 020313 CIAPIN1  SAHKESSFDIICQV (SEQ ID NO: 22) 2.22 NM 006716 DBF4  ss 4.09 NM 017996 DET1  TRHLLKSMSTRAARQQRTYCRDTKEKSCPM 2.67 AMTSGQ (SEQ ID NO: 23) NM 012100 DNPEP  GWLQ (SEQ ID NO: 24) 2.36 NM 006705 GADD45  LRGQGG (SEQ ID NO: 25) 2.38 G NM 000849 GSTM3  LLTMIEANGWM (SEQ ID NO: 26) 3.82 NM 201612 IKIP  CGRNLKLSWNN (SEQ ID NO: 27) 15.43 NM 001012634 IL32 HQAIERFYDKMLQNQDVDR  4.63 (SEQ ID NO: 28) NM 015416 LETMD1  ESLEPGHASH 3.08 ILPASSLVETSFEDSYNCDSPTGQGFGKAG  D WPADCSGSKIGLLSPWPEFYAYW  (SEQ ID NO: 29) NM 002405 MFNG  GPTLWSPTAPRNTATQLCPARWLLSSTPSWPV 2.47 GLGGSAMVVTMTTM (SEQ ID NO: 30) NM 198883 MTX1 KYNADYDLSARQGADTLAFMSLLEEKLLPVL 3.08 (SEQ ID NO: 31) NM_152298,  NASP SNH 3.65 NM 002482 NM 006985 NPIP  SRSQLGMAVIFLFTPR (SEQ ID NO: 32) 2.11 NM 153681 PIGP  KNLKGSRVC (SEQ ID NO: 33) 3.69 NM 018845 RAG1API  KLR 2.29 NM 015014 RBM34  GKRSSEC (SEQ ID NO: 34) 11.08 NM 83400 RNF14 AICSMQALRQPMGRTPWQRGPVCLDAIS 11.73 (SEQ ID NO: 35) NM 016211 SEC31A PSEWLE (SEQ ID NO: 36) 2.33 NM 001009939 SEPT5- VENQAHCDFVKLRNMLIRTHMHDLKDVTCDVHY 2.63 ENYRA HCIQQMTSKLTQDSRMESPIPILPLPTPDAET (SEQ ID NO: 37) NM 005827 SLC35B1 WWIVPGAGSM 9.45 LPVLSPIWVPWSPAIQHYSLSTTQLRSLV NPASQSQSCSLG (SEQ ID NO: 38) NM 003473 STAM GVILKYVKN (SEQ ID NO: 39) 2.14 NM 003763 STX16  A 2.70 NM 016086 STYXL1 GTGCISAIPH (SEQ ID NO: 40) 7.27 NM 032026 TATDN1 VYDYRWKSTRQ (SEQ ID NO: 41) 3.63 NM 001001563 TIMM50 DHRAHQPLPSPRPSAGTVLPATLHARFGAH 2.92 RRPLAS (SEQ ID NO: 42) NM 100486 WAC MEDKHSSDASSLLPQNILSQTSRH  2.70 NDRDYRLPRAETHSSST PVQHPIKPVVHPTATPSTVPSSPFTLQ SDHQPKKSFDA NG ASTLSKLPTPTSSV PAQKTERK (SEQ ID NO:43) NM 024061 ZNF655 GHTSPPSHHPDS (SEQ ID NO: 44) 2.09

Table 2d shows FS variant sequences for which sequence matches were found in the tumor EST databases but for which, in the normal EST databases, no sequence matches were found for either the FS variant or the parent wild type sequence; this prevented computation of an odds ratio, but obviously nonexpression in normal cells is a desirable characteristic. Note that very short FS variant sequences are nevertheless significant since, when expressed, they result in peptides representing fusions of the FS variant with the adjacent unshifted sequence.

TABLE 2d Accession ID Gene Name FS Peptides NM 212533 ABCA2 E NM 001606 NM 172027 ABTB1 VLCLLVWARGAGTLPSGQWSPLRGQHLRW (SEQ ID NO: 45) NM 001033055 AIPL1 VIFHFRTMKCDEERTVIDDSRQVGQPMHIIIGNMFKLEVW EILL TSM RVH EVAEFWCDTI (SEQ ID NO: 46) NM 001707 BCL7B GQSLAMLSRLVVNSWPQAVPRP (SEQ ID NO: 47) NM 004328 BCS1L LES XM 043653 BEXL1 PLTEASYVNLPTIALCNTDSPLRYVDIAIPCNNKGAHS (SEQ ID NO: 48) NM 139343 BIN1 LRKGPPVPPPPKHTPSKEVKQEQILSLFEDTFVPEISVTTPSQPA EAS EVAGGTQPAAGAQEPGETAASEAAS (SEQ ID NO: 49) NM 015412 C3orfl7 G NM 001009186 CCT6A QIQHPTASLIAKVATAQDDITGDGTTSNVLIIGELLKQADLYISE (SEQ ID NO: 50) NM 134445 CD99L2 QPWDHTNNHHNK (SEQ ID NO: 51) NM 033488 CDC2L1 SVCTSPN DERG LQRQSESQPLESQPASAAAGAVRVGRRPEASKRR E NGRKGPAVRLTGHQRQREEDQLGRVLVSRIRLRF  (SEQ ID NO: 52) NM 001005271 CHD3 EMGEEGGGRTGNH (SEQ ID NO: 53) NM 001005273 NM 017828 COMMD4 VRPSTVSMAN PCPVNCSSWGCPKSTRPACAAVMRRSKAPCRSTC GSAAYA (SEQ ID NO: 54) NM 032179 CPSF3L SCLD (SEQ ID NO: 55) NM 004715 CTDP1 KWTTSLEKAATTATARRGGLRSRRRSPSPGSQGPAGSGRSGH LRP ARGARQGAGGPEAT RGS (SEQ ID NO: 56) NM 001930 DHPS AERGRLRCLHQHSPGV (SEQ ID NO: 57) NM 182908 DHRS2 FHGNESLWKNFKEHHQLQRIGESEDCAGIVSFLCSPDASYVN GENI AVAGYSTRL (SEQ ID NO: 58) NM 021931 DHX35 HDLSSQRLQGE (SEQ ID NO: 59) NM 001009894 DKFZp434 ISHTFGLD (SEQ ID NO: 60) N2030 NM 032378 EEF1D AQAPGPPAAPAETTVSSSSGLPVWKWRTRVCVAWYRSCSRP SPS WRPG (SEQ ID NO: 61) NM 024311 ET RRVTEEQCLLP (SEQ ID NO: 62) NM 023109 FGFR1 CIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYY  (SEQ ID NO: 63) NM 001001662 FLJ16636 KDVGEPSLFPLA (SEQ ID NO: 64) NM 024578 FLJ22709 VSLTGRGSPGRASRQKI (SEQ ID NO: 65) NM 005087 FXR1 GKRCD (SEQ ID NO: 66) NM 001013439 NM 002106 H2AFZ VGI NM 014056 HIGD1A VFGDSPALSPRLECSGRISAHCSLCLLGSSDSPTSAS  (SEQ ID NO: 67) NM 003529 HIST1 H3A R NM 153490 KRT13 GPGPSR (SEQ ID NO: 68) NM 019016 KRT24 ATPTWK (SEQ ID NO: 69) NM 015848 KRT2B TLLQEQGTKTVRQNLEPLFEQYINNLRRQLDNIVGERGRLDS (SEQ ID NO: 70) NM 002272 KRT4 ESWYQTKYEELQITAGRHGDDLRNTKQEIAEINRMIQRLRSEI DHV KKQCANLQAAIADAEQRGEMALKDAKNKLE  (SEQ ID NO: 71) NM 153486 LDHD GRRLR (SEQ ID NO: 72) XM 060417 LOCI 27295 LARMCVPTLLLTNLRARLVRKREELSNVLAAMKKA TAKKD (SEQ ID NO: 73) XM 497978 LOC132391 RVRHGVRG PGHRDSRGSG RNGRHPER EGDHAKPER PPGLLPGQ Q (SEQ ID NO: 74) XM 211339 LOC284120 LLSFCCPGWSSVA (SEQ ID NO: 75) XM 208312 LOC284120 LDDSIVVKLVSPGSALPRIFGLSPESLSADH  (SEQ ID NO: 76) XM 293903 LOC284120 IVEERKMHWSPRTWSLGNQFMERRESRFRKEMTKLSTE  (SEQ ID NO: 77) XM 370672 LOC284120 TVKHPVCV (SEQ ID NO: 78) XM 495875 LOC284120 FHVNHVKRSRVPLSVGDHTNSS (SEQ ID NO: 79) XM 372840 LOC391209 LARMCVPTLLLTNLRARLVRKREELSNVLAAMKKATAKKD (SEQ ID NO: 80) XM 497922  LOC391538 RCVLKIGEHTPSALAIMENAKCSGPLCQYLPAEWHCAHRGA (SEQ ID NO: 81) XM 496658  LOC440976 GGGGRAERPAGLAGVQGQTGWVSVLKPPALLPQLRSKVKRL IRF (SEQ ID NO: 82) XM 497335  LOC441632 AKQVLLGRKVVVVRCEGINISGNFYTKQVEVPRFPPQADEHQ LLPR LL PLPGPQPHLLADRARY AAPQDQARPGRSGPPQGV (SEQ ID NO: 83) XM 497347  LOC441641 GNFYRNKLKYLAFLRKRMNTNPSRGPYHFRAPSRIFWRTVRG  ML PHKTKRGQAALDRLKVFDGIPPPTT (SEQ ID NO: 84) XM 497605  LOC441836 VGDEAQSKRGILTLKYPIEHGIVTTPSTTSCAWPRRSTRCC (SEQ ID NO: 85) XM 029323 LOC90133 QAPRL (SEQ ID NO: 86) NM 138779 LOC93081 GTCWRKWHRKCKLPIKSTGLRRQIIPWQ (SEQ ID NO: 87) NM 002383 MAZ GFTTAAYLRIHAVKDHGLQAPRADRILCKLCSVHCKTPAQLA GHM QTHLGGAAPPVPGDAPQPQPTC (SEQ ID NO: 88) NM 174923 MGC31967 REEMSTQWLPTYVPIPPSCHKFPKNSQNHCSPHL  (SEQ ID NO: 89) NM 182523 MGC61571 YFLSSIRFISTF (SEQ ID NO: 90) NM 025259 MSH5 RNPQQMPL (SEQ ID NO: 91) NM 002485 NBN V NM 001001716 NFKBIB RHCTWL (SEQ ID NO: 92) NM 020729 0DF2L WRIFLH (SEQ ID NO: 93) NM 001007157 PHF14 GLADS (SEQ ID NO: 94) NM 015937 PIGT EFSSQLWTLKEGAEVAPGQ (SEQ ID NO: 95) NM 007221 PMF1 SPLLHWDGSAWSPPALWWTVCETGLQLGGVQVTT  GEEGGNL (SEQ ID NO: 96) NM 001017431 RBM3 VVVVKDRETQRSRGFGFITFTN PDLWMVVRSVWI M  QASLLG EPE EVALGPMGVVAATL (SEQ ID NO: 97) NM 015725 RDH8 LFLWLSSQALTLRPCTTSGTSISQPPGSCFAPWDRTHRTWFRP LST SSARLDHPCADRPTSATRR (SEQ ID NO: 98) NM 194452 RNF121 IW NM 001005 RPS3 KLVGNSQKECGVS (SEQ ID NO: 99) NM 058192 RPUSD1 GVSGVGGVLVVTEGKLRHRATKLMLGHPEHQGRAGNKHSC  VLNS TPCSLSASHLTQGPCWLLTDSLGVWLAAILQDRAPPWPCPHQ  W (SEQ ID NO: 100) NM 207521 RTN4 MDLKEQPGNTISAGQEDFPSVLLETAASL (SEQ ID NO: 101) NM 173073 SLC35C2 RAALVLVVLLIAGGLFMFTYK (SEQ ID NO: 102) NM 130849 SLC39A4 VRMARGGAALGRELSRGAEQGR (SEQ ID NO: 103) NM 003096 SNRPG KKLNGGRHVQGILRGFDPFMNLVIDECVEMATSGQQNNI GMVVI R GNSIIMLEALERV (SEQ ID NO: 104) NM 014748 SNX17 VGLAPLP (SEQ ID NO: 105) NM 013403 STRN4 MLLRRRGTPSSPCARTTTAFVPWPSTTASRLCSPPPRTARSSS GTC RRRSRPRRMRR (SEQ ID NO: 106) NM 006521 TFE3 RGLQDPCHVVIFFIEGLAAAAANAGPGAGAGEA  (SEQ ID NO: 107) NM 003299 TRA1 AWTRFAMRA (SEQ ID NO: 108) NM 176880 TRA 16 VHRALRLSTRL (SEQ ID NO: 109) NM 173500 TTBK2 GTKTCEAEPGAVVRAVH QQPQEAAGQH RGGTGSSGLGAEKHAG  P GGGPQEQTMRMKSTSAQQQRMNL (SEQ ID NO: 110) NM 018299 UBE2W SCLLVKIFLFILMFIAMVISVYPF (SEQ ID NO: 111) NM 018206 VPS 3 5 SLIIIKRYGHF (SEQ ID NO: 112) NM 001006612 WBP5 A NM 001006614 NM 017528 WBSCR22 K NM 001033518 WIP1-2 TRYGRCVHCREIVLQQPSGHRQP (SEQ ID NO: 113) NM 001033519 XM 374912 XRRA 1 EDRKRGCCPTSSSLPISLRVRLS (SEQ ID NO: 114)

Table 2e shows FS variant sequences for which the number of sequence matches for the FS variant sequence against the normal EST databases was zero; this number was arbitrarily set at 1 for purposes of computing the odds ratio. RNA expression ratios measured for sequences C7orf24 and ZWILCH were 3.6× and 10.4×, respectively; RNA expression in tumor cells exceeding that in normal cells was confirmed by PCR and inspection of electrophoresis gel band intensities in DYRK4, HNRPULI, MAP3K10, PPP4C, and RIPK2; and expression of the FS variant in tumor cells was confirmed by RNA extraction and sequencing for DYRK4, HNRPULI, RIPK2, and ZWILCH.

TABLE 2e Odds Accession ID Gene name FS peptide Ratio NM 001033054 AIPL1 HTGVYPILSRSLRQMAQGKDPTEWHVHTCGLAN 3.00 MFAY HTLGYEDLDELQKEPQPLVFVIELLQ (SEQ ID NO: 115) NM 005787 ALG3  TQRLTGRPTWPR (SEQ ID NO: 116) 2.79 NM 001002857 ANXA2  VWMRSPLSTF (SEQ ID NO: 117) 4.12 NM_175073 APTX SLRKRQRTLAWKHTGRERDQATVIL  4.92 (SEQ ID NO: 118) NM 005174 ATP5C1  CHQETKVHQKHPENYQVYENGSGSKICPS  2.62 (SEQ ID  NO: 119) NM 001003785 ATP5H  IFFFFGIHLGSIFILWHGNLQRIK  2.57 (SEQ ID NO: 120) NM 004047 ATP6V0B  GS 2.13 NM 080598 BAT1  GCCFFWWSVYQEG (SEQ ID NO: 121) 2.12 NM_ 013980 BNIP1 SNQASWRKANLTCKIAIDNLEKAELLQGGDLLRQRPP 5.33 K RAWPRHPVPSLRASWGSAG (SEQ ID NO: 122) NM 018045 BSDC1  G 2.38 NM 001032363  C1orf151 ESW 4.47 NM 014145 C20orf30  APSCCQATSAKGGQTGPFQC (SEQ ID NO: 123)  6.25 NM 004649 C21orf33  DPGAPEPWRG (SEQ ID NO: 124) 2.31 NM 005768 C3F  AERE (SEQ ID NO: 125) 3.00 NM_024051 C7orf24 ARRG (SEQ ID NO: 126) 5.00 NM 018491 CBWD1  VIQRLLC (SEQ ID NO: 127) 3.04 NM 018246 CCDC25  GKNCDSGEESK (SEQ ID NO: 128) 3.00 NM 001782 CD72  RPRG (SEQ ID NO: 129) 5.83 NM 006319 CDIPT  AACWTLSMDTLLALLIKEPGLGPCWTC  2.11 (SEQ ID NO: 130) NM_024300 CHCHD7 CRSCSTF (SEQ ID NO: 131) 6.55 NM 001009566  CLSTN1 GERRE (SEQ ID NO: 132) 3.79 NM 199442 COPE  RDSIVAELDREMSRSVDVTNTTFLLMAASIYLHDQ 3.30 NPD AALRALHQGDSLE (SEQ ID NO: 133) NM 032589 DSCR8  LQTLEIKKVLE (SEQ ID NO: 134) 7.00 NM 020185 DUSP22  DKTFQRKY (SEQ ID NO: 135) 5.00 NM_003845 DYRK4 IPKVFLKI (SEQ ID NO: 136) 7.33 NM 001967 EIF4A2  DPKGNSGTWRLYGSHLSCLHWWNKCSK  5.62 (SEQ ID  NO: 137) NM 019002 ETAA16  KFKFECNFRSYEYRNYYL (SEQ ID NO: 138) 3.00 NM 032231 FAM96A  VGNLHF (SEQ ID NO: 139) 4.26 NM 005687 FARSLB  NI 5.28 NM 001031704  FLJ20211 GCQPDHGAGAWAACVP (SEQ ID NO: 140) 2.00 NM_013393 FTSJ2 IPALLLASCLG (SEQ ID NO: 141) 2.22 NM 203504 G3BP2  EL 2.82 NM 004127 GPS1  SCRTHPTPSLRAAWSPQPWTRPGWRPRGRRRC   6.31 (SEQ ID NO: 142) NM 012203 GRHPR  AVRWSSGTRMSPSLPRS (SEQ ID NO: 143) 17.27 NM 147149 GSTM4  LPYLIDGAHKITQSNAI LCYIARKH NLCGETEEEKI  2.41 RVDI LENQAMDVSNQLARVCYSPDFEKL (SEQ ID NO: 144) NM 000853 GSTT1  VWPSCST (SEQ ID NO: 145) 6.32 NM 145871 GSTZ1  LAIIEYLEEMRPTPRLLPQDPKKRASVRMISDLIAGGIQ 7.31 P LQ (SEQ ID NO: 146) NM 000858 GUK1  GR 2.68 NM 000187 HGD  GTA 3.33 NM 003537 HIST1H3B  RW 2.15 NM 001002032  HN1 GEGDIHENVDTDLPGSLGQSEEKPVPAAPVPSPVAPA 45.29 PV PSRRNPPGGKSSLVLG (SEQ ID NO: 147) NM 144733 HNRPUL1 MPWTILPGRTNSTIPKSSNKKTSQATRGDHWKWSSSR 2.40 PI VQK (SEQ ID NO: 148) NM 016371 HSD17B7  MIKKWLYVICVEDHVSEIRLYISKCWDHA   2.77 (SEQ ID NO: 149) NM 144981 IMMP1L  CQWVMFG (SEQ ID NO: 150) 2.00 NM 024710 ISOC2  EHDPGPPRPGAAGPCGGGRLLLTQPGGPAGGSGPHE 8.85 TE W CLPLHQRR ABS A ACGRCRPPP V QGDPETHQGARPRQ RTAGPLPRPELPPPL (SEQ ID NO:151) NM 005886 KATNB1  A 3.50 XM 371877 K1AA0960  RKAQRYTGQ (SEQ ID NO: 152) 5.00 NM 138787 LOC119710  DLLLLPGEVEQDV STSIPSCIPFV AQPPTCEVKPKPS 5.25 VKR MDKQTEEILGDEVQLFSLDEEFDYDNVMLTSKFSPAE IE NIKELCKQQKRKDTSPDLEKSCD (SEQ ID NO: 153) XM 059341 LOC129293  GSSLL (SEQ ID NO: 154) 2.50 NM 001031744  LOC158160 MIKKWLYVICVEDHVSEIRPYISKCWDHA   3.64 (SEQ ID NO: 155) NM 174928 LOC221143  VPSWKNRQQNSLE (SEQ ID NO: 156) 4.44 XM 290671 LOC339047  CKTWHSAWV (SEQ ID NO: 157) 4.36 NM 001005920  LOC339123 VSACPSVPGHSRPCWARPLSPLPAPAEVPGPVLPRQV 6.67 AGF VWGQSGPAEHRQHLLLPQSGLALPGVCGAAAAPPGP HLP GQ (SEQ ID NO: 158) XM 292085 LOC341457  MPSTASPW AASPLSCLQTSFQRQQETFML  7.66 (SEQ ID NO: 159) XM 495885 LOC440055  YVYQSQYCGFLQPEQNCHPREEGMEFMVLAQKF 6.32 (SEQ ID NO:160) XM 352159 LOC440341  CKTWHSAWV (SEQ ID NO: 161) 2.55 NM 002446 MAP3K10  RMLGPRPPRAARFR (SEQ ID NO: 162) 4.80 NM 181514 MRPL21  G 2.86 NM_145330 MRPL33 KNILVRMVSEAGTGFCFNTKRNRLREKLTLLHYDPV 17.50 VK QRVLFVEKKKIRSL (SEQ ID NO: 163) NM 012333 MYCBP  SVGSLI (SEQ ID NO: 164) 3.78 NM 012225 NUBP2  R 7.14 NM 000430 PAFAH1B1  MKN 2.17 NM 001003 891 PCQAP RGCHEESWCGTQ (SEQ ID NO: 165) 5.60 NM 020992 PDL1M1  I 2.77 NM_002677 PMP2 EVGVGLPPGKWLAWPNLT (SEQ ID NO: 166) 4.50 NM 174930 PMS2L5  LFQL (SEQ ID NO: 167) 2.12 NM 006243 PPP2R5A  KLYCSF (SEQ ID NO: 168) 2.00 NM 180977 PPP2R5D  LFLIH (SEQ ID NO: 169) 3.11 NM 002720 PPP4C  RCAATSMDNSMTSKSCSE (SEQ ID NO: 170) 3.81 NM_032864 PRPF38A RNAMY (SEQ ID NO: 171) 4.44 NM 002767 PRPSAP2  ENKSTNSRVCEGKRCFHHPNCFEGREHHHHGAPDHG 7.38 V CM (SEQ ID NO: 172) NM 021222 PRUNE  K 2.77 NM 003579 RAD54L  DA 2.43 NM 005493 RANBP9  AKFVSYCGASNTRRSGRCQFWATSFRV  (SEQ ID NO: 173) 3.00 NM_006743 RBM3 VSGWSSDPCGSCRQV CSGNQRRWLWGPWAWSQLL 3.81 (SEQ ID NO: 174) NM 181471 RFC2  GH 3.28 NM 003821 RIPK2  RKLNILMLLGH (SEQ ID NO: 175) 4.80 NM 001016 RPS12  YVYQSQYCGFLQPEQNCHPREEGMEFMVLAQKF 6.21 (SEQ ID NO: 176) NM 007008 RTN4  GFVFAPR (SEQ ID NO: 177) 6.68 NM 005888 5LC25A3  YSCEFGSAKYYALCGFGGVLSCGLTHTAVVPLDLV 2.38 (SEQ ID NO: 178) NM 003136 5RP54  VCY 3.38 NM 139276 STAT3  FIDAVWK (SEQ ID NO: 179) 2.31 NM 003195 TCEA2  RLSPSVSHSICRRQQFGV (SEQ ID NO: 180) 4.00 NM_144582 TEX261 D 2.14 NM 005727 TSPAN1  VCETQLHRLMTKSPLAFDTRPWDSQTLLWTPLGS GFCL 4.91 TFPGGGLGQGGHEGLSLPKTQTPVPHSVLLHPPPHLH  C (SEQ ID NO: 181) NM 018943 TUBA8 MRECISVHVGQAGV (SEQ ID NO: 182) 2.85 NM 145345 UBXD5 EDEVDMLSDGCGSEERRSQSLPAMAA  3.67 (SEQ ID NO: 183) NM_005153 USP10 DKNIRELSLVSMKSLNPVTLCREPPATVFQAH   2.07 (SEQ ID NO: 184) NM 022170 WBSCR1 GFRDDFLGGRGGSRPGDRRTGPPMGSRFRDGPPLRGS 2.55 N MDFREPTEEERAQRPRLQLKPRTVATPLNQVANPNSA IFG GARPREEVVQKEQE (SEQ ID NO: 185) NM 024699 ZFAND1 IFFHLCVMIVQEYF (SEQ ID NO: 186) 2.81 NM 017975 ZWILCH CPAEIK (SEQ ID NO: 187) 4.42

Table 2f shows FS variant sequences for which computed odds ratios were less than 2.0, but which are likely to be involved in tumorigenesis; RNA expression of BCL2L13 and DTYMK in tumor cells exceeding that in normal cells was confirmed by PCR and inspection of electrophoresis gel band intensities, and expression of DTYMK in tumor cells was confirmed by RNA extraction and sequencing.

TABLE 2f Accession ID  Gene Name Function FS Peptides NM 015367 BCL2L13 Apoptosis QFWCLWFCYDKCFWN  (SEQ ID NO: 188) NM 012145 DTYMK Kinase IFP NM 152255 PSMA7 ETC RYTQSNGRRPFGISALIVG FDFDGTPRL YQTDPSGTYH A WKANAIGRGAKSVREFLE KNYTDEAIETDDLTIKLVI KALL EVVQSGGKNIELAVM RRDQSLKILNPEEIEKYVA EIEKEKE ENEKKKQKKAS  (SEQ ID NO: 189) NM 024572 GALNT14 ETC KYGPSHTPSRSSRRSCACQS SPCSLAPQWFLSFARME MT  DSNGPKLVPTSST  (SEQ ID NO: 190) NM 003089 SNRP70 ETC RPGPGP  (SEQ ID NO: 191)

Table 2g shows genes for which FS variants were predicted and odds ratios computed as shown, but whose variants arise from indels of less than 10 bp, increasing the likelihood that the difference are due to a sequencing error.

TABLE 2g Odds Accession ID Definition Ratio FS Peptides XP_060328.1-11 PREDICTED: 53.19 VSELACIYSASFCTTMR similar to 60S (SEQ ID NO: 192) acidic NP_001772.1-67 CD69 antigen 48 VQANTHSQCHQTAMFLHALRTGLATR (p60, early T- GNATL FLL (SEQ ID NO: 193) cell) NP_001022.1-13 ribosomal 41.66 SPRSWAGPVLRDSARRCAWNSWTTRA protein S28 DPSSA M (SEQ ID NO: 194) [Homo sapiens] XP_060328.1-51 PREDICTED: 33.65 ATSTLGASSAM similar to 60S (SEQ ID NO: 195) acidic  ribosomal protein P2 NP 000995.1-62 [Homo sapiens] 22.47 VLASLPVYLLVGL (SEQ ID NO: 196) NP 001025172.1-16 ribosomal 20.69 VLALVVSVQTGTV (SEQ ID NO: 197) protein S29 isoform 2 XP 497649.1-13 PREDICTED: 18.67 VSDGVIKGVQRHEGA (SEQ ID NO: 198) similar to Cofilin,

NP_000080.2-10 80 alpha 2 type  16 VHQGPCWPPWSPWPSWTSRCKRWW I collagen  L (Homo 

(SEQ ID NO: 199) XP_170597.1-16  PREDICTED: 14.36 WAASPLSCLQTRSQRQQKIF similar to ATP VL (SEQ ID NO: 200) synthase, H+ LGASSLVMPGTLL NP 005167.1-74 transporting, 14.14 (SEQ ID NO: 201) murine mammar y NP_001559.1-45 tumor 13.52 WTFLVIPTW integration (SEQ ID NO: 202) NP_01002032.1-20 hematological 12.8 CGLQVVDPIFH and (SEQ ID NO: 203) neurological NP_722550A-28 6 reticulon 4 12.5 LQVDVGIYLCWCLV isoform B (SEQ ID NO: 204) [Homo 

NP 01017430.1-47 RNA binding 12.48 VLVSSPSPTQSMLQLP motifprotein 3 (SEQ ID NO: 205) calnexin precursor NP_001737.1-18 [Homo sapiens] 11.66 MLRLMMDMMMM (SEQ ID NO: 206) NP_008939.1-112 reticulon 4 10.71 LQVDVGIYLCWCLV isoform C (SEQ ID NO: 207) [Homo 

NP 001017430.1-48 RNA binding 10.70 LVSSPSPTQSMLQLP motif protein  (SEQ ID NO: 208) 3 NP_954654.1-14 4  Nucleophos-min 10.28 LEVVARFHRKK 1 isoform 2 (SEQ ID NO: 209) [Homo 

NP_97001.1-48 general 10.2 WLMSSRSEWVN transcription (SEQ ID NO: 210) factor IIH, NP_002801.1-36 proteasome 10.11 VIQRPAATLRTTWALSHWLMTVKC 26S non- (SEQ ID NO: 211) ATPase subunit 4 NP_004252.2-93 15 kDa 10.09 VDENWEGSLKSKLC selenoprotein (SEQ ID NO: 212) isoform 1 XP 371019A-12 PREDICTED: 10 CEYSTPTSMGGGK similar to (SEQ ID NO: 213) ribosomal

indicates data missing or illegible when filed

Example 6

FIGS. 7a, 7b, and 7c illustrate examples of a method for assessing the likely utility of a predicted candidate novopeptide as a cancer vaccine component by comparing the RNA expression level of transcripts containing the sequence of the novopeptide in tumor cells with that in non-cancerous cells. FIG. 7a demonstrates amplification of a FS variant in BCL2L13 cDNA from three different human tumor cell lines, but not cDNA obtained from normal tissue. PCR primers were designed such that they flanked the BCL2L13 FS region and amplify a FS of 253 bp if present. The left half of the figure shows amplification of three different human tumor cDNA preparations. Lane labels in FIG. 7 are as follows. Lane M, 100 bp molecular weight marker; Lane 1, MCF-7 human breast cancer cell line; Lane 2, SW480 human colon cancer cell line; Lane 3, DU-145, human prostate cancer cell line; Lane TA beta actin from SW480 cell line. Right side of gel: Lane NA, beta actin from normal colon; Lane NL, normal lung; NB, normal breast; NC normal colon.

FIGS. 7b and 7c show two additional examples of amplification of cDNA from transcripts containing sequence corresponding to frameshifted novopeptides relating to genes designated STYXL1 and HNRPUL1. The agarose gel shows a frameshift encoding a novopeptide present in tumor cells, but not present in cDNA from normal lung, breast and colon. PCR was performed as in 7 a, but with primers that flank the predicted frameshifts. Lanes are the same as FIG. 7a . Arrows mark the FS bands in each figure.

Example 7

Quantitative PCR measurement showed over-expression in tumor samples of transcripts containing sequence corresponding to another frameshift variant, SMC-IA cDNA from four fresh human pancreas tumor samples were tested for relative expression message containing sequence corresponding to SMC-IA FS using PCR primers specific for the FS sequence. Levels ofFS SMC-IA cDNA were compared to SMC-IA cDNA amplified from normal pancreas from the same patient. Table 3 shows that three of four pancreas tumors overexpressed FS SMC-IA, compared to the normal wild type sequence.

TABLE 3 Relative Expression Level Sample FS WT Panc-C 2.69 0.094 Panc-E 30.7 0.852 Panc-F 1.15 0.26 Panc-G 0.512 0.696

Example 8

This example shows that novopeptides actually expressed by tumor cells can be identified via mass spectrometry, and discloses a method for doing so, and also illustrates and discloses a method for identifying subsequences likely to be displayed in MHC. Peptides were eluted from the surface of tumor cells by exposure to 100 mM citric acid for 30 seconds, or phosphate buffered saline for 4 hours, or peptides were competed from cell surface HLA molecules with a biotinylated peptide having high affinity for the HLA molecule of interest. A database of frame shifted peptide sequences was constructed from the sequences predicted bioinformatically as described above, to enable the use of LC-MS/MS to identify novopeptides actually present in the eluted sample. The peptide sequence database was used to search spectra obtained from LC-MS/MS, using Spectrum Mill, for peptides eluted from MCF-7 breast tumor cells HLA-A*0201, -B*18/44 and -Cw*05. The HLA types were determined for the tumor cells of interest as described above. Unexpectedly, peptides longer than 8-10 amino acids were identified from LC-MS/MS analysis of the elutions that matched some sequences in the FS database. These longer peptides have been analyzed using MHC class I binding algorithms, BIMAS and SYFPEITHI, to identify preferred 9-mer sequences that are capable of binding multiple HLA class I molecules as shown below in Table 4a-4e. The algorithms use different methods of scoring peptides for binding. Sometimes the algorithms are complementary, but often they are not. BIMAS values over 150 and SYFPEITHI values over 20 have the best chance for peptides binding to MHC intracellularly and being transported to the cell surface.

TABLE 4a Parent sequence #1 eluted from MCF-7 tumor cells: VIKSLQSWYLRL VI (SEQ ID NO: 225) HLA SEQ BIMASS SYFPEITHI A*0201 SLQSWYLRL (SEQ ID NO: 214) 32    23 A*1101 KSLQSWYLR (SEQ ID NO: 215)  .036 21

TABLE 4b Parent sequence #2 eluted from MCF-7 tumor cells: FLSPMSGLLSTTQQSACTGIHRTS (SEQ ID NO: 226) HLA SEQ BIMASS SYFPEITHI A*0201 FLSPMSGLL (SEQ ID NO: 216) 12.7 23 A*1101 OSACTGIHR (SEQ ID NO: 217)  0.008 23 A*6801 QSACTGIHR (SEQ ID NO 217) 45 20

TABLE 4c Parent sequence #3 eluted from MCF-7 tumor cells: PSPQETEFPGPGVVRPILDVGKIS (SEQ ID NO: 227) HLA SEQ BIMASS SYFPEITHI A*0201 GVVRPILDV (SEQ ID NO: 218) 13 21 A*1301 VVRPILDVG (SEQ ID NO: 219) 0.405 20 B*0702 GPGVVRPIL (SEQ ID NO: 220) 120 23 B*2705 VRPILDVGK (SEQ ID NO: 221) 2000 23 B*5101 RPILDVGKI (SEQ ID NO: 222) 200 24 B*5102 RPILDVGKI (SEQ ID NO: 222) 2640 NA

TABLE 4d Parent sequence #4 eluted from MCF-7 tumor cells: (SEQ ID NO: 228) GQDCYRVPVTED  NO HLA matches

TABLE 4e Parent sequence #5 eluted from MCF-7 tumor cells: AGLGTKLAAEGLAPN (SEQ ID NO: 229) HLA SEQ BIMASS SYFPEITHI A*0301 KLAAEGLAP (SEQ ID NO:223) 0.120 23 A*0801 GTKLAAEGL (SEQ ID NO:224) 4.0 22

In related LC-MS/MS experiments, a 9-mer peptide bioinformatically predicted to be a FS of the BCL2L13 gene was identified in LC-MS/MS spectra from MCF-7 breast tumor cell elution experiments using the methods described above. The sequence of this peptide is CLWFCYDKC (SEQ ID NO: 230) and fits the HLA-A*0201 binding motif.

Example 9

Novopeptides in the FS database in association with particular tumor cell types were identified. As described in Example 8, it was observed that peptides longer than 8-10 amino acids (the expected size for WIC elutions) were obtained that matched FS sequences in the FS database. Typically peptides longer than 8-10 amino acids form epitopes for antibodies. Pursuant to the current teaching that protective or therapeutic antibodies may be generated to FS after vaccination, serum taken from patients with different tumor types was assayed for reactivity with predicted novopeptides by standard ELISA techniques. FIG. 8 shows one cancer patient in 23 with antibody reactivity in sera to peptide FS 6-21 sequence. This finding reveals novopeptides that elicit an anti-tumor antibody response upon vaccination with said novopeptides. Reactive sera 801 is indicated.

Example 10

FIG. 9 shows that the probable immunoprotectiveness of a predicted novopeptide can be assayed by immunological screening via a CTL assay, and discloses one method for doing so. CTLs activated against novopeptide FS 6-21, described above were able to kill WIC-matched tumor cells pulsed with FS 6-21 peptide 901, but not unpulsed SW480 tumor cells 903 as shown by the square symbol. Since SW480 tumor cells do not express FS 6-21 novopeptide endogenously, the cells required peptide pulsing. This is a standard Cr release assay that anyone skilled in the art would be able to do.

Example 11

A predicted novopeptide elicits a strong antibody response by genetic vaccination. A method for assay of this response is shown. Mice were immunized as described above with a gene vaccine encoding FS 6-21 novopeptide. Serum was obtained from the mice and incubated with B16 tumor cells. Antibodies specific to novopeptide FS 6-21 were shown to specifically bind B16 murine tumor cells, while pre-immune sera did not bind. FIG. 10 shows immunofluorescence images demonstrating that the anti-PS 6-21 serum binds specifically to B16 tumor cells and 4Tl breast tumor line cells and the pre-immune serum does not.

Example 12

Novopeptides can also confer therapeutic as well as prophylactic protection. Mice were injected with the B16 tumor cells and then one day later immunized with the FS 1-78 and FS 6-21 novopeptides as gene vaccines. As shown in FIG. 11, the animals receiving both peptides were protected relative to the control animals, but this protection is not as strong as a prophylactic vaccination, as indicated by the lower survival rate (one-third of the mice survived, triangle symbol, compared to 80 percent survival shown in FIG. 6 for prophylactic immunization). On Day 0, mice were injected with 105 tumor cells. One day later, mice were vaccinated with the FS 6-21 peptide sequence 1103, the FS1-78 peptide sequences 1105, a combination of both 1101, or an irrelevant peptide sequence 1107.

Example 13

Candidate novopeptides that are capable of being displayed only in one or a few HLA types that are poorly represented in the target population are less desirable than those capable of being displayed in multiple HLA types that are shared by larger segments of the target population. Here, tumor targets of interest were HLA typed, with the results as shown in Table 5, so that bioinformatically identified candidate novopeptides can then be screened using MHC class I binding algorithms, such as, for example, BIMAS and SYFPEITHI, to determine the novopeptide sequences most likely to be capable of being displayed on the MHC types present in the tumors of interest. This information was used to determine the HLA types for purposes of LC-MS/MS identification and sequencing as described above.

TABLE 5 Tumor Cell Line Histological Type HLA Type MCF-7 Breast A*02/02, B*18/44, Cw*05/05 (epithelial adenocarcinoma) SW480 Colon (adenocarcinoma) A*02/24, B*07/15, Cw*07/07 A549 Lung (carcinoma) A*25/30, B*18/44, Cw*12/16 Panc-1 Pancreas A*02/11, B*38/38, Cw*12/12 (epithelioid carcinoma) DU-145 Prostate (carcinoma) A*03/33, B*50/57, Cw*06/06

Example 14

A novopeptide associated mutation was identified that occurs in all tumors of humans and mouse identified in the public databases. This comprised a frameshift and the frameshifted gene encodes the SMC IA gene and has the sequence NGSGCSGVYCHEEPQGEDSSV (SEQ ID NO: 8) as compared to the normal wild type sequence of: NGSGKSNVMDALSFVMGEKIAN (SEQ ID NO: 7). The frameshift was found through informatic analysis of human cancer cDNA sequences compared to normal tissue. Public databases were used. The presence of the same FS was determined in mouse breast and melanoma tumor lines by sequencing cDNA from these tumor lines in the homolog of the SMC IA gene. Thirty-one (31) human tumor libraries were examined for the presence of the FS. In all 30 that were sequenced, the FS in SMC IA was identified as appearing in all lung, breast and melanoma samples but not normal samples. This correlation indicates that this mutation is oncogenic. This frameshift mutation can be used alone or in combination as a component or entirety of a vaccine, either therapeutic or prophylactic, against cancer. It can also be used diagnostically to detect early cancers. This mutation creates an oncogene that is a new anti-cancer drug target.

The FS was tested for therapeutic value as a vaccine in the mouse tumor model. The B16 melanoma line was inoculated into mice. One day later the mice were vaccinated with a gene vaccine encoding the FS. As shown in FIG. 12a , no therapeutic effect on tumor size progression was noted for the SMC-IFS 1201 relative to the control 1203. However, the 17aa novopeptide is predicted to bind the mouse B16 MHC class I molecules (MHCI) poorly. Therefore epitope-enhanced variants were made based on public programs for improving MHCI binding. When these mice were therapeutically vaccinated using the epitope enhanced novopeptide 1205 there was a positive effect. Similarly, as shown in FIG. 12b , the non-epitope enhanced novopeptide 1201 did not show significant improvement in survival time relative to the control 1203, but the epitope enhanced variant 1205 did show an improvement. Therefore the FS is present specifically in human and mouse tumors and is therapeutic when epitope enhanced for mouse. Epitope enhancement is not necessary for human tumors.

Example 15

An example embodiment of a method for producing vaccine components as disclosed herein is as follows:

(a) The NCI database and/or data from the Cancer Genome Atlas is searched and analyzed to find either a variant in the cDNA (RNA) of tumors or in the genomic DNA of tumors that is rare or absent in normal sequences of cDNA (RNA) or DNA.

(b) The presence of the variant in cDNA or mutation in DNA is confirmed by sequencing the cDNA or DNA of tumor cells and normal cells and comparing the two. A panel of tumor and normal cell cDNA and DNA are used to obtain an initial estimate of the frequency of the mutation or variation in tumors versus normal cells.

(c) RNA is extracted from tumor and normal cells and the relative expression of normal messenger RNA versus the RNA encoding the novopeptide is estimated by PCR. In the case of a mutation noted in the DNA, if the mRNA of that mutation is not present in the tumors, the corresponding novopeptide is not pursued. In the case of a variant in RNA, if the variant RNA is present at nearly the same level in tumors as normal cells, the corresponding novopeptide is not pursued.

(d) Candidates remaining at this point may be screened by mass spectrometry for being present as novopeptides on the surface of tumor cells but not normal cells. The preference is to elute peptides by acid elution or incubation in buffer to collect the medium. While peptides binding the MHCI can be eluted by more specific protocols, these would miss non MHCI peptides that may be targets of anti-tumor antibodies generated by the vaccine. Chromatographs from the mass spectrometry are compared to the unique database of possible frameshift novopeptides described herein. Candidate novopeptides may be confirmed by mass spectrometry sequencing. If a novopeptide is discovered which is longer than 9 amino acids, the MHCI eluted peptides may be specifically analyzed for the presence of a nested peptide sequence that would be predicted to bind the HLA of the particular tumor cell.

(e) The candidate novopeptide sequences or nested subsequences thereof may be screened for predicted binding to human MHCI molecules. Those that are predicted to bind tightly to common MHCis receive relatively higher scores than those predicted to bind weakly, or to bind strongly to rare MHCis.

(f) For those peptides that receive relatively high scores, mouse tumor cells may be assayed by PCR or sequencing for the presence of the RNA encoding the novopeptide. If present in mouse tumors, mice may be vaccinated with the novopeptide and then challenged with tumor cells to determine if the peptide is protective.

(g) In parallel the high scoring candidates may be screened for their presence in human tumors. A number of tumors of the same type as well as a number of different tumors are screened by PCR or sequencing of RNA to determine the overall frequency in patients. In parallel a large number of cell types and cell types from a large number of normal subjects may be screened in the same fashion for the presence of the novopeptide encoding RNA. Novopeptide variants that are very infrequent or at very low levels in normal RNA and are present at higher levels in at least 10% of tumors of one type or in 10% in all tumor types proceed to the final screen.

(h) A final defining screen may be employed to determine if the candidate is useful in a prophylactic vaccine. This step may be required before testing of a vaccine in human subjects would be permitted or appropriate. The first screen is for T-cell reactivity. T-cells from humans with the relevant MHCis will be activated with the test novopeptide. Once a population of such T-cells are created they will be reacted with human tumor cells with the corresponding MHCI type. If these tumor cells are killed or inhibited in growth, such would confirm that these tumor cells are presenting the novopeptide and are susceptible to the vaccine. This same T-cell preparation will also be reacted against a panel of normal cells of the same MHCI. If these cells are not killed or growth inhibited by the novopeptide activated T-cells, such would confirm that this novopeptide is a validated candidate for a cancer vaccine.

(i) For antibody screening the process is simpler. Antibody will be generated to the test novopeptide. This antibody will be reacted against tumor cells to determine if it binds to the surface. If it does this indicates that the tumor is susceptible to the antibody. As above, the same antibody will be reacted to a panel of human normal cells. Novopeptides that induce antibody specific binding are validated as components of a prophylactic cancer vaccine.

Example 16

Novopeptides useful (in their entirety, or operable portions or equivalents thereof) as peptide components of an anti-cancer vaccine are disclosed in Tables 6, 7, and 8 and were identified as follows: Bioinformatic screening was performed to identify chimeric transcripts in the NCBI EST sequence database by screening for transcripts containing a continuous sequence that aligns to two distinct RefSeq sequences simultaneously, and that, on translation, would produce a frameshift relative to wild type in the portion corresponding to the downstream RefSeq. Approximately 8 million sequences were screened, resulting in approximately 5,000 candidates. From this candidate set, candidates were excluded if a functional transcriptional coding sequence was not present in the upstream portion; if the chimeric EST sequence was not present in at least two independent cDNA libraries, or in three or more copies in one library, or had a junction point at an exon boundary of both portions; if the upstream portion corresponded to a reverse strand; or if the candidate was too short (less than 6 residues, or otherwise too short to accommodate primers for PCR verification). The remaining 233 candidates were screened against 50 breast cancer lines by RTPCR using primer pairs designed to amplify the predicted chimeric sequences. Of the candidates screened, 48 were verified as present in cDNA of the cancer lines. Table 6 shows these validated sequences, in which the first 10 residues are the 10 residues of the upstream sequence immediately adjacent to the junction point, read in their wild type reading frame, and the remaining residues are the downstream sequence from the junction point to the first stop codon, read in the non-wild-type reading frame arising from the out of frame junction. Also shown are the two reference exons to which the two conjoined domains align.

TABLE 6 REFERENCE NOVOPEPTIDE SEQID EXONS SEQUENCE SEQ ID THAP2_Exon2_TME FDFCTHIKSMVTYDLFLRGVGCFLLLFLF NO: 240 M19 Exon3 SEQ ID BOLA2_Exon2_SMG EGKPLLQRHRLLNR NO: 243 1 Exon12 SEQ ID GFOD1_Exonl_C6or LTRQIAVKTLEPGHQRKKISRQKNTGEKKMPRGSVQLSFCSLQ NO: 244 f114 Exon2 HPH MGHLFTPHDAALGESQGTGFKPLGMQPV SEQ ID MDS1_Exon2_EV11_Exon-4 NLKDPSYGWEILDEFYNVKFCIDASQPDVGSWLKYIRFAGCY NO: 245 DQHN LVACQINDQIFYRVVADIAPGEELLLFMKSEDYPHETMAPDIH EERQ YRCEDCDQLFESKAELADHQKFPCSTPHSAFSMVEEDFQQKL ESEN DLQEIHTIQECKECDQVFPDLQSLEKHMLSHTEEREYKCDQCP KAFN WKSNLIRHQMSHDSGKHYECENCAKVFTDPSNLQRHIRSQHV GAR AHACPECGKTFATSSGLKQHKHIHSSVKPFICEV SEQ ID C11orf79_Exon3_Cl NDWDIYYWATGPEGPFRHPGARASGHHGAGAQGSASAPPAA NO: 246 1orf66 ExonS GP GPAGAGELPTWPTLHDVGVQFQVSQGPSRPARFLAEEIDRRKG GE WLHQTVPPEPHCLPTALTGPPWGPCPPPRPECHQVRLPPQDSP T WR SEQ ID ABHD14A_Exon3_A GYRAVALDLPAHHAQRHDQQGSRGGAPIGDALPPVPAYP NO: 247 CY1 Exon2 HCPAQ A SEQ ID RBM14_NA_RBM4_Exon2 GRVIECDVVKGSCQDGEAVHRKPAPGGYRAGDSLTLRAVWE NO: 248 GAG M SEQ ID C20orf29_Exon2_VI LRKEQILAVASLVSSQSIHPSWGQSPLSRI NO: 249 SA Exon2 SEQ ID RRM2_Exon9_C2orf LMLELGFSKVLGDREVQSRWSPGPRGDSTPVREMETNHPPSV NO: 250 48 Exon2 RG SEQ ID ELAC1_Exon2_SMA QLMKSQLKAGYPEYMSNNFPCNVSCCFSLFPKDQNCFRN NO: 251 D4 Exon2 WRHI SEQ ID BCAS4_Exonl_BCAS LFLTPEPGAEVPLTGA NO: 252 3 Exon24 SEQ ID C22orf39_Exon2_HI WEERRNAEAQASRFFQLIFTLTGPSSQLEDKG NO: 253 RA Exon2 RILGRL SEQ ID PMF1_Exon4_BGLA QVQAQQQAWQVRSPAVQSPAKVQPLCPSRRAAR NO: 254 P Exon4 SEQ ID SDHD_Exon3_TEX12 LAAALTLHGHCLQCQIVHSCPLLENQIHLSLKFPDYFIKMK NO: 255 Exon3 PWRKI SEQ ID PRR13_Exon3b_PCB KHHKYHKHGKFLAFTPNQ NO: 256 P2 Exon2 SEQ ID RMNDSA_Exon2_AN VSRVGKAIDKDSL NO: 257 APC1 Exon25 SEQ ID TYMP_Exon9_SCO2 VDVGQRLRRGASDPCCC NO: 258 Exon2 SEQ ID NAIP_Exon13_OCLN ISAEYDPSKLG NO: 259 ExonS SEQ ID Clorf151_Exonl_NB  CLADAVVKIGLWRPRA NO: 260 Ll Exon3 SEQ ID DDIT3_“Exon3_MAR ENGGTYVSPPLPLGASGGFPSATANCFFRSKSFATSAATSFLSAFC NO: 261 S “Exon21 AF SSRTMFPCFVTSSISACICCGLAVVTVSTTAGFGDVFAWPPPK RCLK LSIWSFSNFWNKGLTVPIWCPAGKVHRKFVSRILQAGGGSCS WAW IVALTVGM SEQ ID RIPK3_Exon9_ADCY RTPEPNPVTGADLRPELPDHCAVRAGRLLAAAGPRFPGAATA NO: 262 4 Exon2 ALDA SPVRLGMGRAASARPRLPVHRGRGERLGPGVLFSLRHLHGVC HAA LGHAGRRRRGPRLLTLASAGPRAVSWATAGLTACTAAAVGS KRSA VPVRERGRSVPQGADGARPAGHVPGGTQLPALTPAAGHREEA PG TPSLVHPSCLPGPRDEGRDHGTAAGRTGVTAREH SEQ ID COMMD3_Exonl_B LDAQADEAVLGFFIKQKCIEQRESRSLS NO: 263 Mil Exon2 SEQ ID MED8_Exon7c_ELO KSASMHPYQRVLSQDGGCCELVPRGDEARRSPDPGLPSDGVP NO: 264 VL1 Exon2 LAN DLHSPDLRVLRSLTWASHHG SEQ ID POLR2J3_Exon2_LO DHTLGN 11 KSRACFPFAFCRDCQFPEASPATLSVQPAEL NO: 265 C100134053 NA SEQ ID BGLAP_“Exon2_PM QVQAQQQAWQVRSPAVQSPAKVQPLCPSRRAAR NO: 266 Fl “ExonS SEQ ID TMEM199_ExonS_S QYIFTEMASRPRGAHWAGRDPEPGEGTRTRRAGAERGRHLGA NO: 267 ARM1 Exon2 HV QAFGGDMPEAGGGRRPGRGAVLVPPHGPRAAAPLRAGAGQL RA ARGPGGAATHGREARSRVALPARLLQGGRAASAARLPRSSGV GD SEQ ID C1QTNF6_Exon2_IL2 PYINITILKGLPSSAPPCGCNGGPCSVLASAPPHPPPAPGYLLGIC NO: 268 Exon2 SGE WHFPVHMLLQLESQHLLCLEPRWGSAGHFLPSPCLAGQTAVE PNL SEQ ID LOC100131434    KLEEAGMLEMRPSTPCLHGAALHLHSG NO: 269 NA_FLJ44451 NA HGSGSRLTNSSCFPGTRRL LALQFTQQTGTVG HPTWQPVI R SEQ ID COX19_Exon2_CENT KEYLECRMERSRLGLLHSGRLHLPELLGNPPEYPPGQQGEVRPPGR NO: 270 Al Exon2 L GGGPSGVHGLPRERRRESQV SEQ ID ACSF2_Exon10_CHA  INKINMKDLVRNLRKKLQHGKMDSKAPMSC NO: 271 D “Exon4 SEQ ID TIMM23B_NA_LOCI  TMTGM LYKCTVSEMALDSPFCVLLSGS NO: 272 00132418 NA SEQ ID NDUFA13_Exon4_VJ IIMKDVPDWKGLGAAAPTCRHGKSGA NO: 273 EFN3 Exon2 SEQ ID ADHFEl_Exon13_C8  PALVKGTLPQYPVQPEEEPKALSTS NO: 274 orf46 NA SEQ ID HPS4_Exon13_ASPH QLPALYEMTVSNSCTS NO: 275 D2 “Exon4 SEQ ID KIAA1267_Exon2_A  DIYKQIRANKVSVWRQ NO: 276 RL17P1 Exon3 SEQ ID LOC100129406   RTSALAERTHSIGHISTMLMAF NO: 277 NA_CTTNBP2NL NA SEQ ID K Exon2 LKGHYAITRKVYQPQSLHVSKSSRK NO: 278 SEQ ID DEDD_Exon4_NIT1_Exon6  PYVTLKRRRAAPSGLGL NO: 279 SEQ ID RAD54B_Exon3_LOC LATLDPPHTVQTWMRRHRLVPVHYR NO: 280 100128414 NA SEQ ID TOPORS_Exon2_DD PARPAPASSEKRCSIFRLRKTTRAQWRLPHFFSSSCWSSRRKAG NO: 281 X58 Exon2 SVA FWMP SEQ ID NDUFC2_Exon2_KCT LHPEDFPEEDVYCCGAERRG NO: 282 D14 Exon2 SEQ ID LRRC57_“ExonS_SN CCPRLKILRLSALSVIRFICGF NO: 283 AP23 Exon8 SEQ ID IP011_NA_SLRN LLSLLPSDNSLASKGP NO: 284 NA SEQ ID SNRPF_Exon2_CCDC VSVDGYMNMQQDFHLHLGNIETK NO: 285 38 “Exon12 SEQ ID NDUFB8_Exon4_SEC GDVYPVYQPVDRP NO: 286 31B Exon2 SEQ ID MIA_Exon3_RAB4B_Exon2 KPGKVDVKTDTSSSNSW NO: 287 SEQ ID NIT1_Exon6_DEDD_Exon4 GSITGPAHWEQPVSS NO: 288 SEQ ID Rnf139_Exonl_Nduf IVLQI FLRLFETNTDTLLV NO: 289 b9 Exon2

As already noted, it is accepted by persons of skill in the art that homologous sequences in closely related organisms that are accepted in the art as suitable models one for another are expected to function similarly. Thus, for example, the novopeptides disclosed in Table 6 may be species-adapted for use in other closely related species such as, for example, dog and mouse. A novopeptide identified with respect to a first species may be species-adapted for use as a peptide component of an anti-cancer vaccine for administration in a second species in any manner operable to better adapt the novopeptide to function in the second species. By way of example, a novopeptide identified as having a first domain that aligns with all or part of a first gene of the first species, and a second domain that aligns with all or part of a second gene of the first species, may be adapted by modifying the first domain to improve its alignment with all or part of a gene of the second species that is homologous to the first gene, and modifying the second domain to improve its alignment with all or part of a gene of the second species that is homologous to the second gene. Accordingly, also disclosed herein are several of the novopeptides disclosed in Table 6, that have been species-adapted for dog (Table 7) and mouse (Table 8).

TABLE 7 SEQID RELATED SEQ. NOVOPEPTIDE SEQUENCE SEQ ID THAP2_ Exon2_ FDFCTHLKSMAIYSLFLLG NO: 242 TMEM19 Exon3 VGCSLSSFLF SEQ ID Rbm14_ Exonl_ GRVIECDVVKGAYQDGEAV NO: 236 Rbm4b Exon2 HRKPAPGGHRAGDPLTLRA VWEGAGV SEQ ID IPO11-SLRN LLSLLPSDNSRLTSKGP NO: 306 SEQ ID MIA-RAB4B KPGKI DVKTDSN RTPTTQSAWSLDLG NO: 307 SEQ ID M ED8-ELOVL1 KSASMHPYQRVP NO: 308 SEQ ID ABHD14A-ACY1 YTQEQFWAVKLTKRGA NO: 309

TABLE 8 NOVOPEPTIDE  SEQID RELATED SEQ. SEQUENCE SEQ ID   THAP2_ Exon2_ TMEM19_Exon3 FDFCTHIKSLV NO:238 TFGLFLRGAGC SPSSFLL SEQ ID  Rbm14_ Exon1_ Rbm4b_ Exon2 GRVIECDVVKG NO:232 SCQDGEAVHWK SAPGGHRAGDP LTLRAVREGAGM SEQ ID   Thap2 + Tmem 19(2) FDFCTHIKSLGWWSDSS NO:299 SEQ ID   Rnf 139 + Ndufb 9 GLQIFLRLLGTSTGTLLA NO:300 SEQ ID   Lats2 + Xpo4 IAPEVLLRKGTTFHGQ NO:301 SEQ ID   Slc35a3 + Hiat 1 QSVWIRNIQLASRN RLP NO:302 SEQ ID   Rbm14 + Rbm4b GRVIECDVVKGGMCVG NO:303 SEQ ID   Mia 1 + Rab4b (1) KPGKIDMKTDSNRTPTTL NO:304 SAWSLDPGWSTLGGRL SEQ ID   Lats2 +Xpo4 KPGKIDMKTDTSSSNSW NO:305

Example 17

From the candidate FS peptide sequences disclosed in Table 8 two candidates were selected for in vivo confirmation. The candidates chosen will be referred to herein as FS RBM (SEQ ID NO:232) and FS THAP2 (SEQ ID NO:238), these novopeptides having upstream in-frame portions that align with the mouse Rbm14 and Thap2 genes, respectively. These candidates were chosen as the longest candidates the presence of whose sequence was confirmed by RT-PCR in cDNA of Tubo tumor, a mouse breast cancer cell line derived from the BALB-neuT mouse model intended to be used. The BALB-neuT mouse model is a transgenic mouse breast cancer model, in which all ten mammary glands of a female mouse will develop breast tumor around 20 weeks of age, driven by overexpression of a mutant rat Her2 gene.

FS RBM and FS THAP2 peptides were tested in vivo as candidate peptide components of a prophylactic anti-cancer vaccine. BALB-neuT mice were immunized at 4 to 6 weeks old (primary genetic immunization); 8 to 10 weeks old (boost genetic immunization) and 12 to 14 weeks old (boost peptide immunization). All genetic immunization had the same genetic adjuvant for each bullet for gene gun immunization: 250 ng mixed LTA-LTB/pCMVi and 2.5 μg CpG 2216. All mice received two shots at each ear by gene gun for each genetic immunization. At primary immunization, the vaccine group got two shots of bullets containing 100 ng (high dosage) or 20 ng (low dosage) mixed FS antigen plasmids per bullet; while negative group got two shots of 100 ng mixed empty plasmids for each shot. At boost genetic immunization, all mice received genetic immunizations twice, three days apart, with dosage of 1 μg of mixed FS antigen plasmids or empty plasmids for each bullet. At boost peptide immunization, each mouse received subcutaneously injected total 100 μl vaccine formulated with 50 μl Alum and 50 μg CpG 2216 as adjuvant; and 50 μg total single FS peptide conjugated KLH or equally combined different FS peptide conjugated KLH (vaccine group) or 50 μg KLH protein (negative group). There were 14 mice in the no treatment group; 30 mice in the negative control group; 22 mice in the FS RBM group and 24 mice in the FS THAP2 group.

Both FS RBM and FS THAP2 showed significant prophylactic protection in inhibiting first tumor onset and tumor progression in BALB-neuT mice as compared to the non-treated group and negative control group, as shown in FIGS. 13a and 13b . The data shown combines two experiments with different dosages at the primary genetic immunization (20 ng and 100 ng of the vector); no significant difference in results was noted as between the two dosages. FIG. 13a shows the percent tumor-free status over the course of the experiment for the no-treatment group 1301, the negative control 1303, the FS RBM group 1305, and the FS THAP2 group 1307. FIG. 13b shows percent tumor-free status of the 10 mammary glands over the course of the experiment for the no-treatment group 1301, the negative control 1303, the FS RBM group 1305, and the FS THAP2 group 1307. By both measures it can be seen that tumor progression is significantly delayed for the immunized groups as compared to the controls.

Example 18

In vivo evaluation of prophylactic immunization using anti-cancer vaccine compositions including several pooled FS antigens was performed with results as shown in FIGS. 14a and 14b for four groups: control group (44 mice, including no-treatment group and negative control group); individual FS group (102 mice) including groups each immunized with one of FS SMC IA (SEQ ID NO:8), FS 1-78 (SEQ ID NO:2), FS RBM (SEQ ID NO: 232) or FS THAP2 (SEQ ID NO: 238); three antigen group, immunized with a vaccine composition wherein FS SMCIA, FS 1-78, and FS RBM were pooled; and four antigen group, immunized with a vaccine composition wherein FS SMC IA, FS 1-78, FS THAP2, and FS RBM were pooled. Mice were immunized substantially in accordance with the protocol disclosed in Example 17 above.

FIG. 14a shows the percent tumor-free status over the course of the experiment for the control group 1401, the individual FS group 1403, the three antigen group 1407, and four antigen group 1405. FIG. 14b shows percent tumor-free status of the 10 mammary glands over the course of the experiment for the no-treatment group 1401, the individual FS group 1403, the three antigen group 1407, and four antigen group 1405. It can be seen that all the immunized groups showed significant protection relative to the control group, and the pooled three antigen group showed superior protection relative to the individual FS group.

Example 19

Sequences, 23 in number, for use as peptide components of an anti-cancer vaccine were determined based on frameshifts as bioinformatically predicted to arise from microsatellite loci in mouse. These are enumerated in Table 9.

TABLE 9 SEQID NO Mouse Gene ID Sequence SEQ ID NM 153511.3 TLCMEVMLRWNTRELGYLYLQLCFLNTHFLHTSQEEKLLT NO: 310 LGRFLTWTS RCGSFVIRPL SEQ ID NM 053009.3 ICMSPPLLWATLQAPETTSAACKASYRPEGLYL NO: 311 SEQ ID NM 010086.4 YFSCDKRCIKHYAGNKSLLTFSGY NO: 312 SEQ ID NM 001114663.1 KKSCPRYDPTLISLLYQCVS NO: 313 SEQ ID NM 146792.2 FLFPAFSCM PDLFITFLVTNTLLYFIQFSLPC NO: 314 SEQ ID NM 001081355.3 SAGTESDPSEEQICEAEGRPEGHFRGVLTYLPLL NO: 315 SEQ ID NM 029998.3 LSKTPSKKCSLRM NTKFYRSFTSLKSLIVTFLRMVWWM NO: 316 LLRLEPISWKI SEQ ID NM 001163189.1 HIQGQAEAGAVPGRALACWDLSAPVLPFTWDEGVEIYR NO: 317 GPNTVVLL SEQ ID NM 147003.1 FPPPGRCGLSSLDSHGL NO: 318 SEQ ID NM_ 009499.3 HPQVCPPQGYLGQVMEQGQPH PLHPHSLQH RAPIVGVPG NO: 319 PQAWLL PLLEPNSGK SEQ ID NM 130448.3 KKRASPLLGRTPLATRIRETLAHHLCYQK NO: 320 SEQ ID NM 033618.3 IPSWGRSFYCGNVLPSYHSEWWQL NO: 321 SEQ ID NM 001081302.1 GLFHARISVQEQYQGELPLLGGKCGERSL NO: 322 SEQ ID NM 028664.1 GVNGARRNSRIGEFRKVTIFLTARV NO: 323 SEQ ID NM_ 001034881.3 VTAGYQEEEMEASACGAKGPGLAPWPPSWLALQDSLLCV NO: 324 VVALADLR RKSCC SEQ ID NM 001033226.4 SLSLSFLH RWMDKTVGTI NO: 325 SEQ ID NM 153511.3 TLCMEVMLRWNTRELGYLYLQLCFLNTHFLHTSQEEKLLT NO: 326 LGRFLTWTS RCGSFVIRPL SEQ ID NM 001160399.1 RVYSKLENQKAAKEGGNTQVKRKGGHRASAFSKQS NO: 327 RR SEQ ID NM 025441.3 AKEQAAAEAAE EQAAACRCGSQPVSLCQCQKIL NO: 328 SEQ ID NM 001109759.1 RQKKIRPPKKKRSIQGQRQKPPRDHRCECDQLFCFFW NO: 329 WGGNP SEQ ID NM 028787.4 LLCVVFG KFVIPRSTFRHTGCHSEYFVFNFWTFYFN NO: 330 PCSCISE SEQ ID NM 027009.2 LKSAPLQATTTLKLIPVMRGTATEL NO: 331 SEQ ID NM 001081345.2 VLPNLPSQSSTF NO: 332

The first three peptides (SEQ ID NO: 310, SEQ ID NO: 311, and SEQ ID NO: 312) were tested in vivo and shown effective in prophylactically inhibiting tumor progression in BALB/C-4Tl mouse transplant breast tumor model. Primary genetic immunization was administered with the three peptide components (10 mice) or with empty vector (negative controls, 4 mice) at 7 weeks old and 13 weeks old. Three weeks after the last immunization, all mice were challenged with 5,000 4Tl tumor cells. Tumor size was measured each day after palpable tumors appeared. FIG. 15 shows average tumor size for the negative control group 1501 and the immunized group 1503. Error bars show standard error.

Human and dog peptide candidate sequences homologous to those of Table 9 are shown in Tables 10 and 11, respectively (not all of the mouse sequences of Table 9 have homologs in human and dog).

TABLE 10 SEQID NO Human Gene ID Sequence SEQ ID NM 015866.4 SASTESNSSEKQICKAEGRLEKCL NO: 333 SEQ ID NM 152512.3 QSRIPSKKCSLRKSTKSYKSCTN LRNLAPT NO: 334 SEQ ID NM 003370.3 PPHPQVCPLRGSQLQRTEQGEDHPLHPLSRQHRALVVGELGP NO: 335 QAWPQ LLLEPNSGKSASRRRPQGGPQPPKLRVVEAEVGDSWK R SEQ ID NM 007192.3 IPCWGRPFYCGNVLPSYHSEWWQL NO: 336 SEQ ID NM 007118.2 KEGLLHAGIPV NO: 337 SEQ ID NM 152549.2 RVNSDLEN NO: 338 SEQ ID NM 025181.3 LLCVVFGKFVISRSTFRHTSCYS NO: 339 SEQ ID NM 002915.3 LKLAPLQVTTTLKLILVMLEIVTE NO: 340 SEQ ID NM 001271.3 KLLNLSCQSCT NO: 341

TABLE 11 SEQID NO Dog Gene ID Sequence SEQ ID XM 850372.3 QSRIPSKKCSLRKSTKSYKSCTSLKSLVPT NO: 342 SEQ ID NM HPLVCPSQGALRQGTEQGEAHPLRPLSPQH KAPVVGEQG NO: 343 001003256.1 PPVLQQPLP EPNSGKSASKRRPQGGPQSLKQRALEARAGG SEQ ID XM 846473.3 VPGRGRPFYCGNVLPSYHSEWWQL NO: 344 SEQ ID XM KKGLLDARIPV NO: 345 005639663.1 SEQ ID XM RVYSELENQKAAKEGGNFQVKGKSREPISTLS NO: 346 005626355.1 SEQ ID XM 533330.4 LLCVVSG KFVVSRSTFRHTGCYS NO: 347 SEQ ID XM ILLNLSSESCTF NO: 348 005618324.1

Example 20

Sequences, 142 in number, for use as peptide components of an anti-cancer vaccine were determined by comparing NCBI EST database sequences with human RefSeq generally according to the criteria described in Example 16 above and identifying sequences wherein the upstream non-frameshifted domain and the conjoined frameshifted domain corresponded to different genes. These are tabulated in Table 12. Sequences shown are the 10 residues of the upstream non-frameshifted domain immediately adjacent to the junction point, together with the full sequence of the frameshifted domain up to the first stop codon.

TABLE 12 SEQID NO Upstream ID Downstream ID Sequence SEQ ID NM001080414.2 NM198530.2 MDVTVSELLEN NO: 349 SEQ ID NM001127716.1 NM004589.2 MFRAAAPGQLS NO: 350 SEQ ID NM001005409.1 NM001127398.1 MPAGPVQAVPS NO: 351 SEQ ID NM182568.3 NM002767.2 MASWGGEKRGL NO: 352 SEQ ID NM000094.3 NM033199.3 MTLRLLVAALA NO: 353 SEQ ID NM004536.2 NM002538.2 MATQQKASDEG NO: 354 SEQ ID XM001725801.1 XM377073.4 MTPVRMQHSLR NO: 355 SEQ ID XM001725801.1 NM182905.3 MTPVRMQHSLR NO: 356 SEQ ID XM001717526.1 NM018081.1 MGSKIYSYEFV NO: 357 SEQ ID NM001131028.1 XM001715307.1 MEEDEFIGEKV NO: 358 SEQ ID NM080664.2 NM016106.2 MAEGSRIPQAGF NO: 359 SEQ ID NM016616.3 NM017549.3 MASKKREVQLII NO: 360 SEQ ID NM004136.2 NM181354.4 M DAPKAGYAFEI NO: 361 SEQ ID NM015004.3 NM003278.2 MASVTLSEAESA NO: 362 SEQ ID NM013293.3 NM024322.1 MSDVEENNFEVF NO: 363 SEQ ID NM005085.2 NM175878.3 MGDEMDAMIPAP NO: 364 SEQ ID XM001129743.1 NM001031716.1 MAFGEVEHTDDA NO: 365 SEQ ID XM001721832.1 NM053052.2 MRARLRFLPSDC NO: 366 SEQ ID NM001145.3 NM002937.3 MVMGLGVLLLHL NO: 367 SEQ ID NM033542.2 NM001048225.1 MAGQFRSYVWWS NO: 368 SEQ ID NM018281.2 NM004462.3 MLRVLCLLRPDLP NO: 369 SEQ ID NM002300.5 NM016078.4 MATLKEKLIAGSF NO: 370 SEQ ID NM022780.2 NM022662.2 M DQCVTVEREDSL NO: 371 SEQ ID XM001717653.1 NM152705.1 MYFLNDALCAGKQ NO: 372 SEQ ID XM001719888.1 NM004906.3 MAERGGWREADSR NO: 373 SEQ ID XM001717673.1 NM201554.1 MGGGPAREKGPTL NO: 374 SEQ ID NM005004.2 NM015490.3 MAVARAGVLGDRP NO: 375 SEQ ID NM020984.3 NM001042427.1 MAAKTPSSEELCWP NO: 376 SEQ ID NM016406.3 NM005614.3 MADEATRRVVGNPH NO: 377 SEQ ID NM032775.2 NM182895.1 MAEEQEFTQLRDQV NO: 378 SEQ ID NM030940.3 NM016548.2 MSASLVRATVDSQR NO: 379 SEQ ID NM001002001.1 XM001715885.1 MPHIDNDVKLGADK NO: 380 SEQ ID NM001031827.1 NM015092.3 MASAKSLDRWFCTE NO: 381 SEQ ID XM001718309.1 NM015681.3 MRTGSRAPSEVSRV NO: 382 SEQ ID XM943571.2 NM022483.3 M RRPRLPAQAVLEM NO: 383 SEQ ID XM001716831.1 NM017897.1 MYFHKKPPALGMCF NO: 384 SEQ ID NM001013845.1 XM001720996.1 MKFGCLSFRQLQNP NO: 385 SEQ ID NM178124.3 XM001720996.1 MKFGCLSFRQLQNP NO: 386 SEQ ID NM014251.2 NM006304.1 MAAAKVALTKLGWLR NO: 387 SEQ ID NM001928.2 NM005481.2 MHSWERLAVLTLTRS NO: 388 SEQ ID NM016374.5 NM001037277.1 MKISFEV NO: 389 SEQ ID NM005600.1 NM032998.2 MLGFITRPPHQPVSS NO: 390 SEQ ID NM001487.2 NM002905.3 MLSRLLKEHQGFLVW NO: 391 SEQ ID NM001032363.1 NM182744.2 MSESELGRKWLWRPRA NO: 392 SEQ ID NM001010974.1 NM001099432.1 MQRTGGGAPRVPLTGA NO: 393 SEQ ID NM006868.3 NM001402.5 MMAIRELKVCCRENYP NO: 394 SEQ ID NM015215.1 NM018948.2 MWRAEGKWLPGMKATG NO: 395 SEQ ID NM001002840.1 NM001013739.2 MQHREVRVKCNTEKSA NO: 396 SEQ ID XM001130925.2 XM001126402.2 MASASCSPGRWNNPKF NO: 397 SEQ ID NM001134779.1 NM181506.4 MVQPIIHLGYLASKGP NO: 398 SEQ ID NM006328.3 NM002896.2 MKIFVGNVDGGGMCVG NO: 399 SEQ ID NM152350.2 NM014288.3 MFPGSLSRGRHDVAIKS NO: 400 SEQ ID NM015004.3 NM003278.2 MASVTLSEAECCEHKDV NO: 401 SEQ ID NM014662.3 NM004147.3 MRTTKVYKLVLWSGVSL NO: 402 SEQ ID NM006837.2 NM012207.2 MAASGSG MAQVTMG KAA NO: 403 SEQ ID NM001113756.1 NM005138.2 MAALMTPGTGASDPCCC NO: 404 SEQ ID NM032998.2 NM005600.1 MAGLKRRASQAPSGLGL NO: 405 SEQ ID NM001113756.1 NM005138.2 MAALMTPGTGASDPCCC NO: 406 SEQ ID XM001714553.1 NM001114620.1 MWNAALPGPTHGCLLIP NO: 407 SEQ ID NM133638.3 NM014031.3 MRLTHICCCCERRKCRNH NO: 408 SEQ ID NM001005354.2 NM001128914.1 MWN PNAGGPPFLAFTPNQ NO: 409 SEQ ID XM001715546.1 NM020987.2 MANETLFSSPSLM PMQVT NO: 410 SEQ ID NM004388.2 NM005274.2 MSRPQLRRWRKFPRQLQT NO: 411 SEQ ID NM016622.3 NM022912.2 MAASAFAGAVSRGFGGRG NO: 412 SEQ ID NM000296.2 XM001725512.1 MPPAAPARLAVDGRMATWM NO: 413 SEQ ID NM001098504.1 NM005839.3 LPTGFVAPILKSLGLKMML NO: 414 SEQ ID NM012112.4 NM001031711.2 MSQVKSSYSYMEMCGMHMS NO: 415 SEQ ID NM018233.3 NM031885.2 MNGKRPAEPGPRKKLSPLA NO: 416 SEQ ID NM022739.3 XM001719702.1 MSNPGGRRNGVLSRVMTTP NO: 417 SEQ ID NM182471.1 NM001005.3 MSKPHSEAGTGSANIQEEEVCR NO: 418 SEQ ID XM001722372.1 NM018704.2 MAGRPGSQEQSIGNISTMLMAF NO: 419 SEQ ID NM153260.2 NM003825.2 MGNSALRAHVSALSVIRFICGF NO: 420 SEQ ID NM014774.2 NM022745.3 M KKRKELNALRCLGETVCEQRIH NO: 421 SEQ ID NM016040.3 NM015361.2 MGDKIWLPFPIKLYPTSSKTTKE NO: 422 SEQ ID XM001714221.1 XM001714962.1 MRTLPLRFAGYFNSRPHLCPAGS NO: 423 SEQ ID NM182533.2 XM001714962.1 MEAARRPRLGYFNSRPHLCPAGS NO: 424 SEQ ID NM003095.2 NM182496.1 MSLPLNPKPFQDFHLHLGNIETK NO: 425 SEQ ID NM001127184.1 NM015147.2 MSAEVIHQVEDILLSAGRADLLAV NO: 426 SEQ ID NM030980.1 NM052998.2 MSTLLLNLDFGSAAKAADGCRTGG NO: 427 SEQ ID NM001630.2 XM001715226.1 MAWWKAWDSGILPLRNALLLG NO: 428 SEQ ID NM207116.1 NM021163.3 MEEGNNNEEVVYQPQSLHVSKSSR NO: 429 K SEQ ID NM012415.2 XM001722896.1 MRRSAAPSQLQTWM NO: 430 RRHRLVPVHYR SEQ ID NM182641.3 NM002266.2 MRGRRGRPPKSFLPLSHNHVHQREC NO: 431 SEQ ID NM015965.5 NM198537.2 MQEPRRVTPCGLGAAAPTCRHGKS NO: 432 GA SEQ ID NM005833.2 XM001715611.1 MKQLPVLEPGTGFHRVSQDGLDLLT NO: 433 S SEQ ID NM001128208.1 NM001100916.1 MAGIKALIS LRVQM SASGTYPSSPG NO: 434 L SEQ ID NM014637.2 XM001720291.1 MLGWIKRLIRSLPAGFIQPHVSKHCL NO: 435 G SEQ ID XM928114.3 XM001719607.1 M EGGGGSG N NO: 436 KVSEMALDSPFCVLLSGS SEQ ID NM016026.3 NM006370.1 MVELMFPLLLWQRWRRSYVMHPC NO: 437 LSETP SEQ ID NM022730.1 NM002867.2 MAGEQKPSSNVETGFHLVSQDGLD NO: 438 LLTS SEQ ID NM006454.2 NM006503.2 MELNSLLILLSRQGGSEDPAGAAES NO: 439 DGWI SEQ ID NM025149.4 NM001267.2 MAVYVGMLRLRNLRKKLQHGKMD NO: 440 SKAPMSC SEQ ID NM000031.5 NM024939.2 MQPQSVLHSGSIVFEARGDKAEIRD NO: 441 GALQQG SEQ ID NM006116.2 NM018133.2 MAAQRRSLLQTFATRSYCTHQLHLP NO: 442 TLCLQNL SEQ ID NM007221.2 NM199173.3 MAEASSANLGVRSPAVQSPAKVQPL NO: 443 CPSRRAAR SEQ ID NM007221.2 NM199173.3 MAEASSANLGVRSPAVQSPAKVQPL NO: 444 CPSRRAAR SEQ ID NM007221.2 NM199173.3 MAEASSANLGVRSPAVQSPAKVQPL NO: 445 CPSRRAAR SEQ ID NM005358.4 NM000358.2 M NO: 446 KKIRICHIFKCWTPWSAMSTLSCSM PSATIWW AGES SEQ ID NM016075.2 NM018676.2 MDRFVWTSGLCFWGKKSQSGREKG NO: 447 HEETKDLGF CQSE SEQ ID NM001012754.2 NM170719.2 MARFWVCVAGFQGGLQSSSCYDIFL NO: 448 WNNPRKSI SQRKT SEQ ID NM014637.2 XM001720291.1 MLGWIKRLIRVPSSWLYSAPRVQAL NO: 449 SGIALYWKT WPIL SEQ ID NM018049.1 NM032482.2 MRYNEKELQATETPRDPRQACPASQ NO: 450 GMLRAMD SREIQK SEQ ID NM145301.1 NM173622.3 MLQQDSNDDTEPSEMSCTRNFKREF NO: 451 SAGRRGRQ DIRTRI SEQ ID NM024061.3 XM001716989.1 MEEIPAQEAADFQFPSLMGSPSWNR NO: 452 IYRSLIWKL RLEKS SEQ ID XM001715735.1 NM014393.1 MVARPLHSTERLPTTRTLAYFLKIEEK NO: 453 KEDRKRRTQ RYTK SEQ ID XM001719043.1 NM138401.2 MSVSVLAPAGSPAPSRGHPPALARA NO: 454 SRRNLATSC ALVLWAA SEQ ID NM006098.4 NM015458.3 MTEQMTLRGTVRPGWSAVVRSRLT NO: 455 ASSASRVHTI LLPQPPE SEQ ID NM001013839.1 XM001725398.1 MIPPQEASARISPGHEHDFRVKHLSE NO: 456 ALNDKHGPL AGEYRSPA SEQ ID NM018696.2 NM005359.5 MSMDVTFLGTYPEYMSNNFPCNVS NO: 457 CCFSLFPKD QNCFRNWRHI SEQ ID NM001034.1 NM182626.1 MLSLRVPLAPLGDREVQSRWSPGPR NO: 458 GDSTPVRE METNHPPSVRG SEQ ID XM001714450.1 XM001714789.1 MGSSAVQSQLWHFSTPLEPMPRRNKGCA NO: 459 ASPW LTQWPRPRKSQR SEQ ID XM001721832.1 NM023007.1 MRARLRFLPSTG LRCSLLCLDRPG RARPH NO: 460 LHHTQC EEGLGTHHS SEQ ID NM006328.3 NM002896.2 M KlFVGNVDGGSCQDG NO: 461 EAVHRKPAPGGYRAG D SLTLRAVWEGAGM SEQ ID NM001006947.1 NM017771.3 MAGIIKKQILNILFECKEEFLWKTAGRLL NO: 462 EDTVTLIC LTTAYRLQA SEQ ID NM001031665.1 NM001105552.1 MLREEATKKSGSIDIQGCGHRILSGGVEMP NO: 463 GPCSE DSIQRCDVGEL SEQ ID NM003002.1 NM031275.4 MAVLWRLSAVCLQCQIVHSCPLLENQIH NO: 464 LSLKFPD YFIKMKPWRKI SEQ ID NM006743.3 XM001127723.2 MSSEEGKLFVLGGGGQRQTEPGRLGGDD NO: 465 WSCM RPRSHLWMVDLPWA SEQ ID NM207116.1 NM018053.2 MEEGNNNEEVGLASAHPSWASRGHCST NO: 466 TTGPCA PASPPSRSWAWAPP SEQ ID NM001079673.1 NM001984.1 MAEHPPLLDTN NO: 467 RLPFGASKKQSAIGQEKNGIEAD FQQQVLWGIAESF SEQ ID NM005802.2 NM014314.3 MGSQPPLGS PKRCSI NO: 468 FRLRKTTRAQWRLPHFFSSS CWSSRRKAGSVAFWMP SEQ ID NM007273.3 NM181642.2 MAQNLKDLAGALRGPARHRTLQGEHP NO: 469 ALVLQPL QRTLRPLYLWWLLRQQEQL SEQ ID NM001320.5 NM021221.2 MSSSEEVSWISSCSRHPDVPLLPRRRPFCR NO: 470 MHFRL REVYHQQLIPVHGDHHLL SEQ ID XM001132260.1 NM018427.3 MAKRRRPKKRDSQRHFWNISGKNCRTQVI NO: 471 LPSSG RLLEII LEAFWQELN LFLLLL SEQ ID NM000972.2 NM000787.3 MPKGKKAKGKLSHPPGPGGVPGALMEC NO: 472 QLHPG GHPFPAPGAEAQGWRPVWDVRPWRA SEQ ID XM001723697.1 XM001716892.1 MRGQTEEVVASASWAVPSTCCFRSCKP NO: 473 LLAMAS GYLWSRQEQLERRWILPRVAMPSASS GF SEQ ID NM007221.2 NM199173.3 MAEASSAN NO: 474 LGCEAQRCRVQQRCSLCVQAGGQR GSEETQALPVSMAGSPSPLPGSPGAQE GGV SEQ ID XM001721832.1 NM053052.2 MRARLRFLPSEAEEAWTLAHTDPGTDE NO: 475 QGCLHP HLAVHLLPGAQEAMGYWTAVLNIAV AQVH D SEQ ID NM006396.1 NM001098785.1 MALNGAEVD DGGAAAVG NO: 476 HVLVVPAVG PVRVNP GLQTPVPRPELLPGPVILPPFGQLLPTG CGPV SEQ ID NM153260.2 NM130798.1 MGNSALRAHVM LLHGQTQRPQH NO: 477 LLSSVKVFSVS LMSLFIWSKPSSMRFSCSFCSSSIVMVL IPAS SEQ ID XM001713865.1 XM001714058.1 MDPASRGCLGRPSTPCLHGAALHLHSGHG NO: 478 SGSRL TNSSCFPGTRRLLALQFTQQTGTVGHPTW QPVI R SEQ ID NM000985.3 NM001035005.2 MVRYSLDPENLRSSSLGKWCAFLVSSFQF NO: 479 CSGSTK NSWSHIYTLWFPPSLVVYGLRKQYKNP MIQTKAK SEQ ID NM017882.1 NM033429.2 M EATRRRQH NO: 480 LRKWRAGFLHFSDHYAHAN KTRRP KERNSSSHVDGGQGEERLRHGVRPAVKTH ESGG EAHPQGSG SEQ ID NM012447.2 NM005395.2 MSSPLQRAVGLDYVDMEIHLPLSTAPLP NO: 481 APLPSPP LHDDVWLG DNHTPQKLDGCSSPTSHPRMLSSHQ GPVAATPPG SEQ ID NM015001.2 NM001042704.1 MVRETRH LWVFWN NO: 482 PGAEDHVGGCDLGGLPGY QELWGQGGGPLLHPGHRQHPVPGQSGPFR APV CNDRCLPGPCAHHDHRGA SEQ ID NM003755.3 NM207346.2 MPTGDFDSKPPWSFSISLCCRQHTFLME NO: 483 VPGCW RSLGAWKSSLM FTRPTLWPHSERITLANPMPGCA LVDLMSLSQTSAASSGCLTRVGMSL SEQ ID NM182486.1 NM000878.2 MQWLRVRESPLPSSAPPCGCNGGPCSVLA NO: 484 SAPP HPPPAPGYLLGICSGEWHFPVHMLLQLESQ HLLCL EPRWGSAGHFLPSPCLAGQTAVEPNL SEQ ID NM020987.2 NM005888.2 MAHAASQLKKSGCVIAILGKRCSRPWRT NO: 485 WRGRT PSTRHICSWCTMVSGTSAAAPQGPRAS PAALAT WQPPPWKSSIAVTMDLADSLSFVD LEELLAVAQH IQHWFL SEQ ID NM000921.3 NM001128220.1 MAVPGDAARVEQDCQWRLPQRPPGAE NO: 486 PQPHR ARCGPHHEPARQPPVHLPPQPWPGAAP RTDQE QPGRQQASRPLAHTDPGGAAAEPALRDH LCLGW RPQLQPLALPH RAQRLCRARACQLPEATERCHHL SEQ ID NM000921.3 NM001128220.1 MAVPGDAARVEQDCQWRLPQRPPGAE NO: 486 PQPHR ARCGPHHEPARQPPVHLPPQPWPGAAP RTDQE QPGRQQASRPLAHTDPGGAAAEPALRDH LCLGW RPQLQPLALPH RAQRLCRARACQLPEATERCHHL SEQ ID NM178276.4 XM001722866.1 MSAQCCAGQLATKVPTSRASSAGAGPSSG NO: 487 SRWP PAGYACCCTCVRWSLPSAAPPGSSLCDDIG GPLGF VGLQPGKCHLLNSVPGAGTGALCLSGSEK ALRLHS GTSSLLFPPSYFGKFSSRSSHVFSIQLSCH SFS SEQ ID NM004083.4 NM004990.2 MAAESLPFSFLPLGASGGFPSATANCFFRS NO: 488 KSFATS AATSFLSAFCAFSSRTMFPCFVTSSISACIC CGLAVV TVSTTAGFGDVFAWPPPKRCLKLSIWSFS NFWNK GLTVPIWCPAGKVHRKFVSRILQAGGG SCSWAWI VALTVGM SEQ ID XM001716912.1 NM199511.1 MREVQKDQRSPFSTSHSCVFPQPGKHINPS NO: 489 AFTP GNKETKPDYGG KGDKKDPGTLKRERVRFRNRQD WTLRDVLCQHKGLAHTDTRDRGETADK WRYKDL EGQLLSPH PTCPEG KKTQPERKG IGSALRSGQAVD LWRYSESWSCSTPLLYCSPSVKRERAGRKSS SSRKL SWEPNF SEQ ID NM006871.3 NM139247.2 MSCVKLWPSGADLRPELPDHCAVRAGR NO: 490 LLAAAG PRFPGAATAALDASPVRLGMGRAASARPR LPVHR GRGERLGPGVLFSLRHLHGVCHAALGHA GRRRR GPRLLTLASAGPRAVSWATAGLTACTAAA VGSKR SAVPVRERGRSVPQGADGARPAGHVPGGT QLPA LTPAAGHREEAPGTPSLVHPSCLPGPRDEG RDHG TAAGRTGVTAREH

Example 21

Sequences tabulated in Table 13 for use as peptide components of an anti-cancer vaccine were determined by identifying tumor-associated frameshift alternative splicing variant peptides. The NCBI EST sequence database was screened against the human RefSeq database to identify single EST sequences that align with two RefSeqs, in which an exon is skipped, and in which the sequence downstream of the splice is frameshifted relative to the normal wild type when the EST sequence is translated. From these, sequences were identified wherein either the sequence corresponded to at least 3 tumor EST sequences and no non-cancerous EST sequences, or in which the sequence corresponded to at least three times as many tumor EST sequences as non-cancerous EST sequences.

TABLE 13 SEQID NO Name ID Sequence SEQ ID C11orf2 NM0132652 PCTGLSLHPMAPRIWSRWSFPAGRCQDRPNK NO: 491 HVWPPQ KKKKKKKKKKK SEQ ID C20orf96 NM080571.1 CFTSSPLRW NO: 492 SEQ ID CYBASC3 NM001161452.1 LLLQLR PGSRPFPVTYVSVTG RQPYKSW NO: 493 SEQ ID KRT8 NM0022733 LLRSRHSTRILPTAAGLRLRACTRSSMRSCRAWL NO: 494 GSTGM TCGAQRLRSLR SEQ ID MVK NM001114185.1 GGPRRIWS NO: 495 SEQ ID NAA10 NM003491.2 RSVKWSPNTMQMGRTPMP NO: 496 SEQ ID PDCD2 NM001199462.1 GLWLFRPQNVLQMPQSILLQQGASDPRLEI NO: 497 GT SEQ ID RPS3A NM001006.3 FGKAHGASW NO: 498 SEQ ID TFE3 NM006521.4 CSAQARNRSE DETQPLPLGTLLAF NO: 499 SEQ ID HNRNPA2B NM031243.2 KEGVLLQVTN EEVVNHRVFKK NO: 500 SEQ ID NOL12 NM0243112 VPTACCRCCFCWDV NO: 501 SEQ ID RPLP0 NM001002.3 GVRQWQHLQP NO: 502 SEQ ID DPH2 NM001384.4 LPCSSLTSYWEM LWLWLH NO: 503 DWRRRQGQRCSFWVTQPT AAAAWMCWVLSKLELRLSYILALPA SEQ ID GNB2LI NM006098.4 GWPGHVMGSQRRQTPLHARWWGHHQRP NO: 504 VLQP SEQ ID RPL8 NM000973.3 IRELCHRYLPQP NO: 505 SEQ ID IGFLR1 NM024660.2 NCPVWRHNPCLASWMSWRCWKS NO: 506 SEQ ID KARS NM001130089.1 VGSMPKELLGESSSSMIFEERG NO: 507 SEQ ID MRPS28 NM014018.2 EIPERNQGPVAAIRS NO: 508 SEQ ID HNRNPA2B NM031243.2 EGVLLQVTNEEVVNHRVFKK NO: 509 SEQ ID SMC1A NM006306.2 CCGIYCHEEPQREDSSI NO: 510 SEQ ID NRM NM007243.1 AGDAVLGAHTQRPCVVGGSG NO: 511 SEQ ID PRSS27 NM031948.3 PLRRPCTRSCWGQGS NO: 512 SEQ ID TXN2 NM012473.3 CQRCPLCWP NO: 513 SEQ ID RDH11 NM016026.3 SLPPNPSAARETKGISPIKDSKCVFPRTSPGK NO: 514 DPLP SEQ ID BORA NM024808.2 FSLKMSSYPLLGLIM KGNSFH NVIPVNALT NO: 515 SEQ IN RPS3 NM001005.3 GLLWCAAVH NO: 516 HGEWGQRLRGCGVWETPRTEG SEQ ID SAALI NM138421.2 GDGGSGSKGRPVEQTEVFLCISKPSSFL NO: 517 SEQ ID SEMA3B NM00I0059141 LPQQDLWHLQFHQGLPRRCHPVCAEPPPHVQLC NO: 518 PAHW GAPSFPTSWSQLHLHSNCRGPGCSR SEQ ID FPGS NM0010180781 AGPSPGTWTVRTPPAARRPACAGSARRCRAA NO: 519 RGRAVA PRFESCSSM LPGTGTRRPC SEQ ID SLC13A3 NM001193342.1 GIGAVCMDWWAAAPPGECAPRPGCAAHHCG NO: 520 HRLLH SEQ ID ARHGEFI NM199002.1 GVPPPILPPETPPVSAWGELCPPAWLHL NO: 521 SEQ ID FANCI NM001113378.1 VSPGVSELRRNSKKYGKAGEAVWFSSDPPVLFF NO: 522 HFLRTE SEQ ID SARS2 NM017827.3 LHARAPGPRGPPLLCPCCLRVSH NO: 523 SEQ ID CAPN3 NM000070.2 CLQKHLPVALSTSLC NO: 524 SEQ ID SPAG5 NM006461.3 ISVSIMWTQRRKL NO: 525 SEQ ID ZNF263 NM005741.4 SHSQSGGPRHPGGTRRKAMGSQCPELQGGPEPQ NO: 526 RPSS RRREI SEQ ID DFFA NM213566.1 SPKLPLVRRWMQ NO: 527 SEQ ID NSLI NM001042549.1 GAKPGGLALGAV NO: 528 SEQ ID C17orf85 NM018553.3 CYQHPFPKKSQFPGAYWTSFEGEEEGSGQLT NO: 529 LPGP SEQ ID CIRHIA NM032830.2 LLSSHHPLKRRNLEP NO: 530 SEQ ID APEH NM001640.3 SPSQAMWATRM NO: 531 SEQ ID DPP3 NM130443.2 HFPACQLLP LCDLISSALPYVE NO: 532 SEQ ID EEFlAI NM0014025 CLQNWWYWYCSCWPSGDWCSQTRYGG NO: 533 HLCSSQRYN GSKICRNAP SEQ ID ARMC8 NM014154.2 RHEKCCNWKQQAESQSHCFRSCSKIVVLASARN NO: 534 LKHRA EN SEQ ID TMEM179 NM207379.1 QFRTPGWPLKALAGRGWPEDASPGQEPSKGA NO: 535 GRGWA SEQ ID VASP NM003370.3 WPQLLLEPNSGKSASRRRPQGGPQPPKLRVVEA NO: 536 EVGDS WKR SEQ ID MRPL43 NM032112.2 PASGGSDLVNHSFLCKWHP NO: 537 SEQ ID MRPL43 NM032112.2 CLLLGAVTL NO: 538 SEQ ID DEDO NM001039712.1 AAAAAHHHSPRPAALRHPQEETGCVP NO: 539 SEQ ID AURKB NM004217.2 DHGGVG RCSNVLPWEEG DSQRH NO: 540 KARKSALRAQG RAED C SEQ ID CRCP NM001040648.1 TSASQIQAILVP NO: 541 SEQ ID WTAP NM152858.1 GLMASDYSEEVATSEKFPF NO: 542 SEQ ID NUP43 NM198887.1 QENCSNPGGRGCSDPRSCHFTPAWAKEQNAI NO: 543 SKNIHI SEQ ID SRSF5 NM006925.3 VKGVLHSLTAAGQTH NO: 544 SEQ ID HSPHI NM006644.2 DSCGIVNSY NO: 545 SEQ ID IGFLRI NM024660.2 NCPVWRH NO: 546 NPCLASWMSWRCWKSDEVFALPLAHLLQT QNQGYTH FCRGGH FRYTLPVFLHG PHRVWG SEQ ID NUDT8 NM1818431 LTAVITEFALQLLAPGTYQPRLAGLTCSGAEGLA NO: 547 RPKQPL ASPCQASSTPGLNKGL SEQ ID STK25 NM006374.3 KHQAMDHHGVPGRRLSTGLA NO: 548 SEQ ID TNFAIP2 NM0062912 PRAAVSG IQQWWNG NO: 549 RQNWKRKKEKMSSRLAGAFRVL WRAVSTASIRRHIQVAPRPLQAGPAMGP SEQ ID TTLLl2 NM015140.3 LIVGGGAPDRKGFQ NO: 550 SEQ ID UQCC NM001184977.1 GVRCLIHSIHGFL NO: 551 SEQ ID WDR34 NM0528443 VAARAWAQPPLPGAECGHRREGATLAGHRGRP NO: 552 AAAHR GLRPGHAAAATEHQAQEASPRGDRGGRHGSGL LQLHR DSRGSGRNGRHPEREGDHAKPERPPGLLPGQSE EPGDR EPEAG SEQ ID: KRT18 NM1991871 EQNPGALGEEGTPGQRLEPLLQDHRGPEGSDLR NO: 553 KYCGQ CPHRSAD SEQ ID NOP16 NM016391.4 SGKTSSILCRRGRWRWS NO: 554 SEQ ID SNX27 NM030918.5 HFPDGEVTAERCGHLAFPYPLPFPSPPSSYSFHVP NO: 555 FQTE SEQ ID RAB25 NM020387.2 GTIVVQWG PSWCLT NO: 556 SEQ ID ATP5B NM001686.3 TTNPSRISLPSWVWM NFLRKTS NO: 557 SEQ ID BFAR NM0165612 WSCSSITGAAGNLNTTSWSTRLWPNGRRKKLSS NO: 558 GWSS WALGHLFTGKGFYLNE SEQ ID C160rf62 NM020314.5 GSADRDDGKV NO: 559 SEQ ID C190rf40 NM152266.3 DAAFFMSPKLrWWQEMATERGLFGLEIPIILK NO: 560 ELRVQGT SEQ ID C90rfi40 NM1784483 FPAAPGLQGCPRTGPSQPSMQLPSYPEDGSGLS NO: 561 RGHKD VRPGPPGQERVQVLRACAPQPQHQVDCSAVG GPVAAR EKPPVSRLGSAHQGLPTSAFEGACHALGDPGIF TGLEAG DRTVSVPG SEQ ID DERA NM015954.2 LLQPPFVFI PPGCVM L NO: 562 SEQ ID EXOSC2 NM014285.5 GFWSRFPPPW NO: 563 SEQ ID GTPBP5 NM015666.3 GPRGHAGEGGRQSCGRPVLRGR NO: 564 SEQ ID HSPHl NM006644.2 DSCGIVNSY NO: 565 SEQ ID ISTl NM0147612 IVGPGPKPEASAKLPSRPADNYDNFVLPELPSVP NO: 566 DTLPTA SAGASTSAS EDIDFDDLSRRFEEL SEQ ID MAGED2 NM1774331 RCQPDRHSHIWALRWPWWSWCQHQWQLW NO: 567 CLWFLL QV SEQ ID MED19 NM153450.1 ETPSDSDHKKKKKKKEEDPERKRKKKEKK NO: 568 KKKVE SEQ ID MRPL2 NM015950.3 AGNVRSNSRPSIQR NO: 569 SEQ ID MTFRl NM001145839.1 LHWGSTKVH LLLI NO: 570 SEQ ID MVK NM0004312 GGPRRIWS NO: 571 SEQ ID NUPL2 NM007342.2 AKFCPTFNKSMEEQGK NO: 572 SEQ ID PEX13 NM002618.3 DYRRLPPGPANFFCIFSRDGVSPCYPGWSPSPDL NO: 573 VMSPL RSPKVLGLQA SEQ ID PSPH NM004577.3 CDLNSLCIFVAIFHTKCFKCGESIKHLYSGLW NO: 574 MVVRSVWI MQASLLG EPEEVALG PMGVVAATLEVVGTRAM SEQ ID RBM3 NM006743.4 GVAGIMTVDLEGMDMDMDVPETIMAETR NO: 575 VVMTATQE EITETIMTT SEQ ID RNF217 NM1525532 GLFVFPIYCLC NO: 576 SEQ ID RPL7Ll NM198486.2 EVWRHLLGRPHS NO: 577 SEQ ID SENP2 NM021627.2 GIFELFIL NO: 578 SEQ ID SLC29A2 NM001532.2 SPCPSSPPSQPW NO: 579 SEQ ID SLC35B2 NM178148.2 VLSDLGCAAGKSDDPQLWGHSHITG NO: 580 SEQ ID TH NM199293.2 HQALGAVPSCEGV NO: 581 SEQ ID WIPl2 NM001033519.1 RYGRCVHCREIVLQQPSGHRQP NO: 582 SEQ ID XRRAI NM182969.1 DRKRGCCPTSSSLPISLRVRLS NO: 583 SEQ ID CIRHIA NM032830.2 MTSLLSSHH PLKRRN LEP NO: 584 SEQ ID TATDN2 NM014760.3 GDQQPDRTQAGLKSVSQVEDVFRELIGTQKTRT NO: 585 GCFPPS GS SEQ ID GTSEI NM016426.6 VQMKMM KSSSDPLDI KKDVLLPAWN NO: 586 SEQ ID C190rf2 NM1344471 GFAASWLFKKPRPSECHTVIFKEESYM N NO: 587

CONCLUDING MATTER

For clarity and to ensure completeness, certain of the aspects and/or embodiments disclosed herein may be overlapping in scope, described repetitively, or represent recitals of the same or equivalent elements or combinations expressed in alternative language. It will be apparent that the choice of particular phraseology and/or of particular aspects or elements to assert as claims involves many complex technical and legal considerations, and no inference should be drawn that alternative descriptions of a particular element or combination in this written description necessarily do or do not encompass different subject matter; except where context otherwise requires, each described aspect or element should be interpreted according to its own description.

It is intended that this specification be interpreted in accordance with the normal principles of English grammar and that words and phrases be given their ordinary English meaning as understood by persons of skill in the pertinent arts except as otherwise explicitly stated. If a word, term, or phrase is intended to be further characterized, specified, or narrowed in some way, then additional adjectives, modifiers, or descriptive text have been included in accordance with the normal principles of English grammar. It is intended that the meanings of words, terms, or phrases should not be modified or characterized in a manner differing from their ordinary English meaning as understood by persons of skill in the relevant arts except on the basis of adjectives, modifiers, or descriptive text that is explicitly present.

Except as otherwise explicitly stated, terms used in this specification, including terms used in the claims and drawings, are intended as “open” terms. That is, for example, the words “including” and “comprising” should be interpreted to mean “including but not limited to,” the word “having” should be interpreted to mean “having at least,” the word “includes” should be interpreted to mean “includes but is not limited to,” the phrases “for example” or “including by way of example” should be interpreted as signifying that the example(s) given are non-exhaustive and other examples could be given, and other similar words and phrases should be given similar non-exclusive meanings. Except as explicitly stated, ordinals used as adjectives (e.g. “first object”, “second object”, etc.) in this specification, including claims and drawing figures, are intended merely to differentiate and do not imply that any particular ordering is required. Thus, for example, unless otherwise explicitly stated, “first measurement” and “second measurement” do not imply that the first measurement necessarily takes place before the second measurement, but merely that they are distinct measurements.

In the written description and appended claims, the indefinite articles “a” and/or “an” are intended to mean “at least one” or “one or more” except where expressly stated otherwise or where the enabling disclosure requires otherwise. The word “or” as used herein is intended to mean “and/or”, except where it is expressly accompanied by the word “either”, as in “either A or B”. Applicants are aware of the provisions of 35 U.S.C. § 112, 6. The use of the words “function,” “means” or “step” in the written description, drawings, or claims herein is not intended to invoke the provisions of 35 U.S.C. § 112, 6, to define the invention. To the contrary, if the provisions of 35 U.S.C. § 112, 6 are sought to be invoked, the claims will expressly include one of the exact phrases “means for performing the function of” or “step for performing the function of”. Moreover, even if the provisions of 35 U.S.C. § 112, 6 are explicitly invoked to define a claimed invention, it is intended that the claims not be limited only to the specific structure, material or acts that are described in the preferred embodiments, but in addition, extend to any and all structures, materials or acts that perform the claimed function as described in alternative embodiments or forms of the invention, or that are well known present or later-developed equivalent structures, material or acts for performing the claimed function.

Any of the methods of the present disclosure may be implemented in whole or part in hardware, software, or both, or by a computer program, and may be carried out using any of the disclosed devices or apparatus according to any aspect or embodiment of the present invention, or in any other operable manner.

In the foregoing description, various details, specific aspects, embodiments, and examples have been described in order to illustrate and explain the subject matter, to provide a thorough understanding of the various aspects, to enable persons skilled in the pertinent arts to practice the described subject matter, and to disclose the best mode of doing so known to applicants. These details, specific aspects, embodiments, and examples are not intended to be limiting; rather, it will be apparent to persons of skill in the relevant arts that, based upon the teachings herein, various changes, substitutions, modifications, rearrangements, may be made and various aspects, components, or steps may be omitted or added, without departing from the subject matter described herein and its broader aspects. Except as otherwise expressly stated or where aspects or features are inherently mutually exclusive, aspects and features of any embodiment described herein may be combined with aspects and features of any one or more other embodiments. Descriptions of theoretical principles and/or properties, where given, are intended as explanatory and not limiting. Titles, headings, and subheadings herein and the accompanying abstract are intended merely as a convenience for locating content, and do not limit or otherwise affect the interpretation of the content of the disclosure. The appended claims are intended to encompass within their scope any and all changes, substitutions, modifications, rearrangements, combinations of aspects or features, additions, and omissions that are within the spirit and scope of the subject matter as described herein and/or within the knowledge of a person of skill in the art. The scope of the invention is defined by the claims, and is not limited by or to the particular embodiments or aspects chosen for detailed exposition in the foregoing description, but rather extends to all embodiments or aspects as defined by the claims, as well as any equivalents of such embodiments or aspects, whether currently known or developed in the future.

So as to reduce the complexity and length of the detailed description, and to provide background in certain areas of technology, each of the materials identified in the “REFERENCES” section below is expressly incorporated by reference. Applicants believe that the subject matter incorporated is “non-essential” in accordance with 37 CFR 1.57, because it is referred to for purposes of indicating the background of the invention or illustrating the state of the art. However, if the Examiner concludes that any of the incorporated material constitutes “essential material” within the meaning of 37 CFR 1.57(c)(1)-(3), applicants will amend the specification to expressly recite the essential material that is incorporated by reference as allowed by the applicable rules.

REFERENCES

-   Berzofsky, J., Terabe, M., Oh, S., Belyakov, L, Ahlers, J.,     Janik, J. & Morris, J. (2004) Progress on new vaccine strategies for     the immunotherapy and prevention of cancer. J. Clin. Invest. 2004     June; 113(11): 1515-1525. -   Gite, S., Lim, M., Carlson, R., Olejnik, J., Zehnbauer, B. &     Rothschild, K. (2003) A high-throughput nonisotopic protein     truncation test. Nature Biotechnology: 21(2): 194-197. -   Kerr, C. (2002) Huntington's disease provides cancer clues. The     Lancet. Oncology: 3(9): 518. -   Leaf, C. (2004) Why we're losing the war on cancer. Fortune: 149(6):     76-82: -   Lewis, J. (2004) Therapeutic cancer vaccines: using unique antigens.     PNAS: 101 Suppl 2:14653-6. -   Linnebacher, M., Gebert, J., Rudy, W., Woerner, S., Yuan, Y.,     Bork, P. & von Knebel Doeberitz, M. (2001) Frameshift     peptide-derived T-cell epitopes: a source of novel tumor-specific     antigens. Int. J. Cancer. 93(1): 6-11. -   Saeterdal, I., Bjorheim, J., Lislerud, K., Gjertsen, M., Bukholm, L,     Olsen, O., Nesland, J., Eriksen, J., Moller, M., Lindblom, A., &     Gaudernack, G. (2001) Frameshift-mutation-derived peptides as     tumor-specific antigens in inherited and spontaneous colorectal     cancer. PNAS: 98(23):13255-60. -   Sorensen, S. A., Fenger, K. & Olsen, J. (1999) Significantly lower     incidence of cancer among patients with Huntington disease. Cancer:     86(7):1342-6. -   Sykes, K. F., and S. A. Johnston. (1999) Linear expression elements:     a rapid, in vivo, method to screen for gene functions. Nat     Biotechnol 17(4):355-9. -   Wang, R., Parkhurst, M., Kawakami, Y., Robbins, P. &     Rosenberg, S. A. (1996) Utilization of an alternative open reading     frame of a normal gene in generating a novel human cancer antigen.     The Journal of Experimental Medicine: 183, 1131-1140. 

1. (canceled)
 2. A method of identifying a tumor specific antigen for use in a cancer vaccine, the method comprising: isolating a nucleic acid from a tumor cell; sequencing the nucleic acid from the tumor cell; identifying a mutation in the nucleic acid from the tumor cell, thereby identifying a tumor specific antigen; and preparing a cancer vaccine comprising the identified tumor specific antigen.
 3. The method of claim 1, wherein the mutation comprises a point mutation, frame shift mutation, in-frame insertion or deletion, translocation, improper splicing, post-transcriptional event, variation, or other alteration in a nucleic acid sequence from a non-cancerous reference sequence.
 4. The method of claim 1, wherein the tumor specific antigen comprises an amino acid sequence as set forth in SEQ ID NO: 293, SEQ ID NO: 290, SEQ ID NO: 296, SEQ ID NO: 234, SEQ ID NO: 240, or a combination thereof.
 5. The method of claim 1, wherein the nucleic acid is RNA or DNA.
 6. The method of claim 1, wherein the insertion or deletion results in a frameshift in a gene of the tumor cell.
 7. The method of claim 6, wherein the frameshift in the gene results in a truncated transcript.
 8. The method of claim 1, wherein the tumor specific antigen is a non-oncogene product.
 9. A vaccine comprising: a continuous amino acid chain, or a portion thereof, from 8 to 40 amino acids in length, according to the formula D1-D2, and an effective amount of an adjuvant, wherein D1 and D2 each have at least 90% sequence identity to a polypeptide sequence encoded by a different exon or continuous portion thereof of a genome of a mammalian species, wherein D1 is encoded in a wild type reading frame and D2 is encoded in a non-wild type reading frame.
 10. The vaccine of claim 9, wherein D2 has an amino acid sequence as set forth in SEQ ID NO: 293, SEQ ID NO: 290, SEQ ID NO: 296, SEQ ID NO: 234, SEQ ID NO: 240, or a combination thereof.
 11. The vaccine of claim 9, wherein the adjuvant is an alum, a CpG, a KLH, an oil emulsion, or a combination thereof.
 12. The vaccine of claim 9, wherein a normal transcriptome of the mammalian species does not contain a continuous nucleic acid sequence encoding the sequence of the continuous amino acid chain.
 13. The vaccine of claim 9, wherein the continuous amino acid chain aligns with at least 90% identity to all or a portion of an mRNA transcript expressed in at least one cancer type of a mammalian species.
 14. A vector comprising: a promoter and a nucleic acid encoding a continuous amino acid chain, or a portion thereof, from 8 to 40 amino acids in length, according to the formula D1-D2, wherein D1 and D2 each have at least 90% sequence identity to a polypeptide sequence encoded by a different exon or continuous portion thereof of a genome of a mammalian species, wherein D1 is encoded in a wild type reading frame and D2 is encoded in a non-wild type reading frame.
 15. The vector of claim 14, wherein D2 has an amino acid sequence as set forth in SEQ ID NO: 293, SEQ ID NO: 290, SEQ ID NO: 296, SEQ ID NO: 234, SEQ ID NO: 240, or a combination thereof.
 16. The vector of claim 14, wherein the vector further comprises a nucleic acid encoding an adjuvant comprising a KLH, a GMCSF, an interleukin, or a combination thereof.
 17. A method for designing a cancer vaccine, the method comprising: (a) identifying one or more novopeptides or one or more nucleic acids encoding novopeptides in a cancerous tissue sample from an individual, wherein the one or more novopeptides comprise a polypeptide between 8 and 40 amino acids in length, wherein the polypeptide comprises a frameshift mutation and induces a protective immune response to cancer; and (b) preparing a vaccine comprising one or more polypeptides comprising the one or more novopeptides or one or more nucleic acids encoding the novopeptides.
 18. The method of claim 17, wherein the polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 293, SEQ ID NO: 290, SEQ ID NO: 296, SEQ ID NO: 234, SEQ ID NO: 240, or a combination thereof.
 19. The method of claim 17, wherein identifying the one or more novopeptides comprises: (a) obtaining a first nucleic acid sequence from the cancerous tissue sample; and (b) comparing the first nucleic acid sequence to a second nucleic acid sequence from an individual without cancer or a noncancerous tissue sample from the individual with cancer.
 20. The method of claim 19, wherein the first nucleic acid or the second nucleic acid is a DNA or an RNA.
 21. The method of claim 17, wherein identifying the one or more novopeptides comprises: (a) obtaining a tumor sample from an individual with cancer; (b) isolating polypeptides from the tumor sample; (c) obtaining a sequence of the polypeptides; and (d) comparing the sequence of the polypeptide to a wild type sequence. 